<SEC-DOCUMENT>0001193125-25-002537.txt : 20250107
<SEC-HEADER>0001193125-25-002537.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20250107065803
ACCESSION NUMBER:		0001193125-25-002537
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250107
DATE AS OF CHANGE:		20250107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STRYKER CORP
		CENTRAL INDEX KEY:			0000310764
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				381239739
		STATE OF INCORPORATION:			MI
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13149
		FILM NUMBER:		25513453

	BUSINESS ADDRESS:	
		STREET 1:		1941 STRYKER WAY
		CITY:			PORTAGE
		STATE:			MI
		ZIP:			49002
		BUSINESS PHONE:		2693852600

	MAIL ADDRESS:	
		STREET 1:		1941 STRYKER WAY
		CITY:			PORTAGE
		STATE:			MI
		ZIP:			49002
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d899660d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:syk="http://www.stryker.com/20250106" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2025-01-06_to_2025-01-06">STRYKER CORP</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-399">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-01-06_to_2025-01-06">0000310764</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="syk-20250106.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-01-06_to_2025-01-06"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes0.250Due2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes2.125Due2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes3.375Due2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes0.750Due2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes2.625Due2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes1.000Due2031Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes3.375Due2032Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000310764</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes3.625Due2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-06</xbrli:startDate> <xbrli:endDate>2025-01-06</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-482">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt:datemonthdayyearen" id="ixv-483">January&#160;6, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img src="g899660g0107033853517.jpg" alt="LOGO"/></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Stryker Corporation</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt-sec:stateprovnameen" id="ixv-484">Michigan</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-485">001-13149</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-486">38-1239739</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-487">1941 Stryker Way</ix:nonNumeric><br/><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-488">Portage</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt-sec:stateprovnameen" id="ixv-489">Michigan</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-490">49002</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-491">(269)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-492">385-2600</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt-sec:boolballotbox" id="ixv-493">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt-sec:boolballotbox" id="ixv-494">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt-sec:boolballotbox" id="ixv-495">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt-sec:boolballotbox" id="ixv-496">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-497">Common Stock, $.10 Par Value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-498">SYK</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen" id="ixv-499">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member" id="ixv-500">0.250% Notes due 2024</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member" id="ixv-501">SYK24A</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member" format="ixt-sec:exchnameen" id="ixv-502">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member" id="ixv-503">2.125% Notes due 2027</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member" id="ixv-504">SYK27</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member" format="ixt-sec:exchnameen" id="ixv-505">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member" id="ixv-506">3.375% Notes due 2028</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member" id="ixv-507">SYK28</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member" format="ixt-sec:exchnameen" id="ixv-508">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member" id="ixv-509">0.750% Notes due 2029</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member" id="ixv-510">SYK29</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member" format="ixt-sec:exchnameen" id="ixv-511">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member" id="ixv-512">2.625% Notes due 2030</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member" id="ixv-513">SYK30</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member" format="ixt-sec:exchnameen" id="ixv-514">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member" id="ixv-515">1.000% Notes due 2031</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member" id="ixv-516">SYK31</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member" format="ixt-sec:exchnameen" id="ixv-517">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member" id="ixv-518">3.375% Notes due 2032</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member" id="ixv-519">SYK32</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member" format="ixt-sec:exchnameen" id="ixv-520">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member" id="ixv-521">3.625% Notes due 2036</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member" id="ixv-522">SYK36</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member" format="ixt-sec:exchnameen" id="ixv-523">New York Stock Exchange</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-01-06_to_2025-01-06" format="ixt-sec:boolballotbox" id="ixv-524">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;6, 2025, Stryker Corporation, a Michigan corporation (&#8220;<span style="text-decoration:underline">Stryker</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), by and between Stryker and Inari Medical, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Inari</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, an acquisition vehicle to be formed by Stryker promptly after the execution of the Merger Agreement as a wholly owned subsidiary of Stryker (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;) will commence a tender offer (the &#8220;<span style="text-decoration:underline">Offer</span>&#8221;) to purchase all of the issued and outstanding shares (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of common stock, par value $0.001 per share, of Inari, at a price of $80.00 per Share (the &#8220;<span style="text-decoration:underline">Offer Price</span>&#8221;), net to the seller in cash, without interest and subject to any applicable tax withholding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation of Merger Sub to consummate the Offer is subject to the satisfaction or waiver of customary conditions, including, among others, (i)&#160;there having been validly tendered and not properly withdrawn prior to the expiration of the Offer a number of Shares that, when added to the Shares then owned by Stryker and Merger Sub, would represent at least a majority of Shares issued and outstanding as of immediately following the expiration of the Offer (the &#8220;<span style="text-decoration:underline">Minimum Tender Condition</span>&#8221;), (ii) the expiration or termination of the waiting period applicable to the Offer and the consummation of the Merger (as defined below) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#8220;<span style="text-decoration:underline">Regulatory Condition</span>&#8221;), and (iii)&#160;the absence of any legal prohibition by a governmental entity of competent jurisdiction in effect enjoining, prohibiting or otherwise preventing the consummation of the Offer or the Merger (as defined below) (the &#8220;<span style="text-decoration:underline">Absence of Legal Restraint Condition</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Offer will initially remain open for a minimum of 20 business days from the date of commencement of the Offer. If at the scheduled expiration time of the Offer, any of the conditions to the Offer have not been satisfied or waived, Merger Sub must extend the tender offer for consecutive periods of up to 10 business days each (or for a longer period as mutually agreed by Stryker and Inari) to permit the satisfaction of such conditions. However, Merger Sub will have no obligation to extend the tender offer on more than three occasions in circumstances where the only remaining condition to satisfy at the expiration time is the Minimum Tender Condition. In no circumstances will Merger Sub or Stryker extend the Offer such that the expiration time would occur beyond the End Date (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Offer and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into Inari pursuant to Section&#160;251(h) of the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration:underline">DGCL</span>&#8221;), with Inari being the surviving corporation and a wholly owned subsidiary of Stryker (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;). At the effective time of the Merger, each Share (other than (i)&#160;Shares owned by Inari or any wholly owned subsidiary of Inari as treasury stock or otherwise, (ii)&#160;Shares owned, directly or indirectly, immediately prior to the effective time of the Merger by Stryker, Merger Sub or any other wholly owned subsidiary of Stryker, (iii)&#160;Shares accepted for purchase pursuant to the Offer, and (iv)&#160;Shares held by holders who have properly exercised and perfected their demands for appraisal of such Shares under, and complied in all respects with, Section&#160;262 of the DGCL) will be converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any required withholding of taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger, all Inari equity awards will vest and be converted into the right to receive the Offer Price (less the applicable exercise price in the case of options) in respect of each underlying Share, with performance goals deemed achieved at the maximum level in the case of performance-vesting restricted stock unit awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement includes customary representations and warranties of Stryker, Merger Sub and Inari. In addition, until the earlier of the effective time of the Merger and the termination of the Merger Agreement, Inari has agreed to use commercially reasonable efforts to conduct its business in all material respects in the ordinary course of business consistent with past practice and to not take certain specified actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties have agreed under the Merger Agreement to cooperate and use their respective reasonable best efforts to consummate the Offer and the Merger as promptly as reasonably practicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inari has agreed to customary <span style="white-space:nowrap">&#8220;no-shop&#8221;</span> restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations with third parties regarding alternative acquisition proposals. Notwithstanding these restrictions, Inari may under certain circumstances provide information to and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-2- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
engage in discussions or negotiations with third parties with respect to an alternative acquisition proposal that board of directors of Inari has determined constitutes or would reasonably be expected to lead to, or result in, a superior proposal (as defined in the Merger Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains certain customary termination rights in favor of each of Stryker and Inari, including among others Inari&#8217;s right, subject to certain limitations, to terminate the Merger Agreement in certain circumstances to accept a superior proposal, and Stryker&#8217;s right to terminate the Merger Agreement if the board of directors of Inari changes its recommendation that Inari&#8217;s stockholders tender their Shares in the Offer. In addition, either Stryker or Inari may terminate the Merger Agreement if, subject to certain limitations, the acceptance time of the Offer has not occurred by July&#160;7, 2025 (the &#8220;<span style="text-decoration:underline">End Date</span>&#8221;), which date will be automatically extended to October&#160;6, 2025 if all of the conditions to the Offer have been satisfied or waived as of such time, except for those conditions that by their nature cannot be satisfied until the expiration of the Offer, the Regulatory Condition or the Absence of Legal Restraint Condition (to the extent the applicable legal restraint relates to an antitrust or foreign investment law). In addition, the Merger Agreement provides that, in connection with the termination of the Merger Agreement under specified circumstances, including a termination by Inari to accept and enter into an agreement with respect to a superior proposal in accordance with the Merger Agreement or a termination by Stryker because of a change of recommendation by the board of directors of Inari, Inari will pay Stryker a termination fee of $163&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference. The Merger Agreement has been filed to provide information to investors regarding its terms. It is not intended to provide any other factual information about Stryker, Merger Sub or Inari, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation of the Offer, the Merger or the other transactions contemplated by the Merger Agreement. The Merger Agreement and this summary should not be relied upon as disclosure about Stryker,Merger Sub or Inari. None of Stryker&#8217;s stockholders or any other third parties should rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of Stryker, Merger Sub, Inari or any of their respective subsidiaries or affiliates. The Merger Agreement contains representations and warranties that are the product of negotiations among the parties thereto and that the parties made to, and solely for the benefit of, each other as of specified dates. The assertions embodied in those representations and warranties are subject to qualifications and limitations agreed to by the respective parties and are also qualified in important part by confidential disclosure schedules delivered in connection with the signing of the Merger Agreement. The representations and warranties (i)&#160;may have been made for the purpose of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from&#160;what an investor may view as material and (ii)&#160;may have been made only as of the date of the Merger Agreement or as of another date or dates as may be specified in the Merger Agreement, and information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the public disclosures of Stryker or Inari, if at all. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;6, 2025, Stryker and Inari issued a joint press release announcing their entry into the Merger Agreement, a copy of which is attached as Exhibit 99.1 hereto and which is incorporated herein by reference. The information contained in Item 7.01 of this report, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in Item 7.01 of this report, including Exhibit 99.1, shall not be incorporated by reference into any filing of Stryker, whether made before, on, or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tender offer for the outstanding shares of common stock of Inari referenced in this filing has not yet commenced. This filing and the communications contained in it are for informational purposes only, are not a recommendation and are neither an offer to purchase nor a solicitation of an offer to sell shares of common stock of Inari or any other securities. At the time the tender offer is commenced, Stryker will file with the U.S. Securities and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-3- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Commission (the &#8220;SEC&#8221;) a Tender Offer Statement on Schedule TO, and Inari will file with the SEC a Solicitation/Recommendation Statement on Schedule <span style="white-space:nowrap">14D-9.</span> INARI STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND THE OTHER TENDER OFFER DOCUMENTS), AND THE SOLICITATION/RECOMMENDATION STATEMENT, AS MAY BE AMENDED FROM TIME TO TIME, WHEN SUCH DOCUMENTS BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Inari stockholders and other investors can obtain the Tender Offer Statement, the Solicitation/Recommendation Statement and other filed documents for free at the SEC&#8217;s website at www.sec.gov. Copies of the documents filed with the SEC by Stryker will be available free of charge on Stryker&#8217;s website, www.stryker.com, or by contacting Stryker&#8217;s Investor Relations department at jason.beach@stryker.com. Copies of the documents filed with the SEC by Inari will be available free of charge on Inari&#8217;s website, https://ir.inarimedical.com, or by contacting Inari Investor Relations at IR@inarimedical.com. In addition, Inari stockholders may obtain free copies of the tender offer materials by contacting the information agent for the tender offer that will be named in the Tender Offer Statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This filing contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements, including statements regarding the anticipated benefits to Stryker of the acquisition of Inari and the anticipated timeline to closing the transaction. Such risks and uncertainties include, but are not limited to: uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Inari&#8217;s stockholders will tender their shares in the offer; the failure to satisfy any of the closing conditions to the acquisition of Inari, including the expiration or termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period (and the risk that such governmental approval may result in the imposition of conditions that could adversely affect the expected benefits of the transaction); delays in consummating the acquisition of Inari or the risk that the transaction may not close at all; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Inari; the effects of the proposed Inari transaction (or the announcement thereof) on the parties&#8217; relationships with employees, customers, other business partners or governmental entities; weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products; geopolitical risks, including from international conflicts and elections in the United States and other countries, which could, among other things, lead to increased market volatility; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign currency exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect approval of new products, including Inari products, by the United States Food and Drug Administration and foreign regulatory agencies; inflationary pressures; increased interest rates or interest rate volatility; supply chain disruptions; changes in labor markets; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related and other regulatory and quality matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; changes in tax laws and regulations; the impact of legislation to reform the healthcare system in the United States or other countries; costs to comply with medical device regulations; changes in financial markets; changes in our credit ratings; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Inari; our ability to realize anticipated cost savings; potential negative impacts resulting from climate change or other environmental, social and governance and sustainability related matters; the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties; and breaches or failures of our or our vendors&#8217; or customers&#8217; information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft. Additional information concerning these and other factors is contained in our filings with the SEC, including our Annual Report on Form <span style="white-space:nowrap">10-K</span> and Quarterly Reports on Form <span style="white-space:nowrap">10-Q.</span> The foregoing factors should also be read in conjunction with the risks and cautionary statements discussed or identified in Inari&#8217;s filings with the SEC, including Inari&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> and Quarterly Reports on Form <span style="white-space:nowrap">10-Q.</span> The parties disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-4- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:8%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d899660dex21.htm">Agreement and Plan of Merger, dated as of January&#160;6, 2025, between Inari Medical, Inc. and Stryker Corporation </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d899660dex991.htm">Joint Press Release, dated January&#160;6, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from this Current Report on Form <span style="white-space:nowrap">8-K,</span> formatted in Inline XBRL</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> Stryker agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Furnished, not filed. </p></td></tr></table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-5- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">STRYKER CORPORATION</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;7, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ GLENN S. BOEHNLEIN</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: Glenn S. Boehnlein</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title: Vice President, Chief Financial Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-6- </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d899660dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AGREEMENT AND PLAN OF MERGER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by
and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">STRYKER CORPORATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INARI MEDICAL, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of January&nbsp;6, 2025 </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 1</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">THE OFFER AND MERGER</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Actions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of the Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organizational Documents of the Surviving Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors of the Surviving Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Officers of the Surviving Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 2</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect on Capital Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treatment of Company Equity Awards and Company ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan Payoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 3</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qualification, Organization, Subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate Authority; Binding Nature of this Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reports; Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Absence of Changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Proceedings; Orders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title to Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Real Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual Property; Data Protection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material Contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance with Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governmental Authorizations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee and Labor Matters; Benefit Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Environmental Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeover Statutes; No Rights Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fairness Opinion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Advisors&#146; Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Additional Representations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 4</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qualification, Organization, Subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate Authority Relative to This Agreement; No Violation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Proceedings; Orders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization of Merger Sub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sufficiency of Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finders or Brokers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Solvency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Additional Representations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 5</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">COVENANTS AND AGREEMENTS</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conduct of Business by the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Control of Operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Access</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Solicitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Efforts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeover Statute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Announcements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification and Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholder Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Exchange <FONT STYLE="white-space:nowrap">De-listing;</FONT> Exchange Act
Deregistration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rule <FONT STYLE="white-space:nowrap">14d-10</FONT> Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligations of Parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification of Certain Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director Resignations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Sub Formation; Joinder; Stockholder Consent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 6</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">CONDITIONS TO THE MERGER</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditions to Obligation of Each Party to Effect the Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frustration of Closing Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 7</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">TERMINATION</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination or Abandonment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">ARTICLE 8</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center">MISCELLANEOUS</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Survival of Representations and Warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts; Effectiveness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law; Jurisdiction; Waiver of Jury Trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specific Enforcement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment; Binding Effect</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement; No Third-Party Beneficiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments; Waivers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Headings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interpretation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terms Defined Elsewhere</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit A:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Conditions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit B:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Certificate of Incorporation of the Surviving Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit C:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Joinder</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Disclosure Letter </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent Disclosure Letter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">AGREEMENT AND PLAN OF MERGER, dated as of January&nbsp;6, 2025 (this
&#147;<U>Agreement</U>&#148;), by and between Stryker Corporation, a Michigan corporation (&#147;<U>Parent</U>&#148;) and Inari Medical, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;). Parent and the Company, and, from and after the
execution and delivery of the Joinder, Merger Sub are referred to herein as the &#147;parties&#148; and each, a &#147;party.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U> : </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent desires to acquire the Company on the terms and subject to the conditions set forth in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS in furtherance of such acquisition, Parent will cause Merger Sub to make a tender offer (as it may be extended, amended or
supplemented from time to time in accordance with the terms of this Agreement, the &#147;<U>Offer</U>&#148;) to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share, of the Company (such shares, collectively,
the &#147;<U>Common Stock</U>,&#148; and each, a &#147;<U>Share</U>&#148;), at a price per Share of $80.00 (such amount or, if the Offer is amended in accordance with the terms of this Agreement and a different amount per share is paid pursuant to
the Offer, such different amount, the &#147;<U>Offer Price</U>&#148;), net to the seller in cash, without interest and subject to any applicable tax withholding, on the terms and subject to the conditions set forth in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, in furtherance of such acquisition of the Company by Parent, and on the terms and subject to the conditions set forth in this
Agreement and in accordance with Section&nbsp;251(h) of the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;), as soon as practicable following the Acceptance Time, Merger Sub shall be merged with and into the Company
(the &#147;<U>Merger</U>&#148;), with the Company surviving the Merger as a wholly owned subsidiary of Parent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of
Directors of the Company (the &#147;<U>Company Board</U>&#148;) has unanimously (a)&nbsp;determined that the Offer, the Merger and the other transactions contemplated by this Agreement are fair to and in the best interests of the Company and its
stockholders, (b)&nbsp;duly approved the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement, including the Offer and the Merger, (c)&nbsp;resolved that this Agreement and the
Merger shall be effected pursuant to Section&nbsp;251(h) of the DGCL and that the Merger shall be consummated as soon as practicable following the Acceptance Time, (d)&nbsp;declared advisable this Agreement and the transactions contemplated by this
Agreement, including the Offer and the Merger, and (e)&nbsp;recommended that the holders of Shares accept the Offer and tender their Shares pursuant to the Offer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of Parent has duly approved the execution, delivery and performance of this Agreement and the consummation of
the transactions contemplated by this Agreement, including the Offer and the Merger, and declared it advisable for Parent to enter into this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent, Merger Sub and the Company desire to make certain representations,
warranties, covenants and agreements specified in this Agreement in connection with this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, as promptly as
practicable following the date of this Agreement (but no later than the first Business Day that the Secretary of State of the State of Delaware is open to permit such formation and return evidence thereof), Parent shall form Merger Sub as a Delaware
corporation and a directly wholly owned subsidiary of Parent and cause Merger Sub to enter into the&nbsp;Joinder;<U>&nbsp;provided</U>&nbsp;that from the execution of this Agreement and until such time as Merger Sub is formed and
the&nbsp;Joinder&nbsp;is duly executed and delivered to the Company, Parent shall assume all of the rights and be subject to all of the obligations of Merger Sub pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained in this Agreement,
and intending to be legally bound, Parent, Merger Sub and the Company agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFER AND MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <U>The </U><U>Offer</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement, as promptly as practicable (but in no event, subject to the Company having timely
provided any information required to be provided by it pursuant to <U>Section</U><U></U><U>&nbsp;1.1(e)</U> and <U>Section</U><U></U><U>&nbsp;1.2(c)</U>), later than ten (10)&nbsp;Business Days after the initial public announcement of this
Agreement), Merger Sub shall, and Parent shall cause Merger Sub to, commence the Offer within the meaning of the applicable rules and regulations of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The obligations of Merger Sub to, and of Parent to cause Merger Sub to, accept for payment, and thereafter pay for, any Shares validly
tendered and not properly withdrawn pursuant to the Offer shall be subject only to the satisfaction or waiver of the conditions set forth in <U>Exhibit A</U> (collectively, the &#147;<U>Offer Conditions</U>&#148;). The Offer shall initially be
scheduled to expire at one minute after 11:59 p.m., New York City time, on the 20th business day (determined using Rule <FONT STYLE="white-space:nowrap">14d-1(g)(3)</FONT> of the Exchange Act) following the commencement (within the meaning of Rule <FONT
STYLE="white-space:nowrap">14d-2</FONT> of the Exchange Act) of the Offer. Merger Sub expressly reserves the right to waive any Offer Condition or modify the terms of the Offer in any manner not inconsistent with this Agreement, except that, without
the prior written consent of the Company, Merger Sub shall not, and Parent shall not permit Merger Sub to, (i)&nbsp;reduce the number of Shares subject to the Offer, (ii)&nbsp;reduce the Offer Price, (iii)&nbsp;change the form of consideration
payable in the Offer, (iv)&nbsp;waive, amend or modify the Minimum Tender Condition, the Regulatory Condition, the Absence of Legal Restraint Condition or the Termination Condition, (v)&nbsp;impose conditions or requirements to the Offer other than
the Offer Conditions or amend, modify or supplement any Offer Condition in any manner adverse to the holders of Shares (in their capacity as such), (vi) except as otherwise provided in this <U>Section</U><U></U><U>&nbsp;1.1</U>, terminate, or extend
or otherwise amend or modify the expiration date of, the Offer, (vii)&nbsp;otherwise amend, modify or supplement any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the terms of the Offer in any manner adverse to the holders of Shares or (viii)&nbsp;provide any &#147;subsequent offering period&#148; in accordance with Rule
<FONT STYLE="white-space:nowrap">14d-11</FONT> of the Exchange Act. Notwithstanding the foregoing, Merger Sub shall, and Parent shall cause Merger Sub to, on the terms and subject to the Offer Conditions and conditions of the Offer and this
Agreement, (A)&nbsp;extend the Offer for one or more consecutive increments of not more than ten (10)&nbsp;Business Days each (or for such longer period as may be mutually agreed by Parent and the Company), if at the scheduled expiration time of the
Offer the Minimum Offer Condition or any of the other Offer Conditions shall not have been satisfied or waived, until such time as such conditions shall have been satisfied or waived and (B)&nbsp;extend the Offer for the minimum period required by
any rule, regulation or interpretation or position of the SEC or the staff thereof applicable to the Offer; <U>provided</U>, <U>however</U>, that, notwithstanding the foregoing, if at the otherwise scheduled expiration time of the Offer, each Offer
Condition (other than the Minimum Tender Condition and any conditions that by their nature are to be satisfied at the expiration of the Offer and that would be capable of being satisfied or waived by Parent were the expiration of the Offer to occur
at such time) shall have been satisfied or waived and the Minimum Tender Condition shall not have been satisfied, Merger Sub and Parent shall have no obligation to extend the Offer in such circumstances on more than three (3)&nbsp;occasions, with
each such extension to be for ten (10)&nbsp;Business Days unless the Company agrees otherwise in writing; <U>provided</U> further that in no circumstances shall Merger Sub or Parent extend the Offer such that the Acceptance Time would occur beyond
the End Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On the terms and subject only to the conditions of the Offer and this Agreement, Merger Sub shall, and Parent shall
cause Merger Sub to, (i)&nbsp;accept for payment all Shares validly tendered and not properly withdrawn pursuant to the Offer immediately after the expiration of the Offer (and in any event prior to 8:00 a.m., New York City time, on the first
Business Day starting at (if the expiration time occurs on a Business Day) or following (if the expiration time does not occur on a Business Day) the expiration time of the Offer) (the time of such acceptance, the &#147;<U>Acceptance Time</U>&#148;)
and (ii)&nbsp;pay the Offer Price for such Shares promptly after (and, in any event, no later than the second Business Day after) the Acceptance Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Offer may not be terminated prior to its expiration date (as such expiration date may be extended in accordance with this
<U>Section</U><U></U><U>&nbsp;1.1</U>), unless this Agreement is validly terminated in accordance with <U>Section</U><U></U><U>&nbsp;7.1</U>. If this Agreement is validly terminated in accordance with <U>Section</U><U></U><U>&nbsp;7.1</U>, Merger
Sub shall, and Parent shall cause Merger Sub to, immediately, irrevocably and unconditionally terminate the Offer, and Merger Sub shall neither acquire nor pay for Shares pursuant to the Offer. If the Offer is terminated or withdrawn by Merger Sub
in accordance with the terms of this Agreement, Merger Sub shall, and Parent shall cause Merger Sub to, promptly return, and Parent and Merger Sub shall cause any depository acting on behalf of Merger Sub to return, all tendered Shares to the
registered holders thereof. Nothing contained in this <U>Section</U><U></U><U>&nbsp;1.1</U> shall affect any termination rights set forth in <U>Section</U><U></U><U>&nbsp;7.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As promptly as reasonably practicable on the date of commencement (within the meaning of Rule
<FONT STYLE="white-space:nowrap">14d-2</FONT> of the Exchange Act) of the Offer, Parent and Merger Sub shall file with the SEC a tender offer statement on Schedule TO with respect to the Offer, which shall contain or incorporate by reference an
offer to purchase and a related letter of transmittal and summary advertisement (such Schedule TO and the documents included therein pursuant to which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Offer will be made, together with any exhibits, supplements or amendments thereto, the &#147;<U>Offer Documents</U>&#148;) and shall disseminate the Offer Documents to the holders of Shares
as and to the extent required by applicable U.S. federal securities Laws. The Company shall furnish to Parent and Merger Sub all information concerning the Company required by the Exchange Act to be set forth in the Offer Documents. Each of Parent,
Merger Sub and the Company shall promptly correct any information provided by it for use in the Offer Documents if and to the extent that such information shall have become false or misleading in any material respect, and to correct any material
omissions therefrom, and each of Parent and Merger Sub shall take all steps necessary to amend or supplement the Offer Documents and to cause the Offer Documents, as so amended or supplemented, to be filed with the SEC and disseminated to the
holders of Shares, in each case as and to the extent required by applicable federal securities Laws. Parent and Merger Sub shall provide the Company and its counsel with copies of any written comments, and shall inform the Company and its counsel of
any oral comments, that Parent, Merger Sub or their counsel may receive from the SEC or its staff with respect to the Offer Documents promptly after the receipt of such comments. Except from and after a Change of Recommendation, prior to the filing
of the Offer Documents (including any amendment or supplement thereto) with the SEC or its staff or the dissemination thereof to the holders of Shares, or responding to any comments of the SEC or its staff with respect to the Offer Documents, Parent
and Merger Sub shall provide the Company and its counsel a reasonable opportunity to review and comment on such Offer Documents or response (including the proposed final version thereof), and Parent and Merger Sub shall give reasonable and good
faith consideration to any comments made by the Company or its counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Parent shall provide or cause to be provided to Merger Sub on
a timely basis the funds necessary to purchase any Shares that Merger Sub becomes obligated to purchase pursuant to the Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
Without limiting the other provisions of this Agreement, if, between the date of this Agreement and the Acceptance Time, the outstanding Shares shall have been changed into a different number of shares or a different class of shares by reason of any
stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, exchange of shares or other similar transaction, then the Offer Price shall be equitably adjusted, without duplication,
to proportionally reflect such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>Company Actions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company hereby approves of and consents to the Offer, the Merger and the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Unless the Company Board has made a Change of Recommendation in accordance with <U>Section</U><U></U><U>&nbsp;5.4(c)</U> or
<U>Section</U><U></U><U>&nbsp;5.4(d)</U>, on the date the Offer Documents are filed with the SEC, the Company shall file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer (such Schedule 14D-9, as
amended or supplemented from time to time, together with any exhibits, amendments or supplements thereto, the &#147;<U>Schedule 14D-9</U>&#148;), including a description of the Company Recommendation (except to the extent that the Company Board
shall have withdrawn the Company Recommendation in accordance with Section </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
5.4(c) or Section&nbsp;5.4(d)), and, as and to the extent required by applicable U.S. federal securities Laws, shall disseminate the Schedule 14D-9 to the holders of Shares. The Schedule <FONT
STYLE="white-space:nowrap">14D-9</FONT> shall also contain the notice of appraisal rights required to be delivered by the Company pursuant to Section&nbsp;262(d) of the DGCL at the time the Company first files the Schedule <FONT
STYLE="white-space:nowrap">14D-9</FONT> with the SEC. Parent and Merger Sub shall furnish to the Company all information concerning Parent and Merger Sub required by the Exchange Act to be set forth in the Schedule 14D-9. Each of the Company, Parent
and Merger Sub shall promptly correct any information provided by it for use in the Schedule 14D-9 if and to the extent that such information shall have become false or misleading in any material respect, and to correct any material omissions
therefrom, and the Company shall take all steps necessary to amend or supplement the Schedule 14D-9 and to cause the Schedule 14D-9, as so amended or supplemented, to be filed with the SEC and disseminated to the holders Shares, in each case as and
to the extent required by applicable federal securities Laws. The Company shall provide Parent and its counsel with copies of any written comments, and shall inform Parent and its counsel of any oral comments, that the Company or its counsel may
receive from the SEC or its staff with respect to the Schedule 14D-9 promptly after the receipt of such comments. Except from and after a Change of Recommendation made in accordance with <U>Section</U><U></U><U>&nbsp;5.4(c)</U> or
<U>Section</U><U></U><U>&nbsp;5.4(d)</U>, prior to the filing of the Schedule 14D-9 (including any amendment or supplement thereto) with the SEC or the dissemination thereof to the holders of Shares, or responding to any comments of the SEC or its
staff with respect to the Schedule 14D-9, the Company shall provide Parent and its counsel a reasonable opportunity to review and comment on such Schedule 14D-9 or response (including the proposed final version thereof), and the Company shall give
reasonable and good faith consideration to any comments made by Parent or its counsel. The Company hereby consents to the inclusion in the Offer Documents of a description of the Company Recommendation (except to the extent that the Company Board
shall have withdrawn the Company Recommendation in accordance with <U>Section</U><U></U><U>&nbsp;5.4(c)</U> or <U>Section</U><U></U><U>&nbsp;5.4(d)</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In connection with the Offer, the Company shall cause its transfer agent to promptly furnish Merger Sub with mailing labels containing the
names and addresses of the record holders of Shares as of a recent date and of those Persons becoming record holders subsequent to such date, together with copies of all lists of stockholders, security position listings, computer files and all other
information in the Company&#146;s possession or control regarding the beneficial owners of Shares, and shall furnish to Merger Sub such information and assistance (including updated lists of stockholders, security position listings and computer
files) as Parent may reasonably request in communicating the Offer and disseminating the Offer Documents to the holders of Shares. Subject to the requirements of applicable Law, and except for such steps as are necessary to disseminate the Offer
Documents and any other documents necessary to consummate the transactions contemplated by this Agreement, Parent and Merger Sub shall hold in confidence the information contained in any such labels, lists, listings, files and other information
regarding the beneficial owners of Shares provided pursuant to this <U>Section</U><U></U><U>&nbsp;1.2(c)</U>, shall use such information only in connection with the Offer and the Merger and, if this Agreement shall be terminated, shall, upon
request, deliver to the Company or destroy all copies of such information (and certify in writing to the Company such destruction, if applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3 <U>The Merger</U>. On the terms and subject to the conditions set forth in
this Agreement, and in accordance with Section&nbsp;251(h) of the DGCL, at the Effective Time, Merger Sub shall merge with and into the Company, the separate corporate existence of Merger Sub shall cease and the Company shall continue its corporate
existence under the Laws of the State of Delaware as the surviving corporation in the Merger (the &#147;<U>Surviving Corporation</U>&#148;) and a direct wholly owned Subsidiary of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4 <U>Closing</U>. The closing of the Merger (the &#147;<U>Closing</U>&#148;) shall take place at the offices of Wachtell,
Lipton, Rosen&nbsp;&amp; Katz, 51 West 52nd Street, New York, New York 10019, or remotely by exchange of documents and signatures (or their electronic counterparts), as soon as practicable following (but in any event on the same date as) the
Acceptance Time, except if the conditions set forth in <U>Article 6</U> shall not be satisfied or, to the extent permitted by applicable Law, waived as of such date, in which case the Closing shall take place on the first Business Day on which all
conditions set forth in <U>Article 6</U> are satisfied or, to the extent permitted by applicable Law, waived, unless another date or place is agreed to in writing by the Company and Parent prior to the Acceptance Time. The date on which the Closing
actually occurs is referred to as the &#147;<U>Closing Date</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5 <U>Effective Time</U>. Subject to the provisions
of this Agreement, at the Closing, the Company shall file a certificate of merger (the &#147;<U>Certificate of Merger</U>&#148;) in accordance with Section&nbsp;251(h) of the DGCL with the Delaware Secretary of State and make all other filings or
recordings required by the DGCL in connection with the Merger. The Merger shall become effective at such time as the Certificate of Merger is duly filed with the Delaware Secretary of State or at such later date or time as may be agreed by the
Company and Parent and specified in the Certificate of Merger in accordance with the DGCL (the effective time of the Merger being referred to as the &#147;<U>Effective Time</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6 <U>Effects of the Merger</U>. The Merger shall have the effects set forth in this Agreement and the applicable provisions of
the DGCL. Without limiting the generality of the foregoing and subject thereto, from and after the Effective Time, all property, rights, privileges, immunities, powers, franchises, licenses and authority of each of the Company and Merger Sub shall
vest in the Surviving Corporation, and all debts, liabilities, obligations, restrictions and duties of each of the Company and Merger Sub shall become the debts, liabilities, obligations, restrictions and duties of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.7 <U>Organizational Documents of the Surviving Corporation</U>. Subject to <U>Section</U><U></U><U>&nbsp;5.9</U>, at the
Effective Time: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the certificate of incorporation of the Surviving Corporation shall be amended and restated as of the Effective Time
to conform to <U>Exhibit B</U>; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the bylaws of Merger Sub as in effect immediately prior to the Effective Time (but amended so
that the name of the Surviving Corporation shall be &#147;Inari Medical, Inc.&#148;), as so amended, shall be the bylaws of the Surviving Corporation until thereafter amended in accordance with the DGCL and such bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8 <U>Directors of the Surviving Corporation</U>. Subject to applicable Law, the directors of Merger Sub as of immediately prior
to the Effective Time shall be the initial directors of the Surviving Corporation and shall hold office until their respective successors are duly elected and qualified, or their earlier death, incapacitation, retirement, resignation or removal.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9 <U>Officers</U><U> of the Surviving Corporation</U>. The officers of the
Company as of immediately prior to the Effective Time shall be the initial officers of the Surviving Corporation and shall hold office until their respective successors are duly appointed and qualified, or their earlier death, incapacitation,
retirement, resignation or removal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>Effect on Capital Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, by virtue of the Merger and without any action on the part of the Company, Merger Sub or the holders of any
securities of the Company or Merger Sub: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Conversion of Common Stock</U>. Each Share that is issued and outstanding
immediately prior to the Effective Time, but excluding Cancelled Shares and Dissenting Shares, shall be converted automatically into the right to receive the Offer Price in cash without any interest thereupon (the &#147;<U>Merger
Consideration</U>&#148;) and less any required withholdings as provided in <U>Section</U><U></U><U>&nbsp;2.2(b)(iv)</U>. All Shares that have been converted into the right to receive the Merger Consideration as provided in this
<U>Section</U><U></U><U>&nbsp;2.1(a)</U> shall be automatically cancelled upon the conversion thereof and shall cease to exist, and the holders of Book-Entry Shares or Certificates that immediately prior to the Effective Time represented such Shares
shall cease to have any rights with respect to such Shares other than the right to receive the Merger Consideration, upon surrender of such Certificates or Book-Entry Shares in accordance with <U>Section</U><U></U><U>&nbsp;2.2</U>, subject to
<U>Section</U><U></U><U>&nbsp;2.2(b)(iv)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Cancellation of Shares</U>. Each Share that (i)&nbsp;is owned by the
Company or any wholly owned Subsidiary of the Company as treasury stock or otherwise, (ii)&nbsp;is owned, directly or indirectly, immediately prior to the Effective Time, by Parent or Merger Sub or any wholly owned Subsidiary of Parent, or
(iii)&nbsp;is irrevocably accepted for purchase pursuant to the Offer (collectively, the &#147;<U>Cancelled Shares</U>&#148;) shall be cancelled and shall cease to exist, and no consideration shall be delivered in exchange therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Conversion of Merger Sub Common Stock</U>. Each share of common stock, par value $0.01 per share, of Merger Sub issued
and outstanding immediately prior to the Effective Time shall be converted automatically into and become one validly issued, fully paid and nonassessable share of common stock, par value $0.01 per share, of the Surviving Corporation with the same
rights, powers and privileges as the shares so converted and shall constitute the only outstanding shares of capital stock of the Surviving Corporation. From and after the Effective Time, all certificates representing the common stock of Merger Sub
(if any) shall be deemed for all purposes to represent the number of shares of common stock of the Surviving Corporation into which they were converted in accordance with the immediately preceding sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Dissenters</U><U>&#146;</U><U> Rights</U>. Notwithstanding any provision of this
Agreement to the contrary, if required by the DGCL (but only to the extent required thereby), Shares that are issued and outstanding immediately prior to the Effective Time (other than the Cancelled Shares) and that are held by holders of such
Shares who are entitled to demand and properly demand appraisal of such Shares, as applicable (the &#147;<U>Dissenting Shares</U>&#148;), pursuant to, and who have properly exercised and perfected their demands for appraisal rights under and comply
in all respects with, Section&nbsp;262 of the DGCL (the &#147;<U>Appraisal Rights</U>&#148;) shall not be converted into the right to receive the Merger Consideration, and holders of such Dissenting Shares shall be entitled to receive payment of the
appraised value of such Dissenting Shares in accordance with the Appraisal Rights (it being understood and acknowledged that such Dissenting Shares shall no longer be outstanding, shall automatically be cancelled and shall cease to exist as of the
Effective Time, and any such holder shall cease to have any rights with respect thereto other than the right to receive the appraised value of such Dissenting Shares to the extent afforded by the Appraisal Rights); <U>provided</U>, <U>however</U>,
that if any such holder shall fail to perfect or otherwise shall waive, withdraw or lose the right to payment of the fair value of such Dissenting Shares under the Appraisal Rights, then the right of such holder to be paid the fair value of such
Dissenting Shares shall cease and such Shares shall be deemed not to be Dissenting Shares and shall be deemed to have been converted as of the Effective Time into, and to have become exchangeable solely for the right to receive, without interest
thereon or duplication, the Merger Consideration pursuant to <U>Section</U><U></U><U>&nbsp;2.1(a)</U>, subject to <U>Section</U><U></U><U>&nbsp;2.2(b)(iv)</U>. The Company shall give Parent (i)&nbsp;prompt notice of any demands received by the
Company for appraisals of Shares, withdrawals of such demands and any other instruments served on the Company pursuant to Section&nbsp;262 of the DGCL and (ii)&nbsp;the reasonable opportunity to participate in all negotiations and proceedings with
respect to such demands. The Company shall not, except with the prior written consent of Parent, make any payment with respect to any demands for appraisal or offer to settle or settle any such demands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Certain Adjustments</U>. If, between the date of this Agreement and the Effective Time, the outstanding Shares shall have been changed
into a different number of shares or a different class of shares by reason of any stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, exchange of shares or other similar
transaction, then the Merger Consideration shall be equitably adjusted, without duplication, to proportionally reflect such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Exchange of Certificates</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Paying Agent</U>. Prior to the Acceptance Time, Parent shall enter into an agreement (in form and substance reasonably acceptable to
the Company) with a reputable bank or trust company reasonably acceptable to the Company (which may be the Company&#146;s transfer agent) to act as agent (the &#147;<U>Depository Agent</U>&#148;) for holders of Shares to receive the aggregate Offer
Price to which such holders shall become entitled pursuant to <U>Section</U><U></U><U>&nbsp;1.1</U> and to act as paying agent (the &#147;<U>Paying Agent</U>&#148;) for holders of Shares to receive the aggregate Merger Consideration to which such
holders shall become entitled pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>. Parent shall deposit, or shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cause to be deposited, (x)&nbsp;at or promptly after the Acceptance Time, with the Depository Agent, in trust for the benefit of holders of Shares validly tendered in the Offer, cash in U.S.
dollars sufficient to pay the aggregate Offer Price for all Shares validly tendered in the Offer; and (y)&nbsp;at or promptly following the Effective Time, with the Paying Agent, in trust for the benefit of holders of Shares, cash in U.S. dollars
sufficient to pay the aggregate Merger Consideration in exchange for all of the Shares outstanding immediately prior to the Effective Time (other than the Cancelled Shares and Dissenting Shares), payable upon due surrender of the certificates that,
immediately prior to the Effective Time, represented Shares (&#147;<U>Certificates</U>&#148;) (or effective affidavits of loss in lieu thereof) or for noncertificated Shares represented by book-entry (&#147;<U>Book-Entry Shares</U>&#148;) pursuant
to the provisions of this <U>Article 2</U> (such cash described in clauses <U>(x)</U>&nbsp;and <U>(y)</U>, collectively, being referred to as the &#147;<U>Payment Fund</U>&#148;). In the event the Payment Fund shall be insufficient to pay the
aggregate Offer Price or aggregate Merger Consideration in accordance with <U>Section</U><U></U><U>&nbsp;1.1</U> and <U>Section</U><U></U><U>&nbsp;2.1(a)</U>, Parent shall promptly deposit, or cause to be deposited, additional funds with the
Depository Agent or Paying Agent, as applicable, in an amount that is equal to the shortfall that is required to make such payment. Parent shall cause the Depository Agent to make, and the Depository Agent shall make, delivery of the Offer Price out
of the Payment Fund in accordance with this Agreement. Parent shall cause the Paying Agent to make, and the Paying Agent shall make, delivery of the Merger Consideration out of the Payment Fund in accordance with this Agreement. The Payment Fund
shall not be used for any purpose other than to pay the aggregate Offer Price in the Offer and the aggregate Merger Consideration in the Merger, except as otherwise expressly provided for in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment Procedures</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) As soon as reasonably practicable after the Effective Time and in any event not later than the fifth (5th) Business Day
following the Closing Date, Parent shall cause the Paying Agent to mail to each holder of record of Certificates and Book-Entry Shares (as applicable), in each case, whose Shares were converted into the right to receive the Merger Consideration
pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, (A) a letter of transmittal in customary form reasonably acceptable to the Company and Parent (which shall specify that, with respect to Shares represented by Certificates, delivery shall be
effected, and risk of loss and title to Certificates shall pass, only upon delivery of Certificates (or effective affidavits of loss in lieu thereof) to the Paying Agent), and (B)&nbsp;instructions for use in effecting the surrender of Certificates
(or effective affidavits of loss in lieu thereof) or Book-Entry Shares, as applicable, in exchange for the Merger Consideration. Upon surrender of Certificates (or effective affidavits of loss in lieu thereof) to the Paying Agent, together with such
letter of transmittal, duly completed and validly executed in accordance with the instructions thereto, or receipt of an &#147;agent&#146;s message&#148; by the Paying Agent (or such other evidence, if any, of transfer to the Paying Agent as the
Paying Agent may reasonably request) in the case of such Book-Entry Shares, together with a letter of transmittal, duly completed and validly executed in accordance with the instructions thereto, and, in each case, such other documents as may
customarily be required by the Paying Agent, (A)&nbsp;the holder of such Certificates (or effective affidavits of loss in lieu thereof) or Book-Entry Shares shall be entitled to receive in exchange therefor an amount in cash in U.S. dollars equal to
the product of (x)&nbsp;the number of Shares represented by such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
holder&#146;s properly surrendered Certificates (or effective affidavits of loss in lieu thereof) or Book-Entry Shares and (y)&nbsp;the Merger Consideration, without any interest thereupon and
less any required withholdings as provided in <U>Section</U><U></U><U>&nbsp;2.2(b)(iii)</U>, and (B)&nbsp;such Certificate, if applicable, so surrendered shall be cancelled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Company and Parent shall cooperate to, and Parent shall cause the Paying Agent to, (A)&nbsp;deliver to the Depository
Trust Company (&#147;<U>DTC</U><U>&#148;</U>) to the extent applicable or required, any notice with respect to the effectiveness of the Merger and any instructions for surrendering Book-Entry Shares and (B)&nbsp;establish procedures with DTC to
ensure that the Paying Agent will transmit to DTC as soon as reasonably practicable after the Effective Time, upon surrender of Shares held of record by DTC in accordance with DTC&#146;s customary surrender procedures (but in no event later than the
fifth (5th) Business Day thereafter), the Merger Consideration payable for each such Book-Entry Share (less any required withholdings as provided in <U>Section</U><U></U><U>&nbsp;2.2(b)(iv))</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) No interest shall be paid or accrued on any amount payable upon due surrender of Certificates (or effective affidavits of
loss in lieu thereof) or with respect to Book-Entry Shares. In the event of a transfer of ownership of Shares that is not registered in the transfer records of the Company, payment of the Merger Consideration upon due surrender of a Certificate may
be paid to such a transferee if the Certificate formerly representing such Shares is presented to the Paying Agent, accompanied by all documents required to evidence and effect such transfer and to evidence that any applicable stock transfer Taxes
have been paid or are not applicable.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) The Paying Agent, the Depository Agent, the Company, Parent and Merger Sub, as
applicable, shall be entitled to deduct and withhold from any amounts otherwise payable under this Agreement such amounts as are required to be withheld or deducted under the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;),
or under any provision of applicable state, local or foreign Tax Law with respect to the making of such payment. To the extent that amounts are so deducted or withheld and timely and properly paid over to the relevant Governmental Entity, such
deducted or withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction or withholding was made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Until surrendered as contemplated by this <U>Section</U><U></U><U>&nbsp;2.2(b)</U>, each Certificate or Book-Entry Share
shall be deemed, from and after the Effective Time, to represent only the right to receive the Merger Consideration, as contemplated by <U>Section</U><U></U><U>&nbsp;2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Closing of Transfer Books</U>. The Merger Consideration paid in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;2.2</U>
as a result of the conversion of any Shares shall be deemed to have been paid in full satisfaction of all rights pertaining to such Shares. At the Effective Time, the stock transfer books of the Company shall be closed, and there shall be no further
registration of transfers on the stock transfer books of the Surviving Corporation of Shares that were outstanding immediately prior to the Effective Time. If, after the Effective Time, Certificates are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
presented to the Surviving Corporation or the Paying Agent for transfer or any other reason, the holder of any such Certificates shall be given a copy of the letter of transmittal referred to in
<U>Section</U><U></U><U>&nbsp;2.2(b)</U> and instructed to comply with the instructions in that letter of transmittal in order to receive the cash to which such holder is entitled pursuant to this <U>Article 2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Payment Fund</U>. Any portion of the Payment Fund (including the proceeds of any investments thereof) that remains
undistributed to the former holders of Shares on the first (1st) anniversary of the Effective Time shall thereafter be delivered to the Surviving Corporation upon demand, and any former holders of Shares (other than Dissenting Shares or Cancelled
Shares) who have not received their portion of the Merger Consideration shall thereafter look only to the Surviving Corporation for payment of their claim for the Merger Consideration, without any interest thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>No Liability</U>. Anything in this Agreement to the contrary notwithstanding, none of the Company, Parent, Merger Sub, the Surviving
Corporation, the Paying Agent or any other Person shall be liable to any former holder of Shares for any amount properly delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. Any amounts remaining
unclaimed by holders of Shares two (2)&nbsp;years after the Effective Time (or such earlier date, immediately prior to such time when the amounts would otherwise escheat to or become property of any Governmental Entity) shall become, to the extent
permitted by applicable Law, the property of Parent free and clear of any claims or interest of any Person previously entitled thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Investment of Payment Fund</U>. The Paying Agent shall invest all cash included in the Payment Fund as reasonably directed by Parent;
<U>provided</U>, <U>however</U>, that any investment of such cash shall be limited to direct short-term obligations of, or short-term obligations fully guaranteed as to principal and interest by, the U.S. Government; <U>provided</U>, <U>further</U>,
that no such investment or loss thereon shall affect the amounts payable to holders of Certificates (or effective affidavits of loss in lieu thereof) or Book-Entry Shares pursuant to <U>Article 1</U> or this <U>Article 2</U>, and following any
losses from any such investment, Parent shall promptly provide additional funds to the Paying Agent for the benefit of the holders of Shares receiving the Offer Price pursuant to <U>Section</U><U></U><U>&nbsp;1.1</U> or the Merger Consideration
pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, as applicable. Any interest and other income resulting from such investments shall be paid to the Surviving Corporation pursuant to <U>Section</U><U></U><U>&nbsp;2.2(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Lost Certificates</U>. In the case of any Certificate that has been lost, stolen or destroyed, upon the making of an affidavit of that
fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by the Surviving Corporation or the Paying Agent, the posting by such Person of a bond, in a customary amount as Parent may direct, as indemnity against
any claim that may be made against it with respect to such Certificate, the Paying Agent or the Surviving Corporation, as applicable, shall issue in exchange for the Shares formerly represented by such lost, stolen or destroyed Certificate, the
applicable Merger Consideration to be paid in respect of such Shares, without any interest thereon and less any applicable Tax withholding as required by <U>Section</U><U></U><U>&nbsp;2.2(b)(iv)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>Treatment of Company Equity Awards</U><U> and Company ESPP</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Company RSU Awards</U>. At the Effective Time, and without any action on the part of Parent, the Company or any other Person, each
Company RSU Award that is outstanding immediately prior to the Effective Time, whether vested or unvested, shall fully vest (to the extent unvested) and be canceled in exchange for the right of the holder thereof to receive (subject to any
applicable withholdings) an amount in cash equal to the product of (i)&nbsp;the Merger Consideration, multiplied by (ii)&nbsp;the total number of Shares subject to such Company RSU Award, together with any accrued and unpaid dividends corresponding
to such Company RSU Award. For purposes of clause (ii)&nbsp;of the immediately preceding sentence, the total number of Shares subject to a performance-based Company RSU Award shall be based on deemed achievement of maximum performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Company Options</U>. At the Effective Time, and without any action on the part of Parent, the Company or any other Person, each Company
Option that is outstanding immediately prior to the Effective Time, whether vested or unvested, shall fully vest (to the extent unvested) and be canceled in exchange for the right of the holder thereof to receive (subject to any applicable
withholdings) an amount in cash equal to the product of (i)&nbsp;the excess (if any) of the Merger Consideration over the per share exercise price of such Company Option, multiplied by (ii)&nbsp;the total number of Shares subject to such Company
Option. For the avoidance of doubt, any Company Option that has an exercise price that equals or exceeds the Merger Consideration shall be canceled for no consideration, and the holder thereof shall have no further rights with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Company ESPP</U>. As soon as practicable following the date hereof, the Company shall take all actions with respect to the Company ESPP
that are necessary to provide that (i)&nbsp;with respect to the offering period under the Company ESPP in effect as of the date hereof, if any (the &#147;<U>ESPP Offering Period</U>&#148;), no individual who was not a participant in the Company ESPP
as of the date hereof may enroll in the Company ESPP with respect to such ESPP Offering Period and no participant may increase the percentage amount of his or her payroll deduction election from that in effect on the date hereof for such ESPP
Offering Period, (ii)&nbsp;no new offering period shall be commenced under the Company ESPP prior to the Effective Time, and (iii)&nbsp;if the applicable purchase date with respect to the ESPP Offering Period would otherwise occur on or after the
Acceptance Time, then the ESPP Offering Period will be shortened and the applicable purchase date with respect to such ESPP Offering Period will occur on the day that is five (5)&nbsp;Business Days prior to the date on which the Acceptance Time
occurs. The Company ESPP shall terminate, effective as of no later than the fifth trading day before the Effective Time, subject to the occurrence of the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Company Equity Plans</U>. The Company Equity Plans will each be terminated effective as of the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The payments described in <U>Section</U><U></U><U>&nbsp;2.3(a)</U> and
<U>Section</U><U></U><U>&nbsp;2.3(b)</U> shall be made by the Surviving Corporation as promptly as reasonably possible (and in any event within five (5)&nbsp;Business Days) after the Effective Time or at such later date required to avoid the
imposition of Taxes under Section&nbsp;409A of the Code. Prior to the Effective Time, the Company shall take such actions as are necessary to approve and effectuate the provisions set forth in this <U>Section</U><U></U><U>&nbsp;2.3</U>, including to
make any determinations or adopt resolutions providing for the treatment of Company Equity Awards, the Company Equity Plans and the Company ESPP contemplated by this <U>Section</U><U></U><U>&nbsp;2.3</U>, subject to Parent being provided a
reasonable opportunity to review and comment on the form of such resolutions (which comments shall be considered in good faith by the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Loan Payoff</U>. Prior to or substantially concurrently with the Closing, the Company shall (i)&nbsp;pay, or cause to be
paid (or in the case of any letters of credit, cash collateralize, to the extent Parent shall not have entered into an alternative arrangement with the issuing bank), all amounts necessary to fully repay all then outstanding loans and other
obligations, (ii)&nbsp;use reasonable best efforts to terminate all commitments and release all related Liens and (iii)&nbsp;use reasonable best efforts to satisfy all applicable notification requirements, in each case of clause (i)&nbsp;through
(iii) immediately above, under the Company Credit Agreement and the other Existing Loan Documents (as defined below); <U>provided</U> (x)&nbsp;Parent shall provide all funds required to effect such repayment (or cash collaterization), termination
and release and (y)&nbsp;any notices related thereto shall be expressly conditioned on the Closing. The Company shall use reasonable best efforts to obtain, no later than three (3)&nbsp;Business Days prior to the Closing Date, a draft of, and on or
prior to the Closing Date, an executed copy of, a customary payoff letter from the lenders (or administrative agent on their behalf) under the Company Credit Agreement (the &#147;<U>Payoff Letter</U>&#148;) for the Existing Loan Documents, which
Payoff Letter shall provide, without limitation, (a)&nbsp;the amount of unpaid principal, all accrued but unpaid interest and all fees, expenses and other amounts and obligations required to be paid under the Company Credit Agreement and the other
Loan Documents (as defined in the Company Credit Agreement) (collectively with the Company Credit Agreement, the &#147;<U>Existing Loan Documents</U>&#148;), including any prepayment fees and penalties, in order to repay all amounts due and owing
under the Existing Loan Documents as of the Closing Date (the &#147;<U>Payoff Amount</U>&#148;) and (b)&nbsp;that immediately upon receipt of the Payoff Amount and subject to any applicable cash collateralization or similar requirements in the
Existing Loan Documents, (i)&nbsp;all indebtedness, commitments, liabilities and other obligations (other than any obligations that, by their express terms or as otherwise specified in the Payoff Letter, survive termination of the Existing Loan
Documents) under the Existing Loan Documents shall be paid and discharged in full, (ii)&nbsp;the Company Credit Agreement and other applicable Existing Loan Documents shall be terminated (other than provisions that by their express terms survive
termination of the Existing Loan Documents), (iii)&nbsp;guarantees, if any, securing such borrowings or obligations under the Existing Loan Documents shall be automatically released and terminated and (iv)&nbsp;all security interests, pledges and
Liens granted pursuant to the Existing Loan Documents shall be automatically released and the Company (or its designee, agent or representative) shall be authorized to prepare and file all appropriate termination filings and other documents to
evidence the release of the security interests and termination of the obligations set forth in the Existing Loan Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as disclosed in (a)&nbsp;the disclosure letter delivered by the Company to Parent concurrently with the execution of this Agreement
(the &#147;<U>Company Disclosure Letter</U>&#148;) (it being agreed that disclosure of any item in any section or subsection of the Company Disclosure Letter shall be deemed disclosed with respect to any other section or subsection of the Company
Disclosure Letter to the extent that the relevance thereof is reasonably apparent on the face of such disclosure to such other section or subsection) or (b)&nbsp;any Company SEC Report filed with the SEC at least one (1)&nbsp;Business Day prior to
the date of this Agreement and publicly available on the SEC&#146;s Electronic Data Gathering Analysis and Retrieval System (&#147;<U>EDGAR</U>&#148;) on or after January&nbsp;1, 2022 (the &#147;<U>Filed SEC Reports</U>&#148;), other than any
cautionary, predictive or forward-looking information that is contained under the captions &#147;Risk Factors&#148; or &#147;Forward-Looking Statements&#148; or other similar cautionary, predictive or forward-looking disclosures (such cautionary,
predictive, or forward-looking information, the &#147;<U>Excluded Forward-Looking Information</U>&#148;); <U>provided</U>, <U>however</U>, that the disclosure in the Filed SEC Reports shall not be deemed to qualify the representations in
<U>Section</U><U></U><U>&nbsp;3.2</U>, the Company represents and warrants to Parent and Merger Sub as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1
<U>Qualification, Organization, Subsidiaries</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is a legal entity duly organized, validly existing and in good standing
under the Laws of the State of Delaware. The Company has all requisite corporate power and authority to own, lease and operate its properties and assets and to carry on its business as presently conducted and is qualified to do business and is in
good standing as a foreign corporation in each jurisdiction where the ownership, leasing or operation of its assets or properties or conduct of its business requires such qualification, except, in each case, as has not had, or would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect. The Company has made available to Parent prior to the date of this Agreement a true and complete copy of the certificate of incorporation of the Company and
the bylaws of the Company, each as amended through the date hereof, and the Company is not in material violation of any of the provisions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company&#146;s Subsidiaries and their respective jurisdictions of organization are identified in Section&nbsp;3.1(b) of the Company
Disclosure Letter. Each Subsidiary of the Company is a legal entity duly organized, validly existing and in good standing under the Laws of its respective jurisdiction of organization and has all requisite corporate or similar power and authority to
own, lease and operate its properties and assets and to carry on its business as presently conducted and is qualified to do business and is in good standing as a foreign corporation in each jurisdiction where the ownership, leasing or operation of
its assets or properties or conduct of its business requires such qualification, except, in each case, as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. The
organizational or governing documents of the Company&#146;s Subsidiaries are in full force and effect, and none of the Company&#146;s Subsidiaries is in violation of any of the respective provisions thereof, except, in each case, as has not had, and
would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All of the outstanding shares of capital stock or voting securities of, or other equity
interests in, each of the Company&#146;s Subsidiaries are duly authorized and validly issued, are fully paid and nonassessable (and were not issued in violation of any preemptive rights or the DGCL), and are owned beneficially and of record by the
Company or another Acquired Company, free and clear of all Liens other than restrictions imposed by applicable securities Laws or the organizational documents of any such Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except for its interest in the Company&#146;s Subsidiaries, neither the Company nor any of its Subsidiaries owns, directly or indirectly,
any capital stock, membership interest, partnership interest, joint venture interest or other similar equity interests, or any securities convertible into or exchangeable or exercisable for such equity interests, in any other Person, in each case,
with a fair market value in excess of $5,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2 <U>Capitalization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of the Company consists of: (i) 300,000,000 Shares, of which 58,563,592 Shares were issued and outstanding as
of the close of business on December&nbsp;31, 2024 (the &#147;<U>Measurement Time</U>&#148;), and (ii) 10,000,000 shares of Company Preferred Stock, of which no shares were or are issued and outstanding as of the Measurement Time or the date of this
Agreement. As of the Measurement Time, no Shares are held by the Company as treasury stock. All of the outstanding Shares have been duly authorized and validly issued, and are fully paid and nonassessable (and were not issued in violation of any
preemptive rights or the DGCL). Except for Shares held by the Company as treasury stock, there are no Shares held by any of the Acquired Companies. None of the Acquired Companies is under any obligation, or is bound by any Contract pursuant to which
it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Shares or other securities of the Company (including any Company Equity Awards, except issuances pursuant to the forfeiture conditions of such Company Equity Awards
or the cashless exercise or Tax withholding provisions of or authorizations related to such Company Equity Awards as in effect as of the date of this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the Measurement Time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) 2,465,007 Shares are reserved for future issuance under the Company&#146;s Amended and Restated 2020 Employee Stock
Purchase Plan (the &#147;<U>Company ESPP</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) 1,786,658 Shares are subject to issuance or delivery pursuant to
Company RSU Awards granted and outstanding as of the Measurement Time under the Company Equity Plans (in the case of performance-vesting Company RSU Awards, assuming deemed achievement of maximum performance); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) 1,075,628 Shares are subject to issuance or delivery upon the exercise
of Company Options granted and outstanding as of the Measurement Time under the Company Equity Plans; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) no Company
Equity Awards are outstanding other than those granted under the Company Equity Plans and the Company ESPP and referenced in the preceding clauses (i)&nbsp;through (iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except (A)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;3.2(a)</U> and <U>Section</U><U></U><U>&nbsp;3.2(b)</U>, (B) for Shares
issued following the Measurement Time pursuant to the exercise or vesting of Company Equity Awards outstanding as of the Measurement Time pursuant to the terms of such awards as of the Measurement Time and (C)&nbsp;shares of capital stock, voting
securities or other equity interests of the Company&#146;s Subsidiaries that are held by the Company or another Acquired Company, as of the date of this Agreement there is no: (i)&nbsp;outstanding capital stock, equity security or equity interest or
equity-based compensation award of any Acquired Company; (ii)&nbsp;security, award or right convertible into or exercisable for any security, interest or award described in clause (i); (iii) any subscription, option, call, warrant, right, agreement,
arrangement or undertaking of any kind (whether or not currently exercisable) to which any Acquired Company is a party or by which any Acquired Company is bound obligating any Acquired Company to issue, transfer or sell or cause to be issued,
transferred or sold any security, interest, award or right described in the foregoing clauses (i)&nbsp;or (ii); or (iv)&nbsp;outstanding bond, debenture, note or other debt security of the Company having the right to vote (or any debt security
convertible into, or exercisable for exchangeable for, equity securities having the right to vote) on any matters on which stockholders of the Company may vote. All dividends or other distributions on the Shares that have been authorized or declared
prior to the date of this Agreement have been paid in full (except to the extent such dividends have been publicly announced and are not yet due and payable). There are no voting trusts or other agreements or understandings to which any Acquired
Company is a party with any third Person with respect to the voting of capital stock or other equity interests of any Acquired Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All outstanding Shares, options, warrants, equity-based compensation awards (whether payable in equity, cash or otherwise) and other
securities of the Acquired Companies have been issued and granted in compliance in all material respects with all applicable securities laws and other applicable Laws, including Section&nbsp;409A of the Code.&#8195;All Shares that may be issued
pursuant to any Company Equity Awards or as contemplated or permitted by this Agreement will be, when issued in accordance with the respective terms thereof, duly authorized, validly issued, fully paid and nonassessable (and not issued in violation
of any preemptive rights or the DGCL). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Section&nbsp;3.2(e) of the Company Disclosure Letter sets forth, as of the Measurement Time,
with respect to each Company Equity Award: (i)&nbsp;the name of the award holder; (ii)&nbsp;whether the Company Equity Award is a Company RSU Award or a Company Option (and denoting each Company RSU Award that is subject to performance-based vesting
conditions); (iii) the number of Shares subject to the award (in the case of performance-vesting Company RSU Awards, assuming deemed achievement of maximum performance); and (iv)&nbsp;the exercise price applicable to the award, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <U>Corporate Authority; Binding Nature of this Agreement</U>. The Company
has the necessary corporate power and authority to enter into, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated in this Agreement, including the Offer and the Merger. The Company Board (at a
meeting duly called and held) on or prior to the date of this Agreement has unanimously: (a)&nbsp;determined that the Offer, the Merger and the other transactions contemplated by this Agreement are fair to and in the best interests of the Company
and its stockholders; (b)&nbsp;duly authorized and approved the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement, including the Offer and the Merger; (c)&nbsp;resolved that
this Agreement and the Merger shall be effected pursuant to Section&nbsp;251(h) of the DGCL and that the Merger shall be consummated as soon as practicable following the Acceptance Time; (d)&nbsp;declared advisable this Agreement and the
transactions contemplated by this Agreement, including the Offer and the Merger; and (e)&nbsp;recommended that the holders of Shares accept the Offer and tender their Shares pursuant to the Offer (the &#147;<U>Company Recommendation</U>&#148;),
which resolutions, as of the date of this Agreement, have not been rescinded, modified or withdrawn in any way. This Agreement has been duly executed and delivered by the Company and, assuming due execution and delivery by Parent and Merger Sub,
constitutes the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. Assuming the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;4.8</U> are true and correct, and that the transactions contemplated by this Agreement are consummated in accordance with Section&nbsp;251(h) of the DGCL, no vote of the holders of any class or series of the
Company&#146;s capital stock is necessary to adopt this Agreement and approve the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4 <U>Consents</U>. The
execution, delivery and performance by the Company of this Agreement and the consummation of the Offer, the Merger and the other transactions contemplated by this Agreement by the Company do not and will not require the Company to procure, make or
provide any consent, approval, authorization or permit of, action by, filing with or notification to any Governmental Entity, other than (i)&nbsp;the filing of the Certificate of Merger, (ii)&nbsp;compliance with the HSR Act and other applicable
Antitrust Laws, (iii)&nbsp;compliance with any applicable Foreign Investment Law, (iv)&nbsp;compliance with the applicable requirements of the Exchange Act (including the filing with the SEC of the Schedule
<FONT STYLE="white-space:nowrap">14D-9),</FONT> and compliance with the rules and regulations of the NASDAQ Stock Market, and (v)&nbsp;the other consents or notices set forth in <U>Section</U><U></U><U>&nbsp;3.4</U> of the Company Disclosure Letter
(clauses (i)&nbsp;through (v), collectively, the &#147;<U>Company Approvals</U>&#148;), and other than any consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain has not had, or would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect and would not, individually or in the aggregate, reasonably be expected to prevent, materially delay or materially impede the Offer, the Merger or
any of the other transactions contemplated by this Agreement. As of the date hereof, the Company has no reason to believe that any Company Approval will not be granted or received in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5 <U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></U>. Assuming the receipt of the Company Approvals, the
execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Offer, the Merger and the other transactions contemplated by this Agreement, do not and will not: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) contravene, conflict with or result in a violation of (i)&nbsp;the certificate of incorporation or bylaws of the Company or (ii)&nbsp;any
organizational or governing documents of the Company&#146;s Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) contravene, conflict with or result in a violation of any Law or Order to which any of
the Acquired Companies, or any of the assets owned or used by any of the Acquired Companies, is subject; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) subject to any notices or
Consents set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> of the Company Disclosure Letter, contravene, conflict with or result in a violation or breach of, or result in a default (or an event which, with notice or lapse of time or both, would
constitute a default) under, any provision of any Material Contract, or give any Person the right to: (i)&nbsp;declare a default or exercise any remedy under any Material Contract; (ii)&nbsp;a penalty under any Material Contract;
(iii)&nbsp;accelerate the maturity or performance of any Material Contract; or (iv)&nbsp;cancel, terminate or modify any right, benefit, obligation or other term of any Material Contract; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) result in the creation of any Lien (other than Permitted Liens) upon any asset owned by any of the Acquired Companies; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except, in the case of clauses (b), (c) and (d)&nbsp;above, for any such contraventions, conflicts, violations, breaches, defaults, rights or Liens that has
not had, or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect and would not, individually or in the aggregate, reasonably be expected to prevent, materially delay or materially impede the
Offer, the Merger or any of the other transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.6 <U>Reports; Financial Statements</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All forms, documents and reports required to have been filed or furnished by the Company with the SEC since January&nbsp;1, 2022 (the
&#147;<U>Company SEC Reports</U>&#148;) have been so filed and, as of the date hereof, are publicly available on EDGAR. No Subsidiary of the Company is required to file any documents with the SEC. As of the time it was filed with the SEC (or, if
amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing) each of the Company SEC Reports complied in all material respects as to form with the applicable requirements of the Securities Act and the
Exchange Act (as the case may be) and the respective rules and regulations of the SEC promulgated thereunder applicable to such Company SEC Reports, and none of the Company SEC Reports as of such time contained any untrue statement of a material
fact or omitted to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that no representation is
made as to the accuracy of any financial projections or forward-looking statements or the completeness of any information filed or furnished by the Company to the SEC solely for the purposes of complying with Regulation FD promulgated under the
Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The consolidated financial statements (including any related notes) contained or
incorporated by reference in the Company SEC Reports comply as to form in all material respects with the published rules and regulations of the SEC with respect thereto and fairly present in all material respects, in conformity with GAAP applied on
a consistent basis (except as may be indicated in the notes to such financial statements), the consolidated financial position, the stockholders&#146; equity, the results of operations and cash flows of the Company and its consolidated Subsidiaries
as of the respective dates thereof and the consolidated results of operations and cash flows of the Company and its consolidated Subsidiaries for the periods covered in each statement (except, in the case of unaudited financial statements, for the
absence of footnote disclosure and subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments). As of the date of this Agreement, the Company does not intend to correct in any material respect or restate, and to the
Knowledge of the Company there is not any basis to restate, any of the audited financial statements or unaudited interim financial statements (including, in each case, the notes, if any, thereto) of the Company filed in or furnished with the Company
SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company has established and maintains a system of internal control over financial reporting (as such terms are
defined in paragraph (f)&nbsp;of Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the Exchange Act) as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the Exchange Act designed to provide reasonable assurance
(A)&nbsp;that transactions are recorded as necessary to permit preparation of financial statements for external purposes in conformity with GAAP, (B)&nbsp;that receipts and expenditures of the Company are executed in accordance with the
authorization of the Company&#146;s management and the Company Board and (C)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&#146;s assets that would materially affect the
Company&#146;s financial statements. From the date of the filing of the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023, to the date of this Agreement, the
Company&#146;s auditors and the Company Board have not been advised of (i)&nbsp;any significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the Company&#146;s ability to record, process, summarize and report financial information or (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal
control over financial reporting. The Company is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act and the applicable rules and regulations of the NASDAQ Stock Market and, since January&nbsp;1, 2022, has
not received any notice from the NASDAQ Stock Market asserting any <FONT STYLE="white-space:nowrap">non-compliance</FONT> with such rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company maintains disclosure controls and procedures (as defined in paragraph (e)&nbsp;of Rule
<FONT STYLE="white-space:nowrap">13a-15</FONT> under the Exchange Act) reasonably designed to ensure that (i)&nbsp;all information (both financial and nonfinancial) required to be disclosed by the Company in the reports that it files or submits
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and (ii)&nbsp;all such information is accumulated and communicated to the Company&#146;s management or to
other individuals responsible for preparing such reports as appropriate to allow timely decisions regarding required disclosure and to make the certifications of the principal executive officer and principal financial officer of the Company required
under the Exchange Act with respect to such reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the Knowledge of the Company, as of the date of this Agreement, there are no
inquiries or investigations by the SEC or any internal investigations pending or threatened, in each case regarding any accounting practices of the Company. The Company is not party to, nor has it entered into any Contract to become a party to, any
joint venture, <FONT STYLE="white-space:nowrap">&#147;off-balance</FONT> sheet&#148; partnership or any similar Contract or arrangement (including any Contract relating to any transaction or relationship between or among the Company, on one hand,
and any unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity or person, on the other hand, or any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements (as defined in Item 303(a) of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act)), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Company in
the Company&#146;s audited financial statements or other Company SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) As of the date of this Agreement, there are no
outstanding or unresolved comments in comment letters received from the SEC staff with respect to any of the Company SEC Reports, and, to the Knowledge of the Company, none of the Company SEC Reports are subject to ongoing SEC review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2022, neither the Company nor any of its Subsidiaries has received any material written complaint, allegation,
assertion or claim regarding accounting, internal accounting controls, auditing practices, procedures, methodologies or methods of the Company or any of its Subsidiaries, or unlawful accounting or auditing matters with respect to the Company or any
of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Notwithstanding the foregoing, the Company makes no representation with respect to statements made or
incorporated by reference in any Company SEC Report filed after the date hereof that is based on information supplied by or on behalf of Parent or Merger Sub specifically for inclusion or incorporation by reference in such Company SEC Report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.7 <U>Absence of Changes</U>. (a) From January&nbsp;1, 2024 until the date of this Agreement, the Acquired Companies have
conducted their business in all material respects in the ordinary course of business (except for the execution of this Agreement, the potential sale of the Company and the discussion, negotiations and transactions related thereto), (b) from
October&nbsp;1, 2024 until the date of this Agreement, there has not been any action taken by the Acquired Companies that, if taken during the period from the date hereof through the Effective Time without Parent&#146;s consent, would constitute a
breach of <U>Sections 5.1(b)(i)</U>, <U>(ii)</U>, <U>(iii)</U>, <U>(xi)</U>, <U>(xii)</U>, <U>(xiii)</U>, <U>(xiv)</U>, <U>(xvii)</U> or <U>(xix)</U> (to the extent relating to the foregoing clauses); and (c)&nbsp;since January&nbsp;1, 2024, there
has not been any Company Material Adverse Effect, and no event, change, condition, development, effect, occurrence or circumstance has arisen that, in combination with any other events or circumstances, would reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.8 <U>Legal Proceedings; Orders</U>. As of the date of
this Agreement, there is no pending Legal Proceeding or Order and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding or Order that involves any of the Acquired Companies or any of the assets owned
or used by any of the Acquired Companies, except for Legal Proceedings or Orders that have not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, and would not, individually or in
the aggregate, reasonably be expected to prevent, materially delay or materially impede the Offer, the Merger or any of the other transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.9 <U>Title to Assets</U>. Except as has not had, and would not reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse Effect, and except for real property (for which the representations with respect to title and Liens are the subject of <U>Section</U><U></U><U>&nbsp;3.10</U>) and
Intellectual Property Rights (for which the representations with respect to title and Liens are the subject of <U>Section</U><U></U><U>&nbsp;3.11</U>), (a) the Acquired Companies own, and have good and valid title to or have a valid leasehold
interest in, all assets purported to be owned or leased by them and reflected in the Company Balance Sheet (other than assets that have been sold or disposed or for which a valid leasehold interest has expired and not been renewed, in each case, in
the ordinary course of business or as otherwise permitted by this Agreement) and (b)&nbsp;all of the material tangible personal assets reflected in the Company Balance Sheet (other than such assets that have been sold or disposed or for which a
valid leasehold interest has expired and not been renewed, in each case, in the ordinary course of business or as otherwise permitted by this Agreement) are owned or leased by the Acquired Companies free and clear of any Liens, except for Permitted
Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.10 <U>Real Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) None of the Acquired Companies owns any real property as of the date of this Agreement. <U>Section</U><U></U><U>&nbsp;3.10(a)</U> of the
Company Disclosure Letter sets forth a list of each real property lease, sublease, license or occupancy agreement pursuant to which any of the Acquired Companies leases, subleases, licenses or occupies real property from any other Person as of the
date of this Agreement (the &#147;<U>Leases</U>&#148;). Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;there is no lease, sublease, license or
occupancy agreement granting to any Person (other than the Acquired Companies) any occupancy or use rights of any Leased Real Property and (ii)&nbsp;none of the Acquired Companies have assigned, transferred, mortgaged, collaterally assigned, granted
any security interest in, or pledged any interest in any of the Leases, other than Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had, and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;the Acquired Companies are the sole holders of good and valid leasehold interests in and to all of the Leased Real Property, and the
Acquired Companies&#146; interests in the Leased Real Property are free and clear of any Liens, except for Permitted Liens; (ii)&nbsp;the buildings, improvements, and fixtures on the Leased Real Property, including all mechanical, electrical and
other building systems and equipment located on the Leased Real Property, are in good operating condition and repair (normal wear and tear excepted), without structural or mechanical defect; and (iii)&nbsp;all such buildings, improvements and
fixtures have been constructed, installed and maintained in accordance with all applicable Laws. Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, to the
Knowledge of the Company, there does not exist any actual actions or actions threatened in writing by any Governmental Entity to take, by condemnation or eminent domain any of the Leased Real Property, and no Acquired Company has received any
written notice of the intention of any Governmental Entity to take or use any Leased Real Property or any part thereof or interest therein by condemnation or eminent domain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;(i) All of the Leases are valid, binding on and enforceable against the applicable
Acquired Company and, to the Knowledge of the Company, each of the other parties thereto, subject to the Enforceability Exceptions, (ii)&nbsp;all of the Leases are in full force and effect and have not been modified, amended or supplemented, in
writing or otherwise, and (iii)&nbsp;all rents due to date pursuant to each Lease have been paid, except, in each case, as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the Knowledge of the Company, no Acquired Company has received any written notice of a breach or default under any Lease
to which it is a party, nor, to the Knowledge of the Company, has any other party to any Lease breached such Lease, nor has any event or omission occurred which with the giving of notice or the lapse of time, or both, would constitute a breach or
default under any Lease, except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.11 <U>Intellectual Property</U><U>; Data Protection</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.11(a)</U> of the Company Disclosure Letter sets forth a list of all issued, registered or <FONT
STYLE="white-space:nowrap">applied-for</FONT> patents, trademarks, copyrights and Internet domain names included in the Company IP as of the date of this Agreement (the &#147;<U>Company Registered IP</U>&#148;). Except as has not had, and would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect<I>,</I> (i)&nbsp;the Company Registered IP is solely owned by the Acquired Companies, free and clear of all Liens, other than Permitted Liens and
(ii)&nbsp;the Company Registered IP is subsisting and, to the Knowledge of the Company, not invalid or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as has
not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;none of the Company IP is subject to any Order adversely affecting the use thereof or rights thereto by the Acquired
Companies; (ii)&nbsp;there is no opposition or cancellation Legal Proceeding pending against the Acquired Companies concerning the ownership, validity or enforceability of any Company Registered IP; (iii)&nbsp;(A) the Acquired Companies and the
operation of their business do not infringe, misappropriate, or otherwise violate, and has not within the three (3)-year period prior to the date of this Agreement infringed, misappropriated or otherwise violated, the Intellectual Property Rights of
any other Person, and (B)&nbsp;the Acquired Companies have not, within the three (3)-year period prior to the date of this Agreement received written notice alleging that the conduct of their business infringes, misappropriates or violates the
Intellectual Property Rights of any other Person; (iv)&nbsp;the Acquired Companies have not sent written notice to any third party within the three (3)-year period prior to the date of this Agreement alleging that the conduct of such third party
infringes, misappropriates or violates any Company IP; and (v)&nbsp;to the Knowledge of the Company, (A)&nbsp;no third party is infringing, misappropriating, or otherwise violating, and (B)&nbsp;no third party has within the three (3)-year period
prior to the date of this Agreement infringed, misappropriated, or otherwise violated, any Company IP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect, (i)&nbsp;the Acquired Companies have taken commercially reasonable measures to protect and maintain the confidentiality of the trade secrets and other material confidential information included in
the Company IP and (ii)&nbsp;to the Knowledge of the Company, there has been no misappropriation of any such trade secrets or unauthorized disclosure of any such other material confidential information in the three (3)-year period immediately prior
to the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect, each current and former employee, consultant and contractor of the Acquired Companies who contributed to the development of any material Intellectual Property Rights owned or, to the Knowledge of the Company,
purported to be owned by the Acquired Companies has (i)&nbsp;executed a written Contract assigning all right, title and interest of such employee, consultant or contractor in the Intellectual Property Rights such Intellectual Property Rights
invented, authored, or otherwise developed by such employee, consultant or contractor in the course of their employment by or provision of services to any of the Acquired Companies, or all such right, title and interest is otherwise owned
automatically by one of the Acquired Companies by operation of Law, and (ii)&nbsp;agreed to confidentiality provisions protective of the confidential information included in the Company IP. Except as has not had, and would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect, no funding or resources of any Governmental Entity or research or educational institution were used by any of the Acquired Companies in the development of any part of the
Company IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect, no Contract to which any Acquired Company is a party (other than any Contract to which Parent or any of its other Affiliates is also a party) would, upon Closing, grant to any third party any license, covenant not to sue, or other
rights under Intellectual Property Rights owned by Parent or any of its Affiliates (other than Merger Sub or any of the Acquired Companies). Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect, all Intellectual Property Rights used in the conduct of the business of the Acquired Companies as currently conducted shall be owned or available for use by the Acquired Companies immediately after the Closing on
terms and conditions substantially the same as those under which the Acquired Companies owned or used such Intellectual Property Rights immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company IP does not include any software that is material to the Acquired Companies, taken as a whole, and that cannot reasonably be
replaced by alternative software or solutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect, the IT Systems owned or held by the Acquired Companies are in good repair and (together with the other IT Systems used by the Acquired Companies) are sufficient to perform all information technology
operations necessary to operate the business of the Acquired Companies as currently operated and, to the Knowledge of the Company, such IT Systems owned or held by the Acquired Companies do not contain and have not been affected by any virus,
spyware, malware, worm, Trojan horse, or other disabling codes or instructions, or other similar malicious code, software routines or components. Except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect, the Acquired Companies have not experienced an outage or substandard performance of the IT Systems during the past three (3)&nbsp;years except where the causes of such outage or substandard performance have been
resolved in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except as has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect, each of the Acquired Companies has established an information security program that, to the extent applicable, complies with the Acquired Companies&#146; Data Protection Requirements and includes
commercially reasonable (i)&nbsp;written policies and procedures regarding Personal Data, and the Processing thereof, (ii)&nbsp;administrative, technical and physical safeguards to protect the security, confidentiality, and integrity of any Personal
Data owned, controlled, maintained, held, or Processed by the Acquired Companies, (iii)&nbsp;disaster recovery, business continuity, incident response, and security plans and procedures, and (iv)&nbsp;protections against Security Incidents,
malicious code or defects, and against loss, misuse, unauthorized access to, and disruption of IT Systems owned or held by the Acquired Companies. Except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect, during the three (3)-year period immediately prior to the date of this Agreement, to the Knowledge of the Company, there have not been any vulnerabilities or defects that have resulted in any security breaches,
unauthorized access or other security incidents adversely affecting the IT Systems owned, licensed or controlled by the Acquired Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
during the three (3)-year period immediately prior to the date of this Agreement: (i)&nbsp;the Acquired Companies and, to the extent applicable to and required by Data Protection Requirements and Company Privacy Policies of the Acquired Companies,
to the Knowledge of the Company, their Data Processors&#146; Processing of data (including Personal Data) for or on behalf of the Acquired Companies, have complied in all material respects at all times with all applicable Data Protection
Requirements and Company Privacy Policies; (ii)&nbsp;where any Acquired Company uses a Data Processor to Process Personal Data, the Data Processor has provided guarantees, warranties or covenants in relation to Processing of Personal Data,
confidentiality and security measures, and has agreed to comply with those obligations in a manner sufficient for any Acquired Company&#146;s compliance with Data Protections laws; (iii)&nbsp;the Acquired Companies have not received any written
claim, complaint, notice of investigation or other written notice (including any enforcement notice) from any Governmental Entity or other Person alleging noncompliance by the Acquired Companies of any Data Protection Requirements or Company Privacy
Policies, and no Legal Proceeding has been commenced or is pending or, to the Knowledge of the Company, threatened against the Acquired Companies, alleging noncompliance or potential noncompliance of any Data Protection Requirements; (iv)&nbsp;the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Acquired Companies have taken commercially reasonable actions (including implementing reasonable technical, physical or administrative safeguards) to protect Personal Data in their possession or
under their control against unauthorized use, access or disclosure; (v)&nbsp;to the Knowledge of the Company, there has been no unauthorized use, access, disclosure, theft, destruction or compromise by any third party of any Personal Data in the
possession, custody or control of the Acquired Companies and, to the extent applicable to Personal Data of the Acquired Companies, their Data Processors (&#147;<U>Security Incident</U>&#148;) and the Acquired Companies have not been required and are
not required under applicable Law to notify any Person or Governmental Entity of any Security Incident; and (vi)&nbsp;the Acquired Companies do not transfer Personal Data internationally except where such transfers comply with Data Protections Laws
and Company Privacy Policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.12 <U>Material Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except for this Agreement, the Company Benefit Plans or as filed with the Filed SEC Reports in unredacted form with any material omitted
schedules Made Available to Parent, Section&nbsp;3.12(a) of the Company Disclosure Letter sets forth a true and complete list (excluding any purchase orders or sales orders), as of the date of this Agreement, and the Company has Made Available to
Parent true and complete copies, of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) each Company Contract that would be required to be filed by the
Company as a &#147;material contract&#148; pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) each Company Contract involving a material joint venture, strategic alliance, partnership, sharing of profits or revenue
or similar Contract establishing any material research and development collaboration, except for such Contracts entered into in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) each Company Contract for any capital commitment, capital loan or capital expenditure over the remaining life of such
Company Contract in excess of $3,500,000 that is not included in the Company&#146;s capital expenditure budget set forth in <U>Section</U><U></U><U>&nbsp;3.12(a)(iii)</U> of the Company Disclosure Letter; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) each Company Contract entered into at any time since January&nbsp;1, 2022: (A) governing the disposition or acquisition by
any Acquired Company of any business, product line or other assets outside the ordinary course of business (whether by merger, sale or purchase of assets, sale or purchase of stock or equity ownership interests or otherwise) for consideration in
excess of $3,000,000 or (B)&nbsp;pursuant to which any Acquired Company will acquire any interest, or will make an investment (other than short-term investments including money market funds, bank deposits, commercial paper and other money market
instruments as disclosed in the Company Balance Sheet or the notes thereto, or incurred in the ordinary course of business since the date of the Company Balance Sheet) for consideration in excess of $3,000,000 in any other Person (other than another
Acquired Company); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) each Company Contract governing the disposition or acquisition by any
Acquired Company of any material business, material product line or other material assets or equity securities (whether by merger, sale or purchase of assets, sale or purchase of stock or equity ownership interests or otherwise) with material
remaining guarantee, &#147;earn out&#148;, or similar contingent payment or obligations on the part of any Acquired Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) each Company Contract that by its terms (A)&nbsp;limits the ability of any Acquired Company to engage in any line of
business or compete with any other Person or in any geographic area; (B)&nbsp;grants material exclusive rights in favor of any third party, including material exclusive rights to market, sell or deliver any Company Product; (C)&nbsp;contains any
material &#147;most favored nation&#148; or similar material provision in favor of the counterparty for a Company Product; or (D)&nbsp;contains a right of first refusal, first offer or first negotiation or any similar right with respect to any
material asset owned by an Acquired Company, except, in each case, for any such Contract that may be cancelled without penalty by the Acquired upon notice of sixty (60)&nbsp;days or less; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) each Company Contract for the marketing, sale, licensing or distribution of any Company Product under which payments in
excess of $5,000,000 were made to the Acquired Companies, as a whole, in the fiscal year ended December&nbsp;31, 2023, or are reasonably expected to be made to the Acquired Companies in the fiscal year ended December&nbsp;31, 2024; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) each Company Contract for the purchase, sale or lease of goods or services (including contract manufacturing),
materials, supplies or equipment, under which payments in excess of $5,000,000 were made by the Acquired Companies, as a whole, in the fiscal year ended December&nbsp;31, 2023, or are reasonably expected to be made by the Acquired Companies in the
fiscal year ended December&nbsp;31, 2024; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) each Company Contract pursuant to which an Acquired Company has continuing
obligations or interests involving (A)&nbsp;milestone or similar payments, including upon the achievement of regulatory or commercial milestones, in each case in excess of $3,000,000 of future payments in the aggregate, or (B)&nbsp;payment of
royalties or other amounts calculated based upon any revenues or income of any Acquired Company, in each case in excess of $3,000,000 of future payments in the aggregate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) each settlement, conciliation or similar Company Contract arising out of a Legal Proceeding or threatened Legal Proceeding:
(A)&nbsp;that materially restricts or imposes any material obligation on any Acquired Company or materially disrupts the business of any of the Acquired Companies as currently conducted or (B)&nbsp;that would require any of the Acquired Companies to
pay consideration valued at more than $2,500,000 in the aggregate following the date of this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) any Company Contract (A)&nbsp;pursuant to which an Acquired Company
grants a third party a license, covenant not to sue or other similar right under any material Company IP, other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted to customers, distributors, resellers, or Acquired Company
service providers in the ordinary course of business, (B)&nbsp;pursuant to which a third party grants an Acquired Company a license, covenant not to sue or other similar right under Intellectual Property Rights material to the Acquired
Companies&#146; businesses, taken as a whole, other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses of generally commercially available Intellectual Property Rights (including for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software), or (C)&nbsp;pursuant to which any Intellectual Property Rights material to the business of the Acquired Companies, taken as a whole, have been developed on behalf of the Acquired
Companies, other than by (1)&nbsp;employees or (2)&nbsp;contractors who assigned all of their right, title and interest in and to such Intellectual Property Rights to one or more of the Acquired Companies; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) each Company Contract with any Governmental Entity reasonably expected to involve payments to the Company exceeding
$2,500,000 during the twelve (12)&nbsp;months ended December&nbsp;31, 2024; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) each Company Contract that is a
collective bargaining agreement or other Contract with any labor union, labor or trade organization, works council or other employee representative body; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) each material stockholders&#146;, investors rights&#146;, registration rights or similar Contract to which the Company or
any Subsidiary of the Company is a party (other than the organizational documents of wholly owned Subsidiaries of the Company); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) each Contract with or binding upon the Company, any Subsidiary of the Company or any of their respective properties or
assets that is of the type that would be required to be disclosed under Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) each hedging, derivative or similar Contract (including interest rate, currency or commodity swap agreements, cap
agreements, collar agreements and any similar Contract designed to protect a Person against fluctuations in interest rates, currency exchange rates or commodity prices); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) any Company Contract relating to (A)&nbsp;a financial guaranty of any Person by any Acquired Company or (B)&nbsp;the
incurrence of indebtedness of the Acquired Companies for borrowed money, in each case, in excess of $5,000,000 (whether outstanding or as may be incurred thereunder) (other than any such indebtedness owed to (and any financial guaranty of
indebtedness by an Acquired Company in favor of) another Acquired Company); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) the Leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each Contract of the type described in this <U>Section</U><U></U><U>&nbsp;3.12(a)</U> is referred to herein as a &#147;<U>Material
Contract</U>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect, as of the date of this Agreement, each Material Contract is in full force and effect and is valid, binding and enforceable in accordance with its terms against each Acquired Company which is a party
thereto, subject to the Enforceability Exceptions and assuming the validity, binding nature and enforceability against the counterparty or counterparties thereto and, to the Knowledge of the Company, each other party thereto. As of the date of this
Agreement, except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, none of the Acquired Companies, and, to the Knowledge of the Company, no other Person, has violated
or breached, or committed any default under (and no event has occurred that with the lapse of time or the giving of notice or both would constitute a default under), any Material Contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.13 <U>Liabilities</U>. None of the Acquired Companies has any liabilities or obligations of any nature (whether accrued,
absolute, contingent or otherwise), except for: (i)&nbsp;Liabilities reflected, reserved against or otherwise included or disclosed in the Company Balance Sheet or the notes thereto; (ii)&nbsp;Liabilities that have been incurred by the Acquired
Companies since the date of the Company Balance Sheet in the ordinary course of business; (iii)&nbsp;Liabilities for performance of obligations of the Acquired Companies not yet due under Company Contracts (other than resulting from any breach
thereof by the Acquired Companies); (iv) Liabilities described in <U>Section</U><U></U><U>&nbsp;3.13</U> of the Company Disclosure Letter; (v)&nbsp;Liabilities incurred in connection with the transactions contemplated by this Agreement; and
(vi)&nbsp;other Liabilities that have not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.14 <U>Compliance with Laws</U>. Except as has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Acquired Companies is, and at all times since May&nbsp;22, 2020 has been, in
compliance with all applicable Laws, including all applicable Healthcare Laws. Since May&nbsp;22, 2020, none of the Acquired Companies has received any written notice or, to the Knowledge of the Company, other communication from any Governmental
Entity or other Person regarding any actual or alleged violation of, investigation with respect to, or failure to comply with, any applicable Law, including any applicable Healthcare Law and any applicable anti-corruption Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since May&nbsp;22, 2020, none of the Acquired Companies has (i)&nbsp;been party to a corporate integrity, monitoring, deferred prosecution
or similar agreement, (ii)&nbsp;entered into any consent decree or settlement order with any Governmental Entity or (iii)&nbsp;had any reporting obligations pursuant to a settlement agreement, plan of correction or other remedial measure entered
into with any Governmental Entity, and, as of the date of this Agreement, to the Knowledge of the Company, no such action described in the foregoing clauses has been threatened or is currently pending. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) None of the Acquired Companies, and no director, officer, or employee of the Acquired
Companies acting on behalf of an Acquired Company, and, to the Knowledge of the Company, no agent or third party acting on behalf of any of the Acquired Companies has been since May&nbsp;22, 2020, or is currently, suspended, disqualified, debarred,
convicted or excluded from participating in, or bidding on contracts with, any Governmental Entity or private third party health care program, pursuant to the Department of Health and Human Services Office of Inspector General&#146;s exclusion
authority under 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7(a),</FONT> as implemented at 42 C.F.R. &#167;&#167; 1001.101, 1001.201 or FDA&#146;s suspension and debarment authority under 21 U.S.C. &#167; 335a. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Since May&nbsp;22, 2020, none of the Acquired Companies, and no director, officer, or employee of the Acquired Companies acting on behalf
of an Acquired Company or, to the Knowledge of the Company, any agent or third party acting on behalf of any of the Acquired Companies, has directly or indirectly: (i)&nbsp;used any funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity in violation of applicable anti-corruption or anti-bribery Law or Company policy; (ii)&nbsp;made, promised, offered or authorized any unlawful bribe, rebate, gift, payoff, kickback or other similar
payment or conveyance of value to any foreign or domestic government official or employee of a government instrumentality or to any foreign or domestic political party or campaign in violation of any applicable anti-corruption or anti-bribery Law,
including the Foreign Corrupt Practices Act of 1977 (&#147;<U>FCPA</U>&#148;), and the United Kingdom Bribery Act of 2010 and any other comparable applicable Law of a jurisdiction outside the United States; or (iii)&nbsp;violated any applicable
anti-money laundering Laws or the applicable record-keeping and internal controls provisions of the FCPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Acquired Companies
currently maintain a system or systems of internal controls reasonably designed to (i)&nbsp;ensure compliance with applicable anti-corruption Laws and (ii)&nbsp;prevent and detect violations of applicable anti-corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Since May&nbsp;22, 2020, each of the Acquired Companies (i)&nbsp;has been and is in compliance with all applicable Sanctions, U.S. Export
and Import Laws and Foreign Export and Import Laws and (ii)&nbsp;and has obtained and complied with all licenses, registrations, consents, notices, waivers, approvals, orders, classifications, filings, declarations and other authorizations for
export, <FONT STYLE="white-space:nowrap">re-export,</FONT> deemed export or <FONT STYLE="white-space:nowrap">re-export,</FONT> transfer or import of goods, services, software and technology required in accordance with applicable Sanctions, U.S.
Export and Import Laws and Foreign Export and Import Laws (&#147;<U>Trade Authorizations</U>&#148;) for the conduct of its business. Since May&nbsp;22, 2020, none of the Acquired Companies has been cited, penalized or fined, subjected to any
seizure, forfeiture, revocation of any Trade Authorizations, debarment or denial of future Trade Authorizations, or received any written notice, request or penalty, for any actual or alleged failure to comply with any Sanctions, U.S. Export and
Import Laws or Foreign Export and Import Laws, and no Legal Proceeding, investigation, or inquiry related to Sanctions, U.S. Export and Import Laws, or Foreign Export and Import Laws is or has been pending or, to the Knowledge of the Company,
threatened in writing against any Acquired Company or any officer or director of any Acquired Company (in his or her capacity as an officer or director of any Acquired Company) by or before (or, in the case of a threatened matter, that would come
before) any Governmental Entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Since May&nbsp;22, 2020, none of the Acquired Companies, and no director, officer or
employee acting on behalf of an Acquired Company or, to the Knowledge of the Company, agent or third party acting on behalf of any of the Acquired Companies (i)&nbsp;is or has been a Sanctioned Person or (ii)&nbsp;has violated or made a disclosure
(voluntary or otherwise) to a responsible Governmental Entity regarding compliance with any U.S. Export and Import Law or Foreign Export and Import Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Acquired Companies currently have in place controls and systems reasonably designed to ensure compliance with applicable Laws
pertaining to Sanctions, U.S. Export and Import Laws, and applicable Foreign Export and Import Laws in each of the jurisdictions in which the Acquired Companies does business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.15 <U>Governmental Authorizations</U>. Except as has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect: (i)&nbsp;the Acquired Companies hold, and since May&nbsp;22, 2020 have held all Governmental Authorizations necessary to enable the Acquired Companies to conduct their respective businesses in the
manner in which such businesses are currently being conducted; (ii)&nbsp;all such Governmental Authorizations are valid and in full force and effect or expired at a time when such Governmental Authorizations no longer were required; and
(iii)&nbsp;each Acquired Company is, and since May&nbsp;22, 2020 has been, in compliance with the terms and requirements of such Governmental Authorizations. Since May&nbsp;22, 2020, none of the Acquired Companies has received any written notice
from any Governmental Entity regarding (i)&nbsp;any actual or alleged violation of or failure to comply with any term or requirement of any Governmental Authorization or (ii)&nbsp;any actual or threatened revocation, withdrawal, suspension,
cancellation or termination of any Governmental Authorization, in each case except for such violation, failure, revocation, withdrawal, suspension, cancellation or termination that would not have, individually or in the aggregate, a Company Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.16 <U>Regulatory Matters</U>. Except as has not had, and would not reasonably have, individually or in the
aggregate, a Company Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Acquired Company possesses all Registrations required to conduct its respective
businesses as currently conducted. Each such Registration is valid and subsisting in full force and effect. To the Knowledge of the Company, from January&nbsp;1, 2022 through the date of this Agreement, neither the FDA nor any comparable Regulatory
Authority has provided written notice to any Acquired Company regarding limiting, suspending or revoking any such Registration or changing the marketing classification or labeling of the products of the Acquired Companies. To the Knowledge of the
Company, there is no false or misleading information or material omission in any Registration, product application, or other submission to the FDA or any comparable Regulatory Authority made by an Acquired Company since May&nbsp;22, 2020. Each
Acquired Company is in compliance with, and has since January&nbsp;1, 2022 fulfilled and performed in all material respects its respective obligations under, each such Registration, and, as of the date hereof, since January&nbsp;1, 2022, to the
Knowledge of the Company, no event has occurred or condition or state of facts exists which would constitute a breach or default or would cause revocation or termination of any such Registration. To the Knowledge of the Company, as of the date
hereof, any third Person that is a manufacturer or contractor for the Acquired Companies is in compliance with all Registrations insofar as they pertain to the manufacture of raw materials, components or products for the Acquired Companies, as
applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company Products are in compliance with all applicable Device Regulatory Laws. In
particular, (i)&nbsp;each Acquired Company is in compliance with all applicable Device Regulatory Laws relating to the sourcing, procurement, or import of raw materials and components for the Company Products and the methods and materials used in,
and the facilities and controls used for, the design, manufacture, processing, packaging, labeling, storage, distribution, import, and export of the Company Products; (ii)&nbsp;since January&nbsp;1, 2022, all such raw materials and components and
all Company Products have been developed, tested, investigated, sourced, manufactured, packaged, labeled, stored, handled, marketed, sold, imported, exported, and distributed by the Acquired Companies in compliance with all applicable Device
Regulatory Laws; and (iii)&nbsp;each Acquired Company is, and since January&nbsp;1, 2022, has been, in compliance with all applicable Device Regulatory Laws regarding developing, testing, manufacturing, marketing, distributing, or promoting the
Company Products, including those regarding <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, clinical research, establishment registration, device listing, <FONT STYLE="white-space:nowrap">pre-market</FONT> notification, good
manufacturing practices, labeling, advertising, record-keeping, device importation and exportation, complaint handling, adverse event reporting, reporting of corrections and removals, or the submission of medical device reports regarding the Company
Products. To the Knowledge of the Company, as of the date of this Agreement, any third Person that is a manufacturer or contractor for the Acquired Companies is in compliance with all Device Regulatory Laws or any other applicable Laws insofar as
they pertain to the manufacture of raw materials, components or products for the Acquired Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All preclinical and clinical
investigations sponsored by or on behalf of an Acquired Company with respect to any Company Product are being, and since January&nbsp;1, 2022, have been, conducted in compliance with all applicable Laws and requirements, including Device Regulatory
Laws, Good Clinical Practices requirements, applicable research protocols, corrective action plans, and federal and state Laws relating to patient privacy requirements or restricting the use and disclosure of individually identifiable health
information. Since January&nbsp;1, 2022, no clinical trial sponsored or conducted by or on behalf of the Acquired Companies has been terminated, materially delayed, limited, or suspended prior to completion by the FDA, any comparable Regulatory
Authority, or any institutional review board that has or has had jurisdiction over such clinical trial, and neither the FDA, any comparable Regulatory Authority, nor any institutional review board with jurisdiction, has ordered or commenced, or, to
the Knowledge of the Company, threatened in writing to initiate, any action to place a clinical hold order on, or otherwise terminate, materially delay, limit, modify, or suspend any proposed or ongoing clinical trial conducted or proposed to be
conducted by or on behalf of any Acquired Company or, to the Knowledge of the Company, alleged in writing any violation of any Device Regulatory Laws in connection with any such clinical trial. Since January&nbsp;1, 2022, none of the Acquired
Companies has received any written notices or other written correspondence from the FDA, any comparable Regulatory Authority, or any institutional review board with jurisdiction with respect to any ongoing clinical or
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or tests requiring the termination, suspension or material modification of such studies or tests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As of the date of this Agreement, there are no Legal Proceedings pending or, to the
Knowledge of the Company, threatened in writing by or on behalf of the U.S. DOJ, the FDA or any comparable Regulatory Authority against any of the Acquired Companies. Since January&nbsp;1, 2022, no Acquired Company has received any Form FDA-483,
notice of adverse finding, FDA warning letter, notice of violation or &#147;untitled letter,&#148; notice of FDA action for import detention or refusal, or any other written notice from the FDA or any comparable Regulatory Authority alleging or
asserting noncompliance with any applicable Device Regulatory Laws or Registrations. As of the date of this Agreement, no Acquired Company is subject to any obligation or open, ongoing, or pending commitments arising under an administrative or
regulatory action, FDA inspection, FDA warning letter, FDA notice of violation letter or other notice, response, or commitment made to or with the FDA or any comparable Regulatory Authority. Since January&nbsp;1, 2022, each of the Acquired Companies
have made all notifications, submissions, responses, and reports required by Device Regulatory Laws, including any such obligation arising under any administrative or regulatory action, FDA inspection, FDA warning letter, FDA notice of violation
letter, or other notice, response, or commitment made to or with the FDA or any comparable Regulatory Authority, and all such notifications, submissions, responses, and reports were true, complete, and correct in all material respects as of the date
of submission to the FDA or any comparable Regulatory Authority. Since January&nbsp;1, 2022, no action has been taken by any Regulatory Authority or, to the Knowledge of the Company, is in the process of being taken that would enjoin the
manufacturing of the Company Products or subject the manufacturing of the Company Products to regulatory enforcement action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Since
January&nbsp;1, 2022, the Acquired Companies have maintained records relating to the development, manufacture, testing, storage, handling, labeling, packaging, sale, marketing, promotion, distribution, import or export of the Company Products in
compliance with all applicable Device Regulatory Laws. Since January&nbsp;1, 2022, each Acquired Company and, to the Knowledge of the Company, each of their respective contractors and agents have submitted to FDA and any comparable Regulatory
Authority or institutional review board all supplemental applications, 510(k) premarket notifications, premarket approvals, notices, filings, and annual or other reports and information, including adverse event reports and product deviation reports,
related to the development, manufacture, testing, storage, handling, labeling, packaging, sale, marketing, promotion, distribution, import, or export of the Company Products that are required under the applicable Device Regulatory Laws. Since
January&nbsp;1, 2022, to the Knowledge of the Company, each Acquired Company has made all required filings with, or notifications to, the FDA, and any other comparable Regulatory Authority pursuant to applicable requirements of all Device Regulatory
Laws. Since January&nbsp;1, 2022, the Company Products, where required, are being marketed under and consistent with valid 510(k) clearances or approved Premarket Approval Applications (&#147;<U>PMAs</U>&#148;) exclusively owned by an Acquired
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Since January&nbsp;1, 2022, all manufacturing operations for the Company Products conducted by or on behalf of an Acquired
Company have been and are being conducted in compliance with the FDA&#146;s Quality Systems Regulation (21 C.F.R. Part 820) and any comparable Regulatory Authority requirements and the Company Products are not adulterated within the meaning of 21
U.S.C. &#167; 351 or misbranded within the meaning of 21 U.S.C. &#167; 352. Since January&nbsp;1, 2022, no Company Product distributed or sold by or on behalf of the Acquired Companies has been seized, withdrawn, recalled, detained, or been subject
to a suspension of manufacturing, field notification, notification of misbranding or adulteration, or safety alert, or to the Knowledge of the Company, no such actions have been threatened in writing by the FDA or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comparable Regulatory Authority. To the Knowledge of the Company, as of the date of this Agreement, there are no facts or circumstances reasonably likely to cause (i)&nbsp;the seizure, denial,
withdrawal, recall, detention, field notification, field correction, safety alert, or suspension of manufacturing relating to any Company Product; (ii)&nbsp;a change in the labeling of any Company Product (with respect to this clause <U>(ii)</U>, to
the Company&#146;s Knowledge) or (iii)&nbsp;a termination, seizure, limitation, restriction, modification, or suspension of the marketing or distribution (including for commercial, investigational, or any other use) of any such Company Product. As
of the date hereof, no Proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, correction, suspension, import detention, seizure, or similar action of any such Company Product are pending or, to the Knowledge of
the Company, threatened in writing against the Acquired Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) No Acquired Company or, to the Knowledge of the Company, any
officer, employee, contractor, or agent of an Acquired Company is the subject of any pending Legal Proceeding or, to the Knowledge of the Company, any ongoing investigation or inquiry or has received, since January&nbsp;1, 2022, any written notice
of any actual investigation, inquiry, for cause inspection or audit or other action by FDA pursuant to its &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; policy as stated at 56 Fed. Reg. 46191 (September 10,
1991) (the &#147;<U>FDA Application Integrity Policy</U>&#148;) and any amendments thereto, or by any other similar Governmental Entity pursuant to any similar policy, nor has any Acquired Company or, to the Knowledge of the Company, any officer,
employee, contractor, or agent of an Acquired Company committed since January&nbsp;1, 2022 any act, or made any statement or failed to make any statement that would reasonably be expected to provide a basis for FDA to invoke the FDA Application
Integrity Policy or other similar Governmental Entity to invoke a similar policy. Since January&nbsp;1, 2022, no Acquired Company or, to the Knowledge of the Company, any officer, employee, contractor, or agent of an Acquired Company has knowingly
made any false statements on, or material omissions from, any notifications, applications, approvals, reports and other submissions to a Governmental Entity relating to any Company Product or has voluntarily disclosed any violations of Laws related
to any Company Product. To the Knowledge of the Company, as of the date hereof, no officer, employee, contractor, or agent of an Acquired Company has been since May&nbsp;22, 2020 permanently or temporarily enjoined or otherwise prohibited,
precluded, debarred, or restricted by any Law or Regulatory Authority from engaging in or continuing any conduct or practice in connection with the business or assets of the Acquired Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.17 <U>Tax Matters</U>. Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Acquired Companies has (i)&nbsp;timely filed or caused to be filed (taking into account
any extension of time within which to file) all Tax Returns required to be filed by it and all such filed Tax Returns are accurate and complete, and (ii)&nbsp;paid all Taxes due and payable and required to be paid by it, except, in the case of each
of clauses (i)&nbsp;and (ii), with respect to matters being contested in good faith and/or for which reserves have been established on the financial statements of the Company and its Subsidiaries in accordance with GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No waiver of any statute of limitations relating to Taxes for which an Acquired Company
may be liable is in effect, and no written request for such a waiver is outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No Governmental Entity (whether within or
without the United States) in which the Company or any Subsidiary has not filed a particular type of Tax Return or paid a particular type of Tax has asserted in writing that the Company or such Subsidiary is required to file such Tax Return or pay
such type of Tax in such taxing jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each of the Acquired Companies has withheld from each payment made to any employee,
independent contractor, supplier, creditor, stockholder or other third party all Taxes required to be withheld under applicable Law with respect to the making of such payment and has, to the extent required by applicable Law, paid over such withheld
amounts to the proper Governmental Entity, in each case, except for matters being contested in good faith and for which reserves have been established on the financial statements of the Company and its Subsidiaries in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) There are no Liens for Taxes upon any of the assets of the Acquired Companies other than Permitted Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No audit, claim or proceeding with respect to Taxes or Tax Returns of the Acquired Companies is pending or threatened in writing against
or with respect to any of the Acquired Companies. There is no deficiency for Taxes that has been assessed by any Governmental Entity against any Acquired Company and that has not been fully satisfied by payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) None of the Acquired Companies will be required to include any item of income in, or to exclude any item of deduction from, taxable income
in any taxable period (or portion thereof) ending after the Closing Date as a result of any closing agreement, installment sale or open transaction prior to the Closing Date, any accounting method change or agreement with any Governmental Entity, or
any prepaid amount received prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) None of the Acquired Companies (i)&nbsp;is a party to or bound by, or has any
obligation under, any Tax allocation, sharing, indemnity, or reimbursement agreement or arrangement (other than customary Tax indemnification provisions in ordinary course commercial agreements not primarily related to Taxes, and other than any
agreement or arrangement solely among the Company and the Subsidiaries) or (ii)&nbsp;has any liability for Taxes of any Person (other than the Company or any Subsidiary) under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law) or as a transferee or successor otherwise by operation of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In the two (2)&nbsp;years prior to the date hereof, no Acquired Company has been either a &#147;distributing corporation&#148; or a
&#147;controlled corporation&#148; within the meaning of Section&nbsp;355(a)(1)(A) of the Code in connection with a distribution of stock intended to be governed by Section&nbsp;355 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No Acquired Company has participated in a &#147;listed transaction&#148; within the
meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.18 <U>Employee and
Labor Matters; Benefit Plans</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Company Material Adverse Effect, each Acquired Company is, and since May&nbsp;22, 2020 has been, in compliance in all respects with all applicable Laws respecting labor and employment, including hiring practices, employment practices,
terms and conditions of employment, discrimination, equal pay, wages and hours, overtime, labor relations, leaves of absence, paid sick leave Laws, work breaks, classification of employees (including exempt and independent contractor status),
occupational health and safety, immigration, fair credit reporting, harassment, retaliation, disability rights and benefits, reasonable accommodation, equal employment, fair employment practices, wrongful discharge or violation of personal rights
including the Worker Adjustment and Retraining Notification Act (and any similar foreign, provincial, state or local statute or regulation). As of the date of this Agreement, except as has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect, (i)&nbsp;there are no unfair labor practice charges, grievances or complaints pending, or to the Knowledge of the Company, threatened in writing against any of the Acquired
Companies before the National Labor Relations Board or any other labor relations tribunal or authority; (ii)&nbsp;there are no strikes, work stoppages, slowdowns, lockouts, material arbitrations or material grievances, or other material labor
disputes pending or, to the Knowledge of the Company, threatened in writing against or involving any of the Acquired Companies; and (iii)&nbsp;no Acquired Company is a party to any collective bargaining agreements, and there are not, to the
Knowledge of the Company, any union organizing activities concerning any employees of any Acquired Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had,
and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Acquired Companies are, and since May&nbsp;22, 2020 have been, in compliance with all applicable immigration Laws, including, the
Immigration Reform and Control Act of 1986 and any amendments thereto. The Acquired Companies have properly completed and retained Form <FONT STYLE="white-space:nowrap">I-9</FONT> (Employment Eligibility Verification) for all current and former
employees hired to perform services in the United States, as required by applicable Law. All individuals employed by the Acquired Companies in the United States are authorized to work in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Section</U><U></U><U>&nbsp;3.18(c)</U> of the Company Disclosure Letter contains an accurate and complete list, as of the date of this
Agreement, of each material Company Benefit Plan. The Company has Made Available to Parent, in each case, to the extent applicable and as of the date of this Agreement: (i)&nbsp;accurate and complete copies of all documents setting forth the terms
of each material Company Benefit Plan including all amendments thereto and all related trust documents; (ii)&nbsp;the most recent summary plan description, together with summaries of the material modifications thereto, if any, required under ERISA
with respect to each material Company Benefit Plan; (iii)&nbsp;all trust agreements, insurance contracts and funding agreements, including all amendments thereto; (iv)&nbsp;the most recent IRS determination or opinion letter issued with respect to
each Company Benefit Plan intended to be qualified under Section&nbsp;401(a) of the Code; and (v)&nbsp;annual testing (including nondiscrimination and coverage) results for the three most recently completed plan years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Company Material Adverse Effect, since May&nbsp;22, 2020, each Company Benefit Plan has been established, maintained and operated in accordance with its terms and in compliance with all applicable Laws, including ERISA and the Code.
Any Company Benefit Plan intended to be qualified under Section&nbsp;401(a) of the Code and each trust intended to be qualified under Section&nbsp;501(a) of the Code has obtained a favorable determination letter (or opinion letter, if applicable) as
to its qualified status under the Code and, to the Knowledge of the Company, nothing has occurred since the date of the most recent determination that reasonably would be expected to result in the loss of such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) None of the Acquired Companies, and no ERISA Affiliate, has at any time during the past six (6)&nbsp;years maintained, established,
sponsored, participated in, or contributed to, or been obligated to contribute to or has any Liability in respect of, any: (i)&nbsp;plan subject to Title IV of ERISA or Section&nbsp;412 of the Code; (ii)&nbsp;&#147;multiemployer plan&#148; within
the meaning of Section (3)(37) of ERISA; (iii)&nbsp;plan described in Section&nbsp;413(c) of the Code; (iv) &#147;voluntary employee&#146;s beneficiary association&#148; within the meaning of Section&nbsp;501(c)(9) of the Code; or (v)&nbsp;a
multiple employer welfare arrangement (as defined in Section&nbsp;3(40)(A) of ERISA). No Liability under Title IV (other than any Liability for premiums due to the PBGC (which premiums have been paid when due)) has been incurred by the Acquired
Companies or any ERISA Affiliate that has not been satisfied in full, and no condition exists that presents a material risk to the Acquired Companies or any ERISA Affiliate of incurring any such Liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No Company Benefit Plan or Acquired Company provides, or has any obligation to provide, current or former employees of the Acquired
Companies (or any beneficiaries thereof) welfare benefits (including medical and life insurance benefits) after such Person terminates employment with the Acquired Companies, except for the coverage continuation requirements of Part 6 of Subtitle B
of Title I of ERISA, Section&nbsp;4980B of the Code, or similar state or local Law, continued coverage until the end of the month during which termination occurs, or subsidized healthcare coverage continuation during any post-termination severance
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as expressly required or provided by this Agreement: (i)&nbsp;neither the execution of this Agreement nor the
consummation of the transactions contemplated by this Agreement will (either alone or in combination with another event, whether contingent or otherwise) result in any payment, acceleration, vesting, distribution, increase in benefits or obligation
to fund benefits with respect to any current or former employee of any Acquired Company; (ii)&nbsp;without limiting the generality of the foregoing, no amount payable to any current or former employee of any Acquired Company as a result of the
execution and delivery of this Agreement or the consummation of any of the transactions contemplated by this Agreement (either alone or in combination with any other event) would be an &#147;excess parachute payment&#148; within the meaning of
Section&nbsp;280G; and (iii)&nbsp;no Acquired Company has any obligation to <FONT STYLE="white-space:nowrap">gross-up</FONT> or otherwise reimburse or compensate any current or former employee of any Acquired Company for any Taxes incurred by such
individual under or pursuant to Section&nbsp;409A or Section&nbsp;4999 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.19 <U>Environmental Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
each of the Acquired Companies is, and since January&nbsp;1, 2022 has been, in compliance with applicable Environmental Law, which compliance includes timely applying for, possessing, maintaining in full force and effect, and complying with the
terms and conditions of all Environmental Authorizations, and, as of the date of this Agreement, to the Knowledge of the Company, there are no pending or threatened demands, claims, information requests or notices threatened in writing regarding the
Company or any Subsidiary of the Company relating to any violation of, noncompliance with, liability under or seeking to impose any financial responsibility for any investigation, cleanup, removal, containment or any other remediation or compliance
under, any Environmental Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect, since January&nbsp;1, 2022, there has been no Release of Hazardous Substances at, on, under or from, and, to the Knowledge of the Company, as of the date of this Agreement, no conditions exist that would reasonably
be expected to give rise to any violation of or result in any material liability under any Environmental Law with respect to, (i)&nbsp;any real property currently owned, operated or leased by any Acquired Company or (ii)&nbsp;to the Knowledge of the
Company, at any real property formerly owned, operated or leased by the Acquired Company during its ownership, operation or tenancy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.20 <U>Insurance</U>. The Company has Made Available to Parent all material insurance policies with third party insurers
relating to the business, assets and operations of the Acquired Companies as of the date of this Agreement. Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
(a)&nbsp;each of the material insurance policies relating to the business, assets and operations of the Acquired Companies is in full force and effect, (b)&nbsp;no written notice of a default or termination has been received by any Acquired Company
in respect thereof, the Acquired Companies are in compliance with the terms and conditions of such insurance policies, no event has occurred which, with notice or lapse of time, would constitute a breach or default, or permit termination, or
modification, under any such insurance policies and (c)&nbsp;all premiums due thereon have been paid in full. Since January&nbsp;1, 2022, none of the Acquired Companies has received any written notice from the applicable insurers regarding any:
(a)&nbsp;cancellation or invalidation of or increase in any premiums associated with any insurance policy or (b)&nbsp;refusal of any coverage or rejection of any claim under any insurance policy, except for such cancellation, invalidation, increase,
refusal or rejection that would not have, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.21 <U>Takeover Statutes</U><U>; No Rights Agreement</U>. Assuming the
representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.8</U> are true and correct, there are no &#147;fair price,&#148; &#147;moratorium,&#148; &#147;control share acquisition,&#148; &#147;business combination&#148; or other
similar anti-takeover Laws (each, a &#147;<U>Takeover Statute</U>&#148;) applicable to, and the Company Board has taken all action necessary to render such Takeover Statutes, including Section&nbsp;203 of the DGCL, inapplicable to, this Agreement,
as it relates to the Offer, the Merger or any of the transactions contemplated by this Agreement. As of the date of this Agreement, the Company is not a party to an anti-takeover stockholder rights agreement, &#147;poison pill&#148; or similar
anti-takeover agreement or plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.22 <U>Fairness Opinion</U>. The Company Board has received the oral opinion of Morgan
Stanley&nbsp;&amp; Co. LLC, financial advisor to the Company, to be confirmed by delivery of the written opinion of Morgan Stanley&nbsp;&amp; Co. LLC to the Company Board, to the effect that as of the date of such opinion, and based upon and subject
to the various assumptions, qualifications, limitations and other matters set forth in the written opinion, the consideration to be received by holders of Shares (other than Shares (i)&nbsp;owned, directly or indirectly, by the Company or any wholly
owned subsidiary of the Company, (ii)&nbsp;owned, directly or indirectly, by Parent, Merger Sub or any wholly owned subsidiary of Parent, or (iii)&nbsp;as to which dissenters&#146; rights have been perfected) pursuant to the terms of this Agreement
is fair from a financial point of view to such holders of Shares. A written copy of such opinion shall be provided to Parent solely for informational purposes, promptly following the date of this Agreement; it being understood that such opinion is
for the benefit solely of the Company Board and may not be relied on by Parent, Merger Sub or any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.23
<U>Financial Advisors</U><U>&#146;</U><U> Fees</U>. Except for Morgan Stanley&nbsp;&amp; Co. LLC, no broker, finder, investment banker or other Person is entitled to any brokerage, finder&#146;s, success, completion or similar fee or commission in
connection with the Offer, the Merger or any of the other transactions contemplated by this Agreement based upon arrangements made by or on behalf of any of the Acquired Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.24 <U>Information</U>. None of the information incorporated by reference or supplied or to be supplied by or on behalf of the
Company for inclusion in the Offer Documents or the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> will, at the time such document is filed with the SEC, at any time it is amended or supplemented or at the time it is first published, sent or
given to the Company&#146;s stockholders, contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they are made, not misleading. The
Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> will, at the time such document is filed with the SEC, comply as to form in all material respects with the requirements of the Exchange Act. No representation or warranty is made by the Company
with respect to statements included or incorporated by reference in the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> based on information supplied by or on behalf of Parent or Merger Sub for inclusion or incorporation by reference therein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.25 <U>No Additional Representations</U>. The Company agrees and acknowledges that, except for the express representations
and warranties contained in <U>Article 4</U> (to the extent modified by the Parent Disclosure Letter) and the Joinder, neither Parent nor Merger Sub, or any other Person makes any other express or implied representation or warranty on behalf of
Parent or any of its Affiliates, including with respect to any of their respective businesses or the transactions contemplated by this Agreement. The Company agrees and acknowledges that in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
making the decision to enter into this Agreement and consummate the transactions contemplated by this Agreement, the Company has relied exclusively on the express representations and warranties
contained in <U>Article 4</U> (to the extent modified by the Parent Disclosure Letter) and the Joinder and has not relied on any other representation or warranty, express or implied. The Company agrees and acknowledges that neither Parent nor Merger
Sub, or any other Person has made, and the Company has not relied on, any representation or warranty, express or implied, as to the accuracy or completeness of any information regarding Parent or Merger Sub furnished or made available to the Company
and its Representatives, except as expressly set forth in <U>Article 4</U> (to the extent modified by the Parent Disclosure Letter) and the Joinder and neither Parent nor Merger Sub, or their respective directors, officers, employees, agents or
other Representatives, or any other Person, shall be subject to any liability to the Company or any other Person resulting from Parent or Merger Sub making available to the Company or the Company&#146;s use of such information, or any information,
documents or material made available to the Company in the due diligence materials provided to the Company, including in any data room, other management presentations (formal or informal) or in any other form in connection with the transactions
contemplated by this Agreement. Without limiting the foregoing, Parent and Merger Sub make no representation or warranty to the Company with respect to any business or financial projection, guidance or forecast relating to Parent or any of its
Subsidiaries, whether or not included in any data room or any management presentation. The Company, on its behalf and on behalf of its Affiliates, expressly waives any such claim relating to the foregoing matters. Notwithstanding the foregoing,
nothing in this <U>Section</U><U></U><U>&nbsp;3.25</U> shall limit the Company&#146;s rights and remedies for Fraud with respect to the representations and warranties contained in <U>Article 4</U> (to the extent modified by the Parent Disclosure
Letter) or the Joinder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as disclosed in the disclosure letter delivered by Parent to the Company concurrently with the execution of this Agreement (the
&#147;<U>Parent Disclosure Letter</U>&#148;) (it being agreed that disclosure of any item in any section or subsection of the Parent Disclosure Letter shall be deemed disclosed with respect to any other section or subsection of the Parent Disclosure
Letter to the extent that the relevance thereof is reasonably apparent on its face that such disclosure also qualifies or applies to such other sections or subsections), Parent and Merger Sub jointly and severally represent and warrant to the
Company as follows (in the case of Parent&#146;s representations and warranties with respect to Merger Sub and the representations and warranties made by Merger Sub, upon execution and delivery of the Joinder): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1 <U>Qualification, Organization, Subsidiaries</U>. Each of Parent and Merger Sub is a legal entity duly organized, validly
existing and in good standing under the Laws of its respective jurisdiction of organization and has all requisite corporate or similar power and authority to own, lease and operate its properties and assets and to carry on its business as presently
conducted and is qualified to do business and is in good standing as a foreign corporation in each jurisdiction where the ownership, leasing or operation of its assets or properties or conduct of its business requires such qualification, except, in
each case, as would not, individually or in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate, prevent or materially delay or materially impair the ability of Parent or Merger Sub to consummate the Offer, the Merger and the other transactions contemplated by this Agreement (a
&#147;<U>Parent Material Adverse Effect</U>&#148;). Parent will, promptly following the formation of Merger Sub, make available to the Company a true and complete copy of the certificate of incorporation and bylaws of Merger Sub. Prior to the date
of this Agreement, Parent has made available to the Company a true and complete copy of the certificate of incorporation and bylaws of Parent, as amended through the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <U>Corporate Authority Relative to This Agreement; No Violation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and Merger Sub has all necessary corporate power and authority to enter into this Agreement, to perform its obligations
hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement and the consummation of the Offer, the Merger and the other transactions contemplated by this Agreement, have been duly and
validly authorized by all necessary corporate action on the part of Parent and Merger Sub and, except for the adoption of this Agreement by Parent, as the sole stockholder of Merger Sub (which such adoption shall occur immediately following the
execution of this Agreement), no other corporate proceedings on the part of Parent or Merger Sub are necessary to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement. This
Agreement has been duly and validly executed and delivered by Parent and Merger Sub and, assuming due execution and delivery by the Company, constitutes the valid and binding agreement of Parent and Merger Sub, enforceable against each of Parent and
Merger Sub in accordance with its terms, subject to the Enforceability Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution, delivery and performance by Parent
and Merger Sub of this Agreement and the consummation of the Offer, the Merger and the other transactions contemplated by this Agreement by Parent and Merger Sub do not and will not require Parent, Merger Sub or their Subsidiaries to procure, make
or provide any consent, approval, authorization or permit of, action by, filing with or notification to any Governmental Entity, other than (i)&nbsp;the filing of the Certificate of Merger, (ii)&nbsp;compliance with the HSR Act and other applicable
Antitrust Laws, (iii)&nbsp;compliance with any applicable Foreign Investment Law, (iv)&nbsp;compliance with the applicable requirements of the Exchange Act (including the filing with the SEC of the Offer Documents) and compliance with the rules and
regulations of the securities exchange on which Parent&#146;s common stock is listed, and (v)&nbsp;the other consents or notices set forth on Section&nbsp;4.2(b) of the Parent Disclosure Letter (clauses (i)&nbsp;through (v), collectively, the
&#147;<U>Parent Approvals</U>&#148;), and other than any consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain would not have, individually or in the aggregate, a Parent Material Adverse
Effect. As of the date hereof, Parent has no reason to believe that any Parent Approval will not be granted or received in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Other than the adoption of this Agreement by Parent, in its capacity as the sole stockholder of Merger Sub, no vote of the stockholders of
Parent or Merger Sub or the holders of any other securities of Parent or any of its Affiliates (equity or otherwise) is required by any applicable Law, the certificate of incorporation or bylaws or other equivalent organizational documents of Parent
or any of its Affiliates or the applicable rules of any exchange on which securities of Parent are traded, in order for Parent and Merger Sub to consummate the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Assuming the receipt of the Parent Approvals, the execution, delivery and performance by
Parent and Merger Sub of this Agreement and the consummation by Parent and Merger Sub of the Offer, the Merger and the other transactions contemplated by this Agreement, do not and will not (i)&nbsp;contravene, conflict with or result in a violation
of the organizational or governing documents of Parent or any of its Subsidiaries, (ii)&nbsp;contravene, conflict with or result in a violation of any Law or Order to which any of Parent or any of its Subsidiaries, or any of the assets owned or used
by any of them, is subject, (iii)&nbsp;contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Contract to which Parent or any of its Subsidiaries is a party, or give any Person the right
to: (w)&nbsp;declare a default or exercise any remedy under any such Contract; (x)&nbsp;a penalty under any such Contract; (y)&nbsp;accelerate the maturity or performance of any such Contract; or (z)&nbsp;cancel, terminate or modify any right,
benefit, obligation or other term of any such Contract; or (iv)&nbsp;result in the creation of any Lien (other than Permitted Liens) upon any asset owned by any of Parent or any of its Subsidiaries, other than, in the case of clauses (ii), (iii) and
(iv), any such contraventions, conflicts, violations, breaches, defaults, rights or Liens that would not have, and would not be reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <U>Legal Proceedings; Orders</U>. As of the date hereof, there is no pending Legal Proceeding or Order and, to the Knowledge
of Parent, no Person has threatened in writing to commence any Legal Proceeding or Order that involves Parent or any of its Subsidiaries or any of the assets owned or used by any of them, except for Legal Proceedings or Orders that have not had, and
would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4
<U>Information</U>. None of the information incorporated by reference or supplied or to be supplied by or on behalf of Parent or Merger Sub for inclusion in the Offer Documents or the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> will, at
the time such document is filed with the SEC, at any time it is amended or supplemented or at the time it is first published, sent or given to the Company&#146;s stockholders, contain any untrue statement of a material fact or omit to state any
material fact necessary to make the statements therein, in light of the circumstances under which they are made, not misleading. The Offer Documents will, at the time such documents are filed with the SEC, comply as to form in all material respects
with the requirements of the Exchange Act. No representation or warranty is made by Parent or Merger Sub with respect to statements included or incorporated by reference in the Offer Documents based on information supplied by or on behalf of the
Company for inclusion or incorporation by reference therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5 <U>Capitalization of Merger Sub</U>. The authorized capital
stock of Merger Sub consists of 1,000 shares of common stock, par value $0.01 per share, all of which are validly issued and outstanding. All of the issued and outstanding capital stock of Merger Sub is, and at the Effective Time will be, owned by
Parent. Merger Sub does not have outstanding any option, warrant, right or any other agreement pursuant to which any Person other than Parent may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquire any equity security of Merger Sub. Merger Sub shall not have conducted any business prior to the date of the Joinder and has, and prior to the Effective Time will have, no assets,
liabilities or obligations of any nature other than those incident to its formation and pursuant to this Agreement and the Offer, the Merger and the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6 <U>Sufficiency of Funds</U>. Parent and Merger Sub will have available to them at the Acceptance Time and the Effective Time,
respectively, funds sufficient to enable Parent and Merger Sub to satisfy all of their obligations pursuant to the Offer and under this Agreement, including the payment of the aggregate Offer Price and the aggregate Merger Consideration, and any
fees and expenses of or payable by Parent or Merger Sub or Parent&#146;s other Affiliates in connection herewith or therewith, and for any repayment or refinancing of any outstanding indebtedness of the Company and/or its Subsidiaries contemplated
by, or required in connection with the transactions described in, this Agreement. Each of Parent and Merger Sub expressly acknowledges and agrees that its obligations under this Agreement to consummate the transactions contemplated by this
Agreement, are not subject to, or conditioned on, the receipt or availability of any funds or financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7 <U>Finders or
Brokers</U>. Except for Citigroup Global Markets Inc., neither Parent nor any of its Subsidiaries (including Merger Sub) has employed any broker, finder, investment banker or other Person who may be entitled to any brokerage, finder&#146;s, success,
completion or similar fee or commission in connection with the Offer, the Merger or any of the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8 <U>Ownership of Common Stock</U>. None of Parent, Merger Sub or any of their respective Subsidiaries beneficially owns,
directly or indirectly (including pursuant to a derivatives contract), any Shares or other securities convertible into, exchangeable for or exercisable for Shares or any securities of any Subsidiary of the Company other than ownership of Shares
through passive investments, pension or employee benefit plans or trusts for Parent&#146;s or its Affiliates&#146; employees, or limited partnership funds, mutual funds or similar entities that Parent has invested (where, in each case, Parent and
its Affiliates do not directly or indirectly control the management or policies of such entities), and none of Parent, Merger Sub or any of their respective Subsidiaries has any rights to acquire, directly or indirectly, any Shares, except pursuant
to this Agreement. None of Parent, Merger Sub or any of their &#147;affiliates&#148; or &#147;associates&#148; is, or at any time during the last three (3)&nbsp;years has been, an &#147;interested stockholder&#148; of the Company, in each case as
defined in Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9 <U>Solvency</U>. No transfer of property is being made, and no obligation is
being incurred, in connection with the transactions contemplated by this Agreement with the intent to hinder, delay or defraud either present or future creditors of Parent, the Company, or any of their Affiliates. Immediately after giving effect to
the consummation of the transactions contemplated by this Agreement (including any financings being entered into in connection therewith), Parent and the Surviving Corporation will be Solvent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10 <U>No Additional Representations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and Merger Sub acknowledges and agrees that it and its Representatives have received access to such books and records,
facilities, equipment, contracts and other assets of the Company and its Subsidiaries that it and its Representatives have desired or requested to review and that it and its Representatives have had full opportunity to meet with the management of
the Company and its Subsidiaries and to discuss the business and assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent and Merger Sub agree and acknowledge
that, except for the express representations and warranties contained in <U>Article 3</U> (to the extent modified by the Company Disclosure Letter and/or the Filed SEC Reports (other than any Excluded Forward-Looking Information), as applicable),
neither the Company nor any other Person makes any other express or implied representation or warranty on behalf of the Company or any of its Affiliates, including with respect to value, condition, merchantability or suitability with respect to the
Company or the Subsidiaries of the Company, to any of their respective businesses or the transactions contemplated by this Agreement. Parent and Merger Sub agree and acknowledge that in making the decision to enter into this Agreement and consummate
the transactions contemplated by this Agreement, Parent and Merger Sub have relied exclusively on the express representations and warranties contained in <U>Article 3</U> (to the extent modified by the Company Disclosure Letter and/or the Filed SEC
Reports (other than any Excluded Forward-Looking Information), as applicable) and have not relied on any other representation or warranty, express or implied. Parent and Merger Sub agree and acknowledge that neither the Company nor any Person has
made, and neither Parent nor Merger Sub has relied on, any representation or warranty, express or implied, as to the accuracy or completeness of any information regarding the Company or its Subsidiaries furnished or Made Available to Parent and its
Representatives, except as expressly set forth in <U>Article 3</U> (to the extent modified by the Company Disclosure Letter and/or the Filed SEC Reports (other than any Excluded Forward-Looking Information), as applicable) and neither the Company or
its Subsidiaries, its or their respective directors, officers, employees, agents or other Representatives, nor any other Person, shall be subject to any liability to Parent or any other Person resulting from the Company&#146;s making available to
Parent or Parent&#146;s use of such information, or any information, documents or material Made Available to Parent in the due diligence materials provided to Parent, including in the data room, other management presentations (formal or informal) or
in any other form in connection with the transactions contemplated by this Agreement. Without limiting the foregoing, the Company makes no representation or warranty to Parent or Merger Sub with respect to any business or financial projection,
guidance or forecast relating to the Company or any of its Subsidiaries, whether or not included in the data room or any management presentation. Each of Parent and Merger Sub, on its behalf and on behalf of its Affiliates, expressly waives any such
claim relating to the foregoing matters. Notwithstanding the foregoing, nothing in this <U>Section</U><U></U><U>&nbsp;4.10</U> shall limit Parent or Merger Sub&#146;s rights and remedies for Fraud with respect to the representations and warranties
contained in <U>Article 3</U> (to the extent modified by the Company Disclosure Letter and/or the Filed SEC Reports (other than any Excluded Forward-Looking Information), as applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS AND AGREEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <U>Conduct of Business by the Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From and after the date hereof and prior to the earlier of the Effective Time and the date, if any, on which this Agreement is earlier
terminated pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> (the &#147;<U>Termination Date</U>&#148;), and except (i)&nbsp;as may be required by applicable Law, any Governmental Entity of competent jurisdiction or the rules or regulations of the
NASDAQ Stock Market, (ii)&nbsp;as may be consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned), (iii)&nbsp;as may be expressly required or permitted by this Agreement, or (iv)&nbsp;as set forth
in <U>Section</U><U></U><U>&nbsp;5.1(a)</U> of the Company Disclosure Letter, the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (A)&nbsp;conduct its business in all material respects in the ordinary
course of business consistent with past practice, (B)&nbsp;preserve intact its present business organization, (C)&nbsp;keep available the services of its present officers and key employees (other than for cause) and (D)&nbsp;preserve the present
relationships and goodwill with customers, suppliers, manufacturers, resellers, licensors, licensees, distributors, Governmental Entities, joint venture partners and others having business dealings with the Acquired Companies; <U>provided</U>,
<U>however</U>, that no action by the Company or its Subsidiaries with respect to matters specifically addressed by any provision of <U>Section</U><U></U><U>&nbsp;5.1(b)</U> shall be deemed a breach of this sentence unless such action would
constitute a breach of such other provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the date hereof and prior to the earlier of the Effective Time and the
Termination Date, and except (w)&nbsp;as may be required by applicable Law, any Governmental Entity of competent jurisdiction or the rules or regulations of the NASDAQ Stock Market, (x)&nbsp;as may be consented to in writing by Parent (which consent
shall not be unreasonably withheld, delayed or conditioned), (y)&nbsp;as may be expressly required or permitted by this Agreement, (z)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Letter, the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) shall not, and shall not permit any of its Subsidiaries to, authorize, declare, set aside, accrue or pay any dividends on
or make any distribution with respect to its outstanding shares of capital stock (whether in cash, assets, stock or other securities of the Company or its Subsidiaries), except for dividends and distributions paid by Subsidiaries of the Company to
the Company or to any of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) shall not, and shall not permit any of its Subsidiaries to, directly or
indirectly, purchase, redeem or otherwise acquire any shares of its capital stock or any rights, warrants or options to acquire any such shares, other than the acquisition of Shares from a holder of a Company Equity Award in connection with the
satisfaction of withholding obligations or the payment of exercise price in accordance with the terms of the Company Equity Awards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) shall not, and shall not permit any of its Subsidiaries to, split, combine or reclassify any of its capital stock or
issue or authorize or propose the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) except as required by the terms of any Company Benefit Plan existing as
of the date hereof, shall not, and shall not permit any of its Subsidiaries to (A)&nbsp;establish, adopt or materially amend any material Company Benefit Plan (or any arrangement that would be a material Company Benefit Plan), (B)&nbsp;materially
increase the compensation or other benefits payable or provided to the Company&#146;s directors or employees at the level of Director or higher, (C)&nbsp;enter into any change of control agreement with any of the Company&#146;s directors or
employees at the level of Director or higher, (D)&nbsp;grant any Company Equity Awards or (E)&nbsp;hire, promote or terminate any employee, other than in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) shall not adopt any amendments to the Company&#146;s certificate of incorporation or bylaws or any comparable
organizational documents of any of the Company&#146;s Subsidiaries (including by merger, consolidation or otherwise) or adopt a shareholders&#146; rights plan, or enter into any agreement with respect to the voting of its share capital, equity
interests, or other ownership or voting interests; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) shall not, and shall not permit any of its Subsidiaries to, issue,
sell, pledge, dispose of or encumber, or authorize the issuance, sale, pledge, disposition or encumbrance of, any shares of its capital stock or other ownership interests in any Subsidiaries or joint ventures of the Company or any securities
convertible into, exercisable for or exchangeable for any such shares or ownership interests, other than (A)&nbsp;issuances of Shares in respect of any exercise or settlement of Company Equity Awards outstanding on the date hereof or as may be
granted after the date hereof as permitted under this Section&nbsp;5.1(b), and in accordance with the terms of the Company Equity Awards as in effect as of the execution of this Agreement or upon grant, as applicable, (B)&nbsp;sales or issuances of
Shares pursuant to the Company ESPP in accordance with its terms as in effect as of the execution of this Agreement or <U>Section</U><U></U><U>&nbsp;2.3(c)</U>, (C) any such transactions among the Company and its direct or indirect wholly owned
Subsidiaries or among the Company&#146;s direct or indirect wholly owned Subsidiaries, and (D)&nbsp;with respect to pledges or encumbrances, that solely involve the imposition of Permitted Liens; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) shall not, and shall not permit any of its Subsidiaries to (A)&nbsp;acquire any equity interest in any Person (other than
any direct or indirect wholly owned Subsidiary of the Company) or any division, businesses or equity securities thereof (including by merger, consolidation or otherwise) or all or a material portion of the assets, business or properties of any
Person (other than any direct or indirect wholly owned Subsidiary of the Company), except (I)&nbsp;for any such acquisitions for cash consideration that does not exceed $5,000,000 in the aggregate, (II)&nbsp;purchases of components, raw materials or
supplies, in each case with respect to this clause (II), in the ordinary course of business, or (III)&nbsp;capital expenditures in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)(xvi)</U>, (B) make any loans, advances or capital contributions
to, or investments in, any other Person, in excess of $500,000 in the aggregate, other than (I)&nbsp;to or in any direct or indirect wholly owned Subsidiary of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company, (II)&nbsp;to employees, consultants or independent contractors in the ordinary course of business, or (III)&nbsp;in connection with transactions permitted pursuant to the foregoing
clause (A)&nbsp;or capital expenditures in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)(xvi)</U>; or (C)&nbsp;acquire, directly or indirectly, any real property or interest therein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) except for transactions among the Company and its direct or indirect wholly owned Subsidiaries or among the
Company&#146;s direct or indirect wholly owned Subsidiaries, in each case, in the ordinary course of business, shall not sell, lease, exclusively license, transfer, abandon, subject to any Lien (other than Permitted Liens) or otherwise dispose of
any of its material assets, or disclose any of its material trade secrets (other than pursuant to customary confidentiality arrangements), other than (A)&nbsp;sales or other dispositions of inventory and excess, expired or obsolete properties or
assets in the ordinary course of business, (B)&nbsp;other sales or other dispositions of properties or assets having a fair market value of less than $500,000<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>in the aggregate or (C)&nbsp;as may
be required by any Governmental Entity in order to permit or facilitate the consummation of the transactions contemplated by this Agreement (in compliance with <U>Section</U><U></U><U>&nbsp;5.6</U>); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) shall not, and shall not permit any of its Subsidiaries to, (A)&nbsp;incur, assume, guarantee, or become liable or
responsible (whether directly, indirectly, contingently or otherwise) for any indebtedness for borrowed money, other than (I)&nbsp;any such indebtedness among the Company and its direct or indirect wholly owned Subsidiaries or among the
Company&#146;s direct or indirect wholly owned Subsidiaries, (II)&nbsp;guarantees or credit support provided by the Company or any of its direct or indirect wholly owned Subsidiaries for indebtedness of the Company or any of its direct or indirect
wholly owned Subsidiaries, to the extent such indebtedness is (x)&nbsp;in existence on the date of this Agreement or (y)&nbsp;incurred in compliance with this <U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U> or
<U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U> of the Company Disclosure Letter, and (III)&nbsp;indebtedness not to exceed $1,000,000 individually and $5,000,000 in aggregate principal amount outstanding at any time incurred by the Company or any of
its Subsidiaries other than in accordance with clauses (I)&nbsp;and (II), (B) issue or sell any debt securities of the Company or any of its Subsidiaries, including options, warrants, calls or similar rights, in each case, to acquire any debt
securities of the Company or any of its Subsidiaries, or (C)&nbsp;enter into any &#147;keep well&#148; or similar agreement to maintain any financial condition of another Person (other than the Company or a direct or indirect wholly owned Subsidiary
of the Company); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) shall not, and shall not permit any of its Subsidiaries to, enter into, modify, amend, renew, extend,
terminate or waive any rights under any Material Contract, or under any Contract that would have been a Material Contract had it been entered into prior to the date of this Agreement, except for entry, amendments, renewals, extensions, terminations
or waivers (A)&nbsp;as contemplated by <U>Section</U><U></U><U>&nbsp;2.4</U>, (B) in the case of any Contract of the type described in <U>Section</U><U></U><U>&nbsp;3.12(a)(xi)</U>, but without limiting
<U>Section</U><U></U><U>&nbsp;5.1(b)(viii)</U>, in the reasonable business judgment of the Acquired Companies, and (C)&nbsp;in the case of any Contract of the type described in <U>Section</U><U></U><U>&nbsp;3.12(a)(vii)</U> or
<U>Section</U><U></U><U>&nbsp;3.12(a)(viii)</U>, in the ordinary course of business consistent with past practice; <U>provided</U>, however, that the foregoing exceptions shall not apply to the extent such entry into, modification, amendment,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
termination or waiver of such Contract requires or provides for consent, acceleration, termination or any other material right for the benefit of a third party or material adverse consequence to
the Company that is, in each case, triggered in whole or in part by any of the transactions contemplated by this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) shall not, and shall not permit any of its Subsidiaries to, settle, pay or discharge any Legal Proceeding, other than
(A)&nbsp;any Legal Proceeding relating to Taxes or (B)&nbsp;any Legal Proceeding that results solely in a monetary obligation involving only the payment of monies (without the admission of wrongdoing) by the Company and its Subsidiaries of not more
than $1,000,000 individually and $3,000,000 in the aggregate (net of insurance or indemnification proceeds received); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) shall not, and shall not permit any of its Subsidiaries to, adopt or enter into a plan of complete or partial
liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) other than in the ordinary course of business, shall not, and shall not permit any of its Subsidiaries to,
(A)&nbsp;make, change or revoke any material Tax election, (B)&nbsp;make any material change to any material method of Tax accounting, (C)&nbsp;amend any material Tax Return, or (D)&nbsp;settle or compromise any Legal Proceeding in respect of
material Taxes for an amount materially in excess of the amount accrued or reserved with respect thereto on the financial statements of the Company and its Subsidiaries, in each case, if such action would reasonably be expected to result in a
material increase in the Tax liability of the Company and its Subsidiaries, taken as a whole; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) shall not, and shall
not permit any of its Subsidiaries to, make any change in material accounting methods, principles or practices, except as may be required (A)&nbsp;by GAAP (or any authoritative interpretation thereof), including pursuant to standards, guidelines and
interpretations of the Financial Accounting Standards Board or any similar organization or (B)&nbsp;by Law, including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> promulgated under the Securities Act, in each case as agreed to by the
Company&#146;s independent public accountants; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) shall not, and shall not permit any of its Subsidiaries to,
(A)&nbsp;enter into any new line of business, (B)&nbsp;enter into any agreement, arrangement or commitment that would limit or otherwise restrict the Company or its Affiliates, including following the Effective Time, Parent and its Affiliates, from
engaging or competing in any line of business or in any geographic area or (C)&nbsp;otherwise enter into any agreements, arrangements or commitments imposing material restrictions on their assets, operations or business (taken as a whole); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) shall not, and shall not permit any of its Subsidiaries to, incur any capital expenditure, except for (A)&nbsp;those
contemplated by the capital expenditure budget for the relevant fiscal year, which capital expenditure budget is set forth in <U>Section</U><U></U><U>&nbsp;5.1(b)(xvi)</U> of the Company Disclosure Letter (the &#147;<U>Capex Budget</U>&#148;), and
(B)&nbsp;any unbudgeted capital expenditure in an amount not to exceed in any year 115% of the aggregate amount indicated in the Capex Budget; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) shall not, and shall not permit any of its Subsidiaries to, adopt,
enter into, establish, terminate, amend or modify any collective bargaining agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) shall not, and shall not
permit any of its Subsidiaries to, abandon, withdraw, terminate, suspend, abrogate, amend or modify in any material respect any Registrations of the Company in a manner that would materially impair the operation of the business of the Company and
its Subsidiaries (taken as a whole); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix) shall not, and shall not permit any of its Subsidiaries to, agree, in
writing or otherwise, to take any of the foregoing actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <U>Control of Operations</U>. Nothing contained in this
Agreement shall give Parent or Merger Sub, directly or indirectly, the right to control or direct the Company&#146;s or its Subsidiaries&#146; operations prior to the Effective Time. Prior to the Effective Time, the Company shall exercise,
consistent with the terms and conditions of this Agreement and applicable Law, including any Antitrust Law, complete control and supervision over its and its Subsidiaries&#146; operations. Notwithstanding anything in this Agreement to contrary, the
Company&#146;s obligations under this Agreement to act or refrain from acting, or to cause Subsidiaries of the Company to act or refrain from acting, will, with respect to any joint venture and its subsidiaries, be subject to (A)&nbsp;express
requirements under the organizational documents of such entity and its subsidiaries and (B)&nbsp;the scope of the Company&#146;s or its Subsidiaries&#146; power and authority to bind such entity and its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <U>Access</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to compliance with applicable Laws, the Company shall afford to Parent and to its officers, employees, accountants, consultants,
legal counsel, financial advisors and agents and other representatives (collectively, &#147;<U>Representatives</U>&#148;) reasonable access, solely for reasonable business purposes or purposes reasonably related to consummating the Offer and/or the
Merger and carrying out post-Merger integration or post-Merger planning, during normal business hours, upon reasonable advance notice, throughout the period prior to the earlier of the Effective Time and the Termination Date, to the Company&#146;s
and its Subsidiaries&#146; properties, contracts, commitments, Tax returns, personnel, work papers, books and records, other than any such matters that relate to the negotiation and execution of this Agreement, including with respect to the
consideration or valuation of the Offer or the Merger or any financial or strategic alternatives thereto, or that relate to any Alternative Proposal or Superior Proposal. The foregoing notwithstanding, the Company shall not be required to afford
such access (i)&nbsp;if such access would, in the Company&#146;s good-faith discretion, (x)&nbsp;jeopardize any attorney-client or other legal privilege or trade secret protection or (y)&nbsp;contravene any applicable Law, fiduciary duty or binding
agreement (including any confidentiality agreement to which the Company or any of its Affiliates is a party); or (ii)&nbsp;to such information that relates to the minutes of the meetings of the Company Board or its committees where the Company Board
or any applicable committee discussed the transactions contemplated by this Agreement or any financial or strategic alternatives thereto </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including any presentations or other materials prepared by or for the Company Board or committees thereof, whether in connection with a specific meeting, or otherwise relating to such subject
matter); <U>provided</U> that, in the case of clause (i), the Company shall use commercially reasonable efforts to make appropriate substitute arrangements (including by way of example by entering into a joint defense or other similar agreement) to
permit disclosure to the maximum extent legally permissible that would not violate such attorney-client or other legal privilege or trade secret protection or contravene any applicable Law, fiduciary duty or binding agreement. Notwithstanding
anything contained in this Agreement to the contrary, the Company shall not be required to provide any access or make any disclosure pursuant to this <U>Section</U><U></U><U>&nbsp;5.3</U> to the extent such access or information is reasonably
pertinent to a litigation where the Company or any of its Affiliates, on the one hand, and Parent, Merger Sub or any of their respective Affiliates, on the other hand, are adverse parties or reasonably likely to become adverse parties.
Notwithstanding anything to the contrary in this Agreement, the Company may satisfy its obligations set forth above to provide access to properties, contracts, commitments, Tax returns, personnel, work papers, books and records and any other
documents and information by electronic means if physical access is not reasonably feasible or would not be permitted under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent agrees that all information provided to it or any of its Representatives in connection with this Agreement and the consummation of
the transactions contemplated by this Agreement shall be deemed to be &#147;Information&#148;, as such term is used in, and shall be treated in accordance with, the confidentiality agreement, dated as of December&nbsp;2, 2024, between the Company
and Parent (the &#147;<U>Confidentiality Agreement</U>&#148;) and the Clean Team Agreement, dated as of December&nbsp;19, 2024, between the Company and Parent (the &#147;<U>Clean Team Agreement</U>&#148;), both of which, notwithstanding anything to
the contrary set forth therein, shall continue in full force and effect until the Closing Date. If for any reason this Agreement is terminated prior to the Closing Date, the Confidentiality Agreement and the Clean Team Agreement shall nonetheless
continue in full force and effect in accordance with their respective terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4 <U>No Solicitation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly permitted by this <U>Section</U><U></U><U>&nbsp;5.4</U>, from the date of this Agreement until the earlier of the
Effective Time and the Termination Date, the Company agrees that it shall not, and shall cause its Subsidiaries and its and their respective directors and officers not to, and shall instruct its other Representatives not to, directly or indirectly,
(i)&nbsp;solicit, initiate or knowingly facilitate or encourage the making or submission of any inquiry, proposal, offer or indication of interest that constitutes, or would reasonably be expected to lead to, or result in, an Alternative Proposal,
(ii)&nbsp;participate in any discussions or negotiations regarding an Alternative Proposal or any inquiry, proposal, offer or indication of interest that would reasonably be expected to lead to, or result in, an Alternative Proposal with, or furnish
any nonpublic information in connection with an Alternative Proposal to, any Person (or any of its Representatives in their capacity of Representatives of such Person) that has made or, to the knowledge of the Company, is considering making an
Alternative Proposal or any inquiry, proposal, offer or indication of interest that would reasonably be expected to lead to, or result in, an Alternative Proposal, (iii)&nbsp;enter into any binding or
<FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent, memorandum of understandings, agreement in principle, acquisition agreement, merger agreement or other similar agreement providing for an Alternative Proposal (except for
confidentiality agreements permitted under <U>Section</U><U></U><U>&nbsp;5.4(b))</U> or (iv) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
publicly announce an intention or interest to take, any of the foregoing actions; <U>provided</U> that the Company or the Company Board shall be permitted to grant a waiver of any standstill
agreement with any Person to permit such Person to make an Alternative Proposal to the Company Board if the Company Board determines in good faith, after consultation with the Company&#146;s outside legal counsel, that the failure to take such
action would be reasonably likely to be inconsistent with the Company Board&#146;s fiduciary duties under applicable Law. The Company shall, and shall cause its Subsidiaries and Representatives to, cease immediately and cause to be terminated any
and all existing discussions or negotiations, if any, with any Person and its Representatives conducted prior to the date hereof with respect to any Alternative Proposal or inquiry, proposal, offer or indication of interest that would reasonably be
expected to lead to an Alternative Proposal and shall promptly (and in any event within one (1)&nbsp;Business Day after the date hereof) terminate access by any such Person and its Representatives to any physical or electronic data room relating to
any such discussions or negotiations and promptly (and in any event within five (5)&nbsp;Business Days after the date hereof) request the return or destruction of all <FONT STYLE="white-space:nowrap">non-public</FONT> information furnished by the
Company or on its behalf to any such Person or its Representatives pursuant to any confidentiality agreements entered in the past eighteen (18)&nbsp;months with any such Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding <U>Section</U><U></U><U>&nbsp;5.4(a)</U>, if after the date of this Agreement and prior to the Acceptance Time, the
Company receives a written Alternative Proposal that did not result from a material breach of this <U>Section</U><U></U><U>&nbsp;5.4</U> and the Company Board determines in good faith after consultation with the Company&#146;s financial advisor and
outside legal counsel that (i)&nbsp;such Alternative Proposal constitutes a Superior Proposal or (ii)&nbsp;such Alternative Proposal would reasonably be expected to lead to, or result in, a Superior Proposal (a &#147;<U>Qualifying
Proposal</U>&#148;), the Company may take the following actions during the time prior to the Acceptance Time: (A)&nbsp;furnish information (including <FONT STYLE="white-space:nowrap">non-public</FONT> information) to the third party making such
Alternative Proposal (including its Representatives and prospective equity and debt financing sources), if, and only if, prior to so furnishing such information, the third party has executed a customary confidentiality agreement with the Company
having provisions as to confidential treatment of information that are not less restrictive in the aggregate to such third party than the confidentiality provisions in the Confidentiality Agreement are to Parent (it being understood that such
confidentiality agreement need not contain any &#147;standstill&#148; or similar provisions or otherwise prohibit the making or amendment of any Alternative Proposal); <U>provided</U> that any <FONT STYLE="white-space:nowrap">non-public</FONT>
information concerning the Company or any Subsidiary of the Company provided or made available to the Person making such Alternative Proposal shall, to the extent not previously provided to Merger Sub or Parent, be provided or made available to
Merger Sub or Parent prior to or substantially concurrently with it being provided to such Person making such Alternative Proposal, and (B)&nbsp;engage in or otherwise participate in discussions or negotiations with the third party (including its
Representatives) with respect to the Qualifying Proposal. The Company shall promptly (and in any event within <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;hours) (i) notify Parent in writing if any inquiries, indications of interest,
proposals or offers providing for or that would reasonably be expected to lead to, or result in, an Alternative Proposal are received by the Company or any of its Representatives from any Person or group (other than Parent and its Affiliates) and
(ii)&nbsp;disclose to Parent the material terms and conditions of any such Alternative Proposal (or inquiry, proposal, offer or indication of interest), including the identity of the Person or Persons (and, in the case of a Person owned or managed
by one or more funds managed by a financial sponsor, the identity of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such financial sponsor, and, in the case of any other Person, the identity of the ultimate parent company of such Person, in each case, to the extent known by the Company) making such Alternative
Proposal, or any such inquiry, proposal, offer, or indication of interest. The Company will keep Parent reasonably informed on a reasonably prompt basis (and in any event within <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;hours) of
all material terms and conditions of, and all material developments relating to, such Alternative Proposal (or inquiry, proposal, offer or indication of interest). The Company shall promptly (and in any event within
<FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;hours) provide Parent summaries of any material terms and conditions conveyed orally between the Company (or any of its Representatives) and the Person or Persons making such Alternative
Proposal (or any of their Representatives) relating to such Alternative Proposal (or inquiry, proposal, offer or indication of interest) and copies of any draft agreements, commitment letters (subject to customary redactions of the financial terms
of fee letters that do not affect the availability, timing, conditionality, enforceability, termination or aggregate principal amount of the financing relating thereto) or written proposals relating to such inquiry, proposal, offer, indication of
interest or Alternative Proposal delivered between the Company (or any of its Representatives) and the Person or Persons making such Alternative Proposal (or any of their Representatives). The Company will not enter into any agreement with any
Person that prohibits the Company from providing the information to Parent required under this <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as expressly permitted by this <U>Section</U><U></U><U>&nbsp;5.4</U>, the Company Board, including any committee thereof, shall not
(i)&nbsp;withdraw or withhold the Company Recommendation or qualify or modify in a manner adverse to Parent, the Company Recommendation (or resolve or publicly propose to do so); (ii) fail to include the Company Recommendation in the Schedule <FONT
STYLE="white-space:nowrap">14D-9</FONT> when filed with the SEC or disseminated to the holders of Shares; (iii)&nbsp;(A) if any Alternative Proposal has been publicly disclosed, fail to publicly recommend against such Alternative Proposal within ten
(10)&nbsp;Business Days after a request from Parent to do so, or (B)&nbsp;if any tender offer or exchange offer for the outstanding Shares is commenced pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2</FONT> under the Exchange Act (other than
by Parent or an Affiliate of Parent), fail to recommend, within ten (10)&nbsp;Business Days after such commencement, against acceptance of such tender offer or exchange offer by the Company&#146;s stockholders; (iv)&nbsp;approve, adopt, recommend or
declare advisable any Alternative Proposal or publicly propose to approve, adopt, recommend or declare advisable any Alternative Proposal; or (v)&nbsp;approve, adopt, recommend or declare advisable or enter into any letter of intent, memorandum of
understanding, agreement in principle, acquisition agreement, merger agreement or other similar agreement (except for confidentiality agreements permitted under <U>Section</U><U></U><U>&nbsp;5.4(b)</U>) with respect to any Alternative Proposal (any
such action set forth in the foregoing clauses (i)&nbsp;through (v), a &#147;<U>Change of Recommendation</U>&#148;). Anything to the contrary set forth in this Agreement notwithstanding, prior to the occurrence of the Acceptance Time, the Company
Board may, in response to a Superior Proposal, (x)&nbsp;make a Change of Recommendation or (y)&nbsp;cause the Company to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f) </U>to accept such Superior Proposal; <U>provided</U>,
that the Company Board shall not be entitled to make such a Change of Recommendation or cause any termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)</U> unless (A)&nbsp;the Company shall have given Parent at least four
(4)&nbsp;Business Days&#146; written notice (a &#147;<U>Superior Proposal Notice</U>&#148;) advising Parent of its intention to make such a Change of Recommendation or terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)</U>,
which Superior Proposal Notice shall include a description of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material terms and conditions of the Superior Proposal that is the basis for the proposed action of the Company Board, the identity of the Person or Persons (and, in the case of a Person owned or
managed by one or more funds managed by a financial sponsor, the identity of such financial sponsor, and, in the case of any other Person, the identity of the ultimate parent company of such Person, in each case, to the extent known by the Company)
making the Superior Proposal and unredacted copies of all proposed definitive agreements to be entered into in connection with such Superior Proposal and all commitment letters (subject to customary redactions of the financial terms of fee letters
that do not affect the availability, timing, conditionality, enforceability, termination or aggregate principal amount of the financing relating thereto) related thereto, if any, (B)&nbsp;the Company shall have (and shall have caused its
Representatives to have) negotiated in good faith with Parent and its Representatives (to the extent Parent wishes to negotiate) to enable Parent to make such amendments to the terms of this Agreement as would result in such Alternative Proposal
ceasing to be a Superior Proposal or as would permit the Company Board not to effect a Change of Recommendation or terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)</U> in connection with such Alternative Proposal, and
(C)&nbsp;at the end of the four (4)-Business Day period following the delivery of such Superior Proposal Notice (the &#147;<U>Superior Proposal Notice Period</U>&#148;), after taking into account any commitments made by Parent in writing to amend
the terms of this Agreement during the Superior Proposal Notice Period, the Company Board, after consultation with the Company&#146;s financial advisor and outside legal counsel, concludes that the Superior Proposal giving rise to the Superior
Proposal Notice continues to constitute a Superior Proposal if such amendments were to be given effect and that the failure to either effect a Change of Recommendation or terminate this Agreement and enter into a definitive agreement with respect to
such Superior Proposal would be reasonably likely to be inconsistent with the Company Board&#146;s fiduciary duties under applicable Law; <U>provided</U> that any change or modifications to the financial terms or other material changes or
modifications to the terms of the Superior Proposal shall require an additional notice to Parent and commence a new notice period pursuant to clauses (A), (B) and (C)&nbsp;of two (2)&nbsp;Business Days after the time that Parent receives such
additional notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Anything to the contrary set forth in this Agreement notwithstanding, prior to the occurrence of the Acceptance
Time, the Company Board may, in response to an Intervening Event, make a Change of Recommendation if the Company Board determines in good faith, after consultation with the Company&#146;s outside legal counsel, that the failure of the Company Board
to take such action would be reasonably likely to be inconsistent with its fiduciary duties under applicable Law; <U>provided</U> that the Company Board shall not be entitled to make such a Change of Recommendation unless (i)&nbsp;the Company shall
have given Parent at least four (4)&nbsp;Business Days&#146; written notice (an &#147;<U>Intervening Event Notice</U>&#148;) advising Parent of its intention to make such a Change of Recommendation, which Intervening Event Notice shall include a
reasonably detailed description of the applicable Intervening Event and the Company shall have (and shall have caused its Representatives to have) negotiated in good faith with Parent and its Representatives (to the extent Parent wishes to
negotiate) to enable Parent to make such amendments to the terms of this Agreement as would permit the Company Board not to effect a Change of Recommendation in connection with such Intervening Event and (ii)&nbsp;at the end of the four (4)-Business
Day period following the delivery of such Intervening Event Notice (the &#147;<U>Intervening Event Notice Period</U>&#148;), after taking into account any commitments made by Parent in writing to amend the terms of this Agreement during the
Intervening Event Notice Period, the Company Board determines in good </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
faith, after consultation with the Company&#146;s outside legal counsel, that the failure of the Company Board to make such Change of Recommendation would continue to be reasonably likely to be
inconsistent with its fiduciary duties under applicable Law if such amendments were to be given effect, <U>provided</U> that any material change to the events, changes, occurrences or developments constituting the Intervening Event that was
previously the subject of such Intervening Event Notice hereunder shall require an additional notice to Parent and commence a new notice period pursuant to clauses (i)&nbsp;and (ii) of two (2)&nbsp;Business Days after the time that Parent receives
such additional notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Nothing contained in this Agreement shall prohibit the Company or the Company Board or any committee thereof
from (i)&nbsp;complying with its disclosure obligations under applicable Law (including Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or Rule <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> or Item 1012(a) of Regulation <FONT
STYLE="white-space:nowrap">M-A</FONT> under the Exchange Act) or rules and policies of the NASDAQ Stock Market, (ii)&nbsp;issuing a &#147;stop, look and listen&#148; statement pending disclosure of its position thereunder or (iii)&nbsp;making any
disclosure to its stockholders if the Company Board determines in good faith, after consultation with the Company&#146;s outside legal counsel, that the failure of the Company Board to make such disclosure would be reasonably likely to be
inconsistent with its fiduciary duties under applicable Law; <U>provided</U><I></I>&nbsp;that (A)&nbsp;no such disclosure described in clause (ii)&nbsp;shall in and of itself, be considered a Change of Recommendation and (B)&nbsp;in no event shall
the Company be permitted to make any disclosure that constitutes a Change of Recommendation unless it and the Company Board have complied with <U>Sections 5.4(c)</U> or <U>5.4(d)</U>, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Alternative Proposal</U>&#148; means any proposal, offer or indication of interest made by any Person or group of Persons (other
than Parent, Merger Sub or their respective controlled Affiliates), and whether involving a transaction or series of related transactions, for, or that would result in, (i)&nbsp;a merger, reorganization, dissolution, liquidation, share exchange,
consolidation, business combination, recapitalization or similar transaction involving the Company or any Subsidiary of the Company, in each case, as a result of which the stockholders of the Company immediately prior to such transaction would cease
to own at least 80% of the total voting power of the Company or the surviving entity (or any direct or indirect parent company thereof), as applicable, immediately following such transaction, (ii)&nbsp;the acquisition by any Person or group of
Persons (other than Parent, Merger Sub or their respective controlled Affiliates), whether by sale, lease, exclusive license, exchange, transfer, acquisition, disposition or otherwise, of assets accounting for more than 20% of the net revenues, net
income or total assets of the Company and its Subsidiaries, in each case, on a consolidated basis, or (iii)&nbsp;the acquisition by any Person or group of Persons (other than Parent, Merger Sub or their respective Affiliates) of more than 20% of the
total voting power of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Superior Proposal</U>&#148; means a written Alternative Proposal that did not result from
a material breach of <U>Section</U><U></U><U>&nbsp;5.4(a)</U>, made after the date of this Agreement, substituting in the definition thereof &#147;50%&#148; for &#147;20%&#148; and for &#147;80%&#148; in each place each such phrase appears, that the
Company Board determines in good faith, after consultation with the Company&#146;s financial advisor and outside legal counsel, taking into account all relevant circumstances, including the timing, likelihood of consummation, financial, legal,
regulatory and other aspects of such Alternative Proposal and any revisions to this Agreement made or offered in writing by Parent prior to the time of such determination, to be more favorable to the Company&#146;s stockholders from a financial
point of view than the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Intervening Event</U>&#148; means any material event, change, occurrence or
development that is unknown and not reasonably foreseeable to the Company Board as of the date of this Agreement or, if known or reasonably foreseeable, the material consequences of which were not known or reasonably foreseeable to the Company Board
as of the date of this Agreement; <U>provided</U> that none of the following shall be deemed to constitute an Intervening Event or taken into account in determining whether an Intervening Event has occurred: (i)&nbsp;the receipt, existence or terms
of an Alternative Proposal or any inquiry, offer or proposal that constitutes or would reasonably be expected to lead to an Alternative Proposal or (ii)&nbsp;any change in and of itself in the stock price of the Common Stock of the Company
(<U>provided</U> that the underlying causes thereof may be taken into account). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Nothing in this Agreement shall prohibit (i)&nbsp;the
Company, or the Company Board, directly or indirectly through any Representative, from informing any Person of the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;5.4</U> or (ii)&nbsp;the Company, its Subsidiaries and its and their
respective Representatives from contacting in writing any Persons or group of Persons that have made an Alternative Proposal that did not result from a material breach of this <U>Section</U><U></U><U>&nbsp;5.4</U> solely to request clarification of
(and not to negotiate) the terms and conditions thereof so as to determine whether the Alternative Proposal is, or would reasonably be expected to lead to, or result in, a Superior Proposal, and any such actions shall not be a breach of this
Agreement, <U>provided</U> that in the case of clause (ii), but without limiting <U>Section</U><U></U><U>&nbsp;5.4(b)</U>, (A) such contact and requests for clarification are in writing and provided to Parent in advance of being delivered to such
Person or group of Persons, (B)&nbsp;such contact and requests direct such Person or group of Persons (or their Representatives) to respond only in writing and (C)&nbsp;any responses by such Person or group of Persons (or any of their
Representatives) received by the Company or any of its Representatives relating to such Alternative Proposal (prior to it becoming a Qualifying Proposal) are promptly provided to Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5 <U>Employee Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of twelve (12)&nbsp;months following the Effective Time (the &#147;<U>Benefits Continuation Period</U>&#148;), Parent shall
provide, or shall cause to be provided, to each individual who is an employee of the Company and its Subsidiaries as of immediately prior to the Effective Time (&#147;<U>Company Employees</U>&#148;), while employed with Parent and its Subsidiaries
during the Benefits Continuation Period, (i)&nbsp;base salary or wage rate and target short-term cash incentive opportunities that are no less favorable in the aggregate than were provided to the Company Employee immediately before the Effective
Time (<U>provided</U>, <U>however</U>, that each Company Employee&#146;s base salary or wage rate shall not be reduced during the Benefits Continuation Period), (ii) target equity incentive opportunities that are no less favorable than those
provided by Parent and its Subsidiaries to their similarly-situated employees, and (iii)&nbsp;employee benefits (excluding, for the avoidance of doubt, equity incentive award opportunities, which are addressed in the foregoing clause (ii)) that are
no less favorable than those provided to similarly-situated employees of Parent and its Subsidiaries (<U>provided</U>, <U>however</U>, that Parent shall cause the Company Employees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to transfer onto the employee benefits platform of Parent and its Subsidiaries as soon as administratively practicable following the Closing, and prior to such transfer the Company Employees
shall continue to receive employee benefits that are no less favorable than those provided to them immediately prior to the Effective Time). Without limiting the generality of the immediately preceding sentence, Parent shall or shall cause the
Surviving Corporation to provide to each Company Employee whose employment terminates during the Benefits Continuation Period (other than any Company Employee with severance rights pursuant to an individual agreement or other contractual
arrangement) severance benefits equal to the severance benefits provided to similarly situated employees of Parent and its Subsidiaries under the severance arrangements of Parent and its Subsidiaries; <U>provided</U> that severance benefits shall be
determined without taking into account any reduction after the Effective Time in compensation paid or benefits provided to such Company Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For all purposes under the employee benefit plans of Parent and its Subsidiaries providing benefits to any Company Employees after the
Effective Time (the &#147;<U>New Plans</U>&#148;), but not for purposes of benefit accruals under any defined benefit pension plan, each Company Employee shall be credited with his or her years of service with the Company and its Subsidiaries and
their respective predecessors before the Effective Time, to the same extent as such Company Employee was entitled, before the Effective Time, to credit for such service under any similar Company Benefit Plan in which such Company Employee
participated or was eligible to participate immediately prior to the Effective Time, except to the extent such service credit would result in a duplication of benefits. In addition, and without limiting the generality of the foregoing, Parent shall
cause (i)&nbsp;each Company Employee to be immediately eligible to participate, without any waiting time, in any and all New Plans that provide health or welfare benefits to the extent coverage under such New Plan is comparable to a Company Benefit
Plan in which such Company Employee participated immediately before the Effective Time (such plans, collectively, the &#147;<U>Old Plans</U>&#148;), and (ii)&nbsp;for purposes of each New Plan providing medical, dental, pharmaceutical or vision
benefits to any Company Employee, all <FONT STYLE="white-space:nowrap">pre-existing</FONT> condition exclusions and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">actively-at-work</FONT></FONT> requirements of such New Plan to be
waived for such employee and his or her covered dependents, unless such conditions would not have been waived under the comparable plans of the Company or its Subsidiaries in which such employee participated immediately prior to the Effective Time,
and any eligible expenses incurred by such employee and his or her covered dependents during the portion of the plan year of the Old Plans ending on the date such employee&#146;s participation in the corresponding New Plan begins to be taken into
account under such New Plan for purposes of satisfying all deductible, coinsurance and maximum <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> requirements applicable to such employee and his or her
covered dependents for the applicable plan year as if such amounts had been paid in accordance with such New Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) From and after the
Effective Time, the Company shall, and Parent shall cause the Company to, honor all Company Benefit Plans in accordance with their terms as in effect immediately before the Effective Time. Parent acknowledges that a &#147;change in control&#148; (or
similar phrase) within the meaning of the Company Benefit Plans will occur at or prior to the Effective Time, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Unless otherwise instructed by Parent no later than ten (10)&nbsp;Business Days prior to
the Effective Time, the Company shall, no later than one (1)&nbsp;Business Day prior to the Effective Time, execute resolutions, in a form incorporating any reasonable comments from Parent, effecting the termination of any plan sponsored or
maintained by any of the Acquired Companies that contains a cash or deferred arrangement intended to qualify under Section&nbsp;401(a) of the Code (the &#147;<U>Terminated 401(k) Plans</U>&#148;), subject to the occurrence of the Effective Time.
Individuals who participated in the Terminated 401(k) Plans prior to the Effective Time shall be eligible to participate, as soon as administratively practicable following the Effective Time, in a plan sponsored or maintained by Parent or its
Subsidiaries that contains a cash or deferred arrangement intended to qualify under Section&nbsp;401(a) of the Code (the &#147;<U>Parent 401(k) Plan</U>&#148;) on terms no less favorable than those applicable to similarly situated employees of
Parent and its Subsidiaries. Parent shall take or cause to be taken any and all actions as may be required to permit participants in the Terminated 401(k) Plans to make rollover contributions from the Terminated 401(k) Plans to the Parent 401(k)
Plan of &#147;eligible rollover distributions&#148; (within the meaning of Section&nbsp;401(a)(31) of the Code) in an amount up to the full account balance distributed to such individual from the Terminated 401(k) Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Following the Effective Time, Parent shall establish (or cause to be established) a cash-based retention program for the benefit of
eligible Company Employees, which program shall be designed and administered in accordance with Section&nbsp;5.5(e) of the Company Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Without limiting the generality of <U>Section</U><U></U><U>&nbsp;8.9</U>, the provisions of this <U>Section</U><U></U><U>&nbsp;5.5</U> are
solely for the benefit of the parties to this Agreement, and no current or former director, employee or consultant or any other person shall be a third-party beneficiary of this Agreement, and nothing in this Agreement shall be construed as an
amendment to any Company Benefit Plan or other compensation or benefit plan or arrangement for any purpose. The provisions of this <U>Section</U><U></U><U>&nbsp;5.5 </U>shall survive the consummation of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6 <U>Efforts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions set forth in this Agreement, the Company (and its Subsidiaries) and Parent (and its Subsidiaries and
Affiliates) shall cooperate with the other parties and use their respective reasonable best efforts to consummate and make effective the consummation of the Offer, the Merger and the other transactions contemplated by this Agreement as promptly as
reasonably practicable after the date hereof, and in any event prior to the End Date, including: (i)&nbsp;preparing and filing all documentation necessary to effect all necessary actions or nonactions, waivers, consents, clearances, approvals and
expirations or terminations of waiting periods from any Governmental Entity; (ii)&nbsp;obtaining all necessary actions or nonactions, waivers, consents, clearances, or approvals from third parties; (iii)&nbsp;defending any Legal Proceedings, whether
judicial or administrative, challenging this Agreement or challenging, hindering, impeding, interfering with or delaying the consummation of the Offer, the Merger and the other transactions contemplated by this Agreement, including seeking to have
any stay, temporary restraining order or injunction entered by any court or other Governmental Entity vacated or reversed; and (iv)&nbsp;executing and delivering any additional instruments necessary to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consummate the transactions contemplated by this Agreement; <U>provided</U>, <U>however</U>, that in no event shall Parent, Merger Sub, the Company or any of their respective Subsidiaries be
required to pay prior to the Effective Time any fee, penalty or other consideration to any third party for any consent or approval required for or triggered by the consummation of the transactions contemplated by this Agreement under any contract or
agreement or otherwise (and without the prior written consent of Parent, none of the Company nor any Subsidiary of the Company shall pay or make or commit to pay or make any such payment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and conditions in this Agreement and without limiting the foregoing, the Company (and its Subsidiaries) and Parent
(and its Subsidiaries and Affiliates) shall (i)&nbsp;file, or cause to be filed, all required Notification and Report Forms pursuant to the HSR Act with respect to the Offer, the Merger and the other transactions contemplated by this Agreement
within ten (10)&nbsp;Business Days after the date hereof and file, or cause to be filed, any filing (or draft thereof) required under any other applicable Antitrust Law or Foreign Investment Law, if any, as promptly as practicable after the date
hereof, (ii)&nbsp;supply or cause to be supplied, as promptly as practicable any additional information or documentary material that may be requested pursuant to the HSR Act or any other applicable Antitrust Law or Foreign Investment Law and
(iii)&nbsp;use its reasonable best efforts to obtain all necessary actions or nonactions, waivers, consents, clearances, approvals and expirations or terminations of waiting periods under the HSR Act and any other applicable Antitrust Law or Foreign
Investment Law, if any, as promptly as practicable after the date hereof, and in any event prior to the End Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In furtherance and
not in limitation of the foregoing, Parent (and its Subsidiaries and Affiliates) shall (and at the request of Parent, the Company and its Subsidiaries shall) take, or cause to be taken, all actions and do, or cause to be done, all things necessary,
proper or advisable to resolve such objections any Governmental Entity may assert under any Antitrust Law or Foreign Investment Law with respect to the Offer, the Merger and the other transactions contemplated by this Agreement, and to avoid or
eliminate each and every impediment under any Antitrust Law or Foreign Investment Law that may be asserted by any Governmental Entity with respect to the Offer, the Merger and the other transactions contemplated by this Agreement so as to enable the
Closing to occur as promptly as practicable after the date hereof (and in any event no later than the End Date), including (x)&nbsp;proposing, negotiating, committing to, effecting, agreeing to and executing, by consent decree, settlement,
undertaking, stipulations or otherwise, the sale, divestiture, transfer, license, hold separate or disposition of any and all of the share capital or other equity voting interests, assets (whether tangible or intangible), businesses, divisions,
operations, products or product lines of Parent (including its Subsidiaries and Affiliates) and of the Company (including its Subsidiaries), (y) terminating, transferring or creating relationships, contractual rights or other obligations of Parent
(including its Subsidiaries and Affiliates) and the Company (including its Subsidiaries) and (z)&nbsp;otherwise taking or committing to take any actions or agreeing to any undertakings that would limit Parent&#146;s (including its Subsidiaries&#146;
and Affiliates&#146;, including the Surviving Corporation&#146;s) freedom of action with respect to or their ability to retain, or impose obligations on Parent&#146;s (including its Subsidiaries&#146; and Affiliates&#146;, including the Surviving
Corporation&#146;s) future operations with respect to, assets (whether tangible or intangible), businesses, divisions, personnel, operations, products or product lines of Parent (and its Subsidiaries and Affiliates, including the Surviving
Corporation) or the Company (and its Subsidiaries), in each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case so as to satisfy the conditions to Closing or to avoid the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other order in any Legal Proceeding that
would otherwise have the effect of preventing the Closing, delaying the Closing or delaying the Closing beyond the End Date (each such action in the foregoing clauses (x), (y) and (z), a &#147;<U>Remedy Action</U>&#148;). Anything in this Agreement
to the contrary notwithstanding, (i)&nbsp;none of Parent, Merger Sub or any Subsidiary or Affiliate of Parent shall be required to (A)&nbsp;take or consent or agree to any Remedy Action (or other action pursuant to this
<U>Section</U><U></U><U>&nbsp;5.6(c)</U>) with respect to any of Parent&#146;s or its Subsidiaries&#146; or Affiliates&#146; assets (whether tangible or intangible), businesses, divisions, operations, products, or product lines that, individually or
in the aggregate, generated (or contributed to the generation of) greater than $25,000,000 in revenue during the 2023 fiscal year or (B)&nbsp;take or consent or agree to any action pursuant to <U>Section</U><U></U><U>&nbsp;5.6(a)</U> or this
<U>Section</U><U></U><U>&nbsp;5.6(c)</U> that, individually or in the aggregate, would reasonably be expected to result in a material adverse effect on the Company and its Subsidiaries (taken as a whole); (ii) none of Parent, Merger Sub, or the
Company, nor any of their respective Subsidiaries or Affiliates shall be required to agree to or effectuate any Remedy Action unless the effectiveness thereof is conditioned on the Closing; and (iii)&nbsp;without Parent&#146;s prior written consent,
the Company shall not (and shall not permit any Subsidiary of the Company to) take, commit or agree to any Remedy Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to
the other terms and conditions of this Agreement, each of the Company (and its Subsidiaries) and Parent (and its Subsidiaries and Affiliates) shall use its reasonable best efforts to (i)&nbsp;consult and cooperate in all respects with each other in
connection with any filing or submission with a Governmental Entity in connection with the Offer, the Merger and the other transactions contemplated by this Agreement and in connection with any investigation or other inquiry by or before a
Governmental Entity or any other Person relating to the Offer, the Merger and the other transactions contemplated by this Agreement, (ii)&nbsp;keep the other parties hereto promptly informed of any communication received by such party from any
Governmental Entity and of any communication received in connection with any proceeding by any other Person, in each case regarding the Offer, the Merger and the other transactions contemplated by this Agreement (and in the case of written
communications, furnish the other parties with a copy of such communication), (iii) permit the other parties to review and discuss in advance, and consider in good faith the views of the other parties in connection with, any proposed filing,
submission or other communication to any Governmental Entity or other Person regarding the Offer, the Merger and the other transactions contemplated by this Agreement, and (iv)&nbsp;to the extent not prohibited by the applicable Governmental Entity
or other Person, give the other parties hereto the opportunity to attend and participate in any meetings (whether <FONT STYLE="white-space:nowrap">in-person</FONT> or otherwise), telephone or video calls or other conferences, in each case, regarding
the Offer, the Merger and the other transactions contemplated by this Agreement. Notwithstanding the foregoing, any party may, as it deems advisable and necessary, reasonably (x)&nbsp;redact materials to protect competitively sensitive information
or information concerning valuation, or as necessary to address reasonable attorney-client, attorney work product or other privilege concerns and (y)&nbsp;reasonably designate any competitively sensitive material provided to the other parties under
this <U>Section</U><U></U><U>&nbsp;5.6(d)</U> as &#147;outside counsel only&#148; (such materials and the information contained therein shall be given only to the outside legal counsel of the recipient and will not be disclosed by such outside
counsel to employees, officers, or directors of the recipient, unless written permission is obtained in advance from the party providing the materials). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Subject to the other terms and conditions of this Agreement, if any Legal Proceeding
(administrative or judicial), decree, judgment, injunction or other order, including any proceeding by a private party, is instituted (or threatened to be instituted) challenging, hindering, impeding, interfering with or delaying any transaction
contemplated by this Agreement as violating any Antitrust Law or Foreign Investment Law, each of the Company (and its Subsidiaries) and Parent (and its Subsidiaries and Affiliates) shall cooperate in all respects with each other and shall use their
respective reasonable best efforts to contest and resist any such Legal Proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction or other order, whether temporary, preliminary or permanent, that is in effect
and that prohibits, prevents or restricts consummation of the Offer, the Merger and the other transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company (and its Subsidiaries) and Parent (and its Subsidiaries and Affiliates) shall jointly develop the (i)&nbsp;strategy for
obtaining all necessary actions or nonactions, waivers, consents, clearances, approvals and expirations or terminations of waiting periods so as to enable Closing to occur as soon as practicably possible, (ii)&nbsp;response to any request from,
inquiry by or investigation by (including the timing, nature and substance of all such responses) any Governmental Entity with respect to the Offer, the Merger and the other transactions contemplated by this Agreement and (iii)&nbsp;strategy for the
defense and settlement of any Legal Proceeding brought by or before any Governmental Entity that has authority to enforce the applicable Antitrust Laws or Foreign Investment Laws. No party shall extend any waiting period under the HSR Act (including
by withdrawing and refiling its filing under the HSR Act) or any other Antitrust Law or Foreign Investment Law or enter into any commitment to or agreement with any Governmental Entity to delay, or otherwise not to consummate as promptly as
practicable, the Offer, the Merger or the other transactions contemplated by this Agreement except with the prior written consent of the other party.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Parent shall not, and shall cause its Subsidiaries and Affiliates not to, acquire or agree to acquire, by merging with or into or
consolidating with, or by purchasing all or substantially all of the assets of or equity in, or by any other manner, any Person, business or any corporation, partnership, association or other business organization or division of any business or any
corporation, partnership, association or other business organization, if the entering into of a definitive agreement relating to, or the consummation of such acquisition, merger or consolidation would reasonably be expected to: (i)&nbsp;impose any
material delay in the obtaining of, or materially increase the risk of not obtaining, any consents of any Governmental Entity necessary to consummate the Offer, the Merger or the other transactions contemplated by this Agreement or the expiration or
termination of any applicable waiting period; (ii)&nbsp;materially increase the risk of any Governmental Entity seeking or entering an Order prohibiting the consummation of the Offer, the Merger or the other transactions contemplated by this
Agreement; (iii)&nbsp;materially increase the risk of not being able to remove any such Order on appeal or otherwise; or (iv)&nbsp;materially delay or prevent the consummation of the Offer, the Merger or the other transactions contemplated by this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7 <U>Takeover Statute</U>. If any &#147;fair price,&#148;
&#147;moratorium,&#148; &#147;control share acquisition&#148; or other form of antitakeover statute or regulation shall become applicable to the transactions contemplated by this Agreement (including the Offer and the Merger), each of the Company,
Parent and Merger Sub and the members of their respective boards of directors shall grant such approvals and take such actions as are reasonably necessary so that the transactions contemplated by this Agreement may be consummated as promptly as
practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8 <U>Public Announcements</U>. The parties agree that the initial press release to be issued with respect to this Agreement and
the transactions contemplated by this Agreement shall be in the form heretofore agreed to by the parties. The Company and Parent shall not, and shall cause their respective Subsidiaries to not, issue any press release or other public statement or
public comment relating to this Agreement or the transactions contemplated by this Agreement without the consent of the other party (not to be unreasonable withheld, conditioned or delayed), except (x)&nbsp;as may be required by applicable Law,
(y)&nbsp;by obligations pursuant to any listing agreement with any applicable national securities exchange or (z)&nbsp;if such information is substantially similar to information included in a press release or other communication previously approved
for public distribution by the other parties hereto, and in each such case of clause (x)&nbsp;or (y), the party required to make the release or announcement shall use reasonable best efforts to allow each other party reasonable time to comment on
such release or announcement in advance of such issuance; <U>provided</U> that the restrictions in this <U>Section</U><U></U><U>&nbsp;5.8</U> shall not apply to any Company communication relating to an Alternative Proposal (subject to compliance
with <U>Section</U><U></U><U>&nbsp;5.4</U>) or from and after a Change of Recommendation made in accordance with <U>Section</U><U></U><U>&nbsp;5.4(c)</U> or <U>Section</U><U></U><U>&nbsp;5.4(d)</U>. Prior to making any written (or prepared
broad-based) communications to the officers or employees of the Company or any of its Subsidiaries pertaining to compensation or benefit matters that are affected by the transactions contemplated by this Agreement or compensation or benefits that
are payable or to be provided following the Effective Time, the Company shall provide Parent with a copy of the intended communication (or written summary of any prepared broad-based oral communication) and the Company shall provide Parent a
reasonable period of time to review and comment on the communication, and the Company shall consider any timely comments in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.9 <U>Indemnification and Insurance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of six (6)&nbsp;years after the Effective Time, each of Parent and the Surviving Corporation shall, to the fullest extent
permitted under applicable Law, indemnify and hold harmless (and advance funds in respect of each of the foregoing or any related expenses) each current and former director or officer of the Company or any of its Subsidiaries and each Person who
served as a director, officer, member, trustee or fiduciary of another corporation, partnership or joint venture at the request of or for the benefit of the Company or its Subsidiaries (each, together with such Person&#146;s heirs, executors or
administrators, and successors and assigns, an &#147;<U>Indemnified Party</U>&#148;) against any costs or expenses (including advancing attorneys&#146; fees and expenses in advance of the final disposition of any Action to each Indemnified Party to
the fullest extent permitted by Law, provided that any Indemnified Party to whom expenses are advanced provides an undertaking to repay such advances if it is ultimately determined by final adjudication that such Indemnified Party is not entitled to
indemnification hereunder), judgments, fines, losses, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims, damages, obligations, costs, liabilities and amounts paid in settlement actually and reasonably incurred by such Person in connection with any actual or threatened Legal Proceeding
arising out of, relating to or in connection with any action or omission occurring or alleged to have occurred at or prior to the Effective Time (including acts or omissions in connection with such Persons serving as an officer, director, employee
or other fiduciary in any entity if such service was at the request or for the benefit of the Company or its Subsidiaries). In the event of any such action, Parent and the Surviving Corporation shall cooperate with the Indemnified Party in the
defense of any such Legal Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent and Merger Sub agree that all rights to exculpation, indemnification and advancement of
expenses now existing in favor of the Indemnified Parties as provided in their respective articles or certificates of incorporation, bylaws or other organizational documents or in any indemnification agreement shall survive the Merger and shall
continue at and after the Effective Time in full force and effect. For a period of six (6)&nbsp;years after the Effective Time, Parent and the Surviving Corporation shall maintain in effect the exculpation, indemnification and advancement of
expenses provisions of the Company&#146;s and any of its Subsidiaries&#146; articles or certificates of incorporation, bylaws or other organizational documents as in effect immediately prior to the Effective Time or in any indemnification agreements
of the Company or its Subsidiaries with any of the Indemnified Parties as in effect immediately prior to the Effective Time, and shall not amend, repeal or otherwise modify any such provisions in any manner that would adversely affect the rights
thereunder of the Indemnified Parties; <U>provided</U>, <U>however</U>, that all rights to indemnification in respect of any Legal Proceeding pending or asserted or any claim made within such period shall continue until the final disposition of such
Legal Proceeding or resolution of such claim, even if beyond such six (6)-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For a period of six (6)&nbsp;years from and
after the Effective Time, Parent and the Surviving Corporation shall either cause to be maintained in effect the current directors&#146; and officers&#146; insurance policy maintained by or for the benefit of the Company and its Subsidiaries and
their respective current and former directors and officers or provide a substitute policy for the Company and its Subsidiaries and their respective current and former directors and officers who are currently covered by the directors&#146; and
officers&#146; insurance policy currently maintained by or for the benefit of the Company and its Subsidiaries, in either case, in an amount not less than the existing coverage and having other terms not less favorable to the insured persons than
the directors&#146; and officers&#146; insurance policy currently maintained by or for the benefit of the Company and its Subsidiaries and their respective current and former directors and officers with respect to claims arising from facts or events
that occurred at or before the Effective Time, including in connection with the transactions contemplated by this Agreement (regardless of when prior to the sixth anniversary of the Effective Time such claims are brought) (with either the
Company&#146;s existing insurance carriers or substitute insurance carriers having at least an &#147;A&#148; rating by A.M. Best with respect to directors&#146; and officers&#146; insurance, as applicable), except that in no event shall Parent or
the Surviving Corporation be required to pay with respect to such insurance policies more than 300% of the aggregate annual premium most recently paid by the Company and its Subsidiaries (the &#147;<U>Maximum Amount</U>&#148;), and for the sake of
clarity, the Maximum Amount is set forth in <U>Section</U><U></U><U>&nbsp;5.9(c)</U> of the Company Disclosure Letter. If the Surviving Corporation is unable to obtain the insurance required by this <U>Section</U><U></U><U>&nbsp;5.9(c)</U> because
its cost exceeds the Maximum </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amount, it shall obtain as much comparable insurance as possible for the years within such six (6)-year period for a premium equal to the Maximum Amount. In lieu of such insurance, prior to the
Closing Date the Company may, and if requested by Parent the Company shall (subject to the occurrence of the Effective Time), purchase a six (6)-year prepaid &#147;tail&#148; directors&#146; and officers&#146; insurance policy for the Company and
its Subsidiaries and their respective current and former directors and officers who are currently covered by the directors&#146; and officers&#146; insurance policy currently maintained by or for the benefit of the Company and its Subsidiaries, such
tail to provide coverage in an amount not less than the existing coverage and to have other terms not less favorable to the insured persons than the directors&#146; and officers&#146; insurance policy currently maintained by or for the benefit of
the Company and its Subsidiaries with respect to claims arising from facts or events that occurred at or before the Effective Time, including in connection with the transactions contemplated by this Agreement; <U>provided</U>, <U>however</U>, that
in no event shall the cost of any such tail policy exceed the Maximum Amount. Parent and the Surviving Corporation shall maintain such policies in full force and effect, and continue to honor the obligations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the extent consistent with this <U>Section</U><U></U><U>&nbsp;5.9</U>, following the Effective Time, Parent shall pay all reasonable
expenses, including reasonable attorneys&#146; fees, that may be incurred by any Indemnified Party in enforcing the indemnity and other obligations provided in this <U>Section</U><U></U><U>&nbsp;5.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The rights of each Indemnified Party hereunder shall be in addition to, and not in limitation of, any other rights such Indemnified Party
may have under the articles of incorporation or bylaws or other organizational documents of the Company or any of its Subsidiaries or the Surviving Corporation, any other indemnification arrangement, the DGCL or otherwise. The provisions of this
<U>Section</U><U></U><U>&nbsp;5.9</U> shall survive the acceptance of Shares for payment pursuant to the Offer and the consummation of the Merger and expressly are intended to benefit, and are enforceable by, each of the Indemnified Parties. This
<U>Section</U><U></U><U>&nbsp;5.9</U> may not be amended, altered or repealed after the Acceptance Time in such a manner as to adversely affect the rights of any Indemnified Party without the prior written consent of the affected Indemnified Party.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) In the event that Parent, the Surviving Corporation or any of their respective successors or assigns (i)&nbsp;consolidates with or
merges into any other Person and shall not be the continuing or surviving corporation or entity in such consolidation or merger or (ii)&nbsp;transfers all or substantially all of its properties and assets to any Person, then, in either such case,
proper provision shall be made so that the successors and assigns of Parent or the Surviving Corporation, as the case may be, shall assume the obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10 <U>Stockholder Litigation</U>. Prior to the earlier of the Effective Time or the Termination Date, the Company shall control
(and give Parent notice as soon as reasonably practicable of, and the right to participate in (subject to a customary joint defense agreement) but not control) the defense of any litigation brought or threatened by stockholders of the Company
against the Company or its directors relating to this Agreement, the Offer, the Merger or the other transactions contemplated by this Agreement (whether directly or on behalf of the Company and its Subsidiaries or otherwise); <U>provided</U>,<I>
</I><U>however</U>, that the Company shall keep Parent reasonably informed regarding any such litigation or threatened litigation, give Parent the right to review and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comment on all material filings or responses to be made by the Company in connection with any such litigation or threatened litigation, and the right to consult on the settlement, release, waiver
or compromise of any such litigation or threatened litigation, and the Company shall in good faith take such comments and consultation into account, and no such settlement, release, waiver or compromise of such litigation or threatened litigation
shall be agreed to without Parent&#146;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11 <U>Stock </U><U>Exchange <FONT STYLE="white-space:nowrap">De-listing</FONT></U><U>; Exchange Act Deregistration</U>. Prior
to the Effective Time, the Company shall cooperate with Parent and use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under
applicable Laws and rules and policies of the NASDAQ Stock Market and the SEC to enable the <FONT STYLE="white-space:nowrap">de-listing</FONT> by the Surviving Corporation of the Common Stock from the NASDAQ Stock Market and the deregistration of
the Common Stock under the Exchange Act as promptly as practicable after the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12 <U>Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT></U>. Prior to the Acceptance Time, the Company shall take such steps as may be reasonably necessary or advisable hereto to cause dispositions or cancelations of Company equity securities (including derivative
securities) pursuant to the transactions contemplated by this Agreement by each individual who is a director or officer of the Company to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13 <U>Rule <FONT STYLE="white-space:nowrap">14d-10</FONT> Matters</U>. Prior to the Acceptance Time, the Company (acting
through the Company Board and its compensation committee) shall take all such steps as may be required to cause to be exempt under Rule <FONT STYLE="white-space:nowrap">14d-10(d)</FONT> under the Exchange Act any employment compensation, severance
or other employee benefit arrangement that has been, or after the date of this Agreement will be, entered into by the Company or any of its Subsidiaries with current or future directors, officers or employees of the Company or any of its
Subsidiaries and to ensure that any such arrangements fall within the safe harbor provisions of such rule. Promptly upon Parent or any of its Affiliates entering into any such arrangement with any current or future director, officer or employee of
the Company or any of its Subsidiaries, Parent will provide to the Company any and all information concerning such arrangements as may be needed by the Company to comply with this <U>Section</U><U></U><U>&nbsp;5.13</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.14 <U>Obligations of Parent</U>. Parent shall cause Merger Sub and each of Parent&#146;s other Subsidiaries, and the Surviving
Corporation, to comply with, duly perform, satisfy and discharge on a timely basis, all of their respective covenants, obligations and liabilities under this Agreement, and Parent shall be jointly and severally liable with such Subsidiaries for the
due and timely performance, satisfaction and discharge of each of the said covenants, obligations and liabilities. Additionally, whenever this Agreement requires Merger Sub to take any action, such requirement shall be deemed to include an
undertaking on the part of Parent to cause such Merger Sub to take such action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.15 <U>Notification of Certain Events</U>. Each of the Company and Parent
shall, as promptly as reasonably practicable, notify the other: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) upon becoming aware that any representation or warranty made by it in
this Agreement has become untrue or inaccurate in any material respect, or of any failure of such Person to comply with or satisfy in any material respect any covenant, condition or agreement to be complied with or satisfied by it under this
Agreement, in each case, that would individually or in the aggregate, reasonably be expected to lead to the failure of any of the Offer Conditions or conditions set forth <U>Section</U><U></U><U>&nbsp;6.1</U>; <U>provided</U>, <U>however</U>, that
no such notification shall affect or be deemed to modify any representation or warranty of such party set forth herein or the conditions to the obligations of the other party to consummate the Offer or the Merger, or the remedies available to the
parties; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) to the extent the Company or Parent has Knowledge, as the case may be, of any written communication from any Person
alleging that the consent of such Person is or may be required in connection with the Offer or the Merger, if the subject matter of such communication or the failure of such party to obtain such Consent would be material to the consummation of the
Offer or Merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, that failure to give any notice pursuant to this <U>Section</U><U></U><U>&nbsp;5.15</U> shall not be treated as a
breach of covenant for the purposes of Section (v)&nbsp;of <U>Exhibit A</U> or <U>Section</U><U></U><U>&nbsp;7.1(d)</U> or <U>Section</U><U></U><U>&nbsp;7.1(e)</U> of this Agreement, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.16 <U>Director Resignations</U>. The Company shall use its commercially reasonable efforts to obtain and provide to Parent, on
or prior to the Closing Date, to the extent requested in writing by Parent at least ten (10)&nbsp;Business Days prior to the Closing Date, resignation letters, effective as of and contingent upon the Effective Time, from each of the directors of the
Company as requested by Parent, resigning from such position as a director of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.17 <U>Merger Sub Formation;
Joinder; Stockholder Consent</U>. As promptly as practicable (but no later than the first Business Day that the Secretary of State of the State of Delaware is open to permit such formation and return evidence thereof) following the date of this
Agreement, Parent shall (a)&nbsp;form Merger Sub as a Delaware corporation and a directly wholly owned subsidiary of Parent and (b)&nbsp;cause Merger Sub to enter into the&nbsp;Joinder&nbsp;and deliver such&nbsp;Joinder&nbsp;to the Company. From the
execution of this Agreement and until such time as Merger Sub is formed and the&nbsp;Joinder&nbsp;is duly executed and delivered to the Company, Parent shall assume all of the rights and be subject to all of the obligations of Merger Sub set forth
in this Agreement. Immediately following the execution and delivery of the&nbsp;Joinder,&nbsp;Parent shall cause to be executed and delivered, (i)&nbsp;resolutions of the board of directors of Merger Sub approving this Agreement and the transactions
contemplated hereby and declaring it advisable for Merger Sub to enter into this Agreement (by way of the&nbsp;Joinder) and to consummate the transactions contemplated hereby and (ii)&nbsp;in accordance with Section&nbsp;228 of the DGCL, a written
consent of the sole stockholder of Merger Sub adopting this Agreement. The Company hereby consents to the Joinder being executed and, once executed, no further action of the Company is required for Merger Sub to be deemed a party to this Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <U>Conditions to Obligation of Each Party to Effect the Merger</U>. The respective obligations of each party to effect the
Merger shall be subject to the satisfaction (or mutual waiver by Parent and the Company to the extent permitted by applicable Law) at or prior to the Effective Time of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Legal Restraints</U>. No Law by any Governmental Entity of competent jurisdiction (a &#147;<U>Legal Restraint</U>&#148;) that
enjoins, prohibits or otherwise prevents the consummation of the Merger shall have been enacted, promulgated, issued or entered and shall continue to be in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Acceptance for Payment of Shares</U>. Merger Sub shall have irrevocably accepted for payment all Shares validly tendered and not
properly withdrawn pursuant to the Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <U>Frustration of Closing Conditions</U>. No party hereto may rely, as a basis
for not consummating the Offer or the Merger or terminating this Agreement and abandoning the Offer or the Merger, on the failure of any Offer Condition or any condition set forth in <U>Section</U><U></U><U>&nbsp;6.1</U>, as the case may be, to be
satisfied if such failure was caused by such party&#146;s breach of any covenant or agreement in this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1 <U>Termination or Abandonment</U>. Anything contained in this Agreement to the contrary notwithstanding, this Agreement may
be terminated and abandoned at any time prior to the Acceptance Time (except as expressly provided in <U>Section</U><U></U><U>&nbsp;7.1(i)</U>): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by the mutual written consent of the Company and Parent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by either the Company or Parent, if the Acceptance Time shall not have occurred on or before July&nbsp;7, 2025 (<U>provided</U> that if as
of such date all of the Offer Conditions shall have been satisfied or waived (other than (i)&nbsp;those conditions that by their nature cannot be satisfied until the expiration of the Offer, but provided that such conditions (other than the Minimum
Tender Condition) shall then be capable of being satisfied if the expiration of the Offer were to take place at such time, and (ii)&nbsp;the Regulatory Condition or the Absence of Legal Restraint Condition (only to the extent the applicable Legal
Restraint relates to an Antitrust Law or Foreign Investment Law)), then such date shall automatically be extended to October&nbsp;6, 2025), or such other date as may be agreed in writing between Parent and the Company (such applicable date, the
&#147;<U>End Date</U>&#148;); <U>provided</U> that the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(b)</U> shall not be available to any party (A)&nbsp;whose failure to perform any agreements or covenants
under this Agreement has been the principal cause of, or resulted in, the failure of the Acceptance Time to occur on or before such date or (B)&nbsp;during the pendency of any litigation brought by the other party to enforce the provisions of this
Agreement to cause the other party to effect the Closing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by either the Company or Parent, if any Governmental Entity shall have issued a Legal
Restraint that prohibits the consummation of the Offer or the Merger and such Legal Restraint shall have become final and nonappealable; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement pursuant to this
<U>Section</U><U></U><U>&nbsp;7.1(c)</U> shall not be available to any party whose failure to perform any agreements or covenants under <U>Section</U><U></U><U>&nbsp;5.6</U> has been the principal cause of, or resulted in, such Legal Restraint; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by the Company, if (x)&nbsp;Parent or Merger Sub shall have breached or there is any inaccuracy in any of their representations or
warranties contained in this Agreement, which breach or inaccuracy, would, or would reasonably be expected to, have a Parent Material Adverse Effect or (y)&nbsp;Parent or Merger Sub shall not have complied with or performed in all material respects
each covenant and obligation that Parent or Merger Sub is required to comply with or perform at or prior to the expiration of the Offer, and, in each case, which cannot be cured by the End Date or, if curable, is not cured within twenty
(20)&nbsp;Business Days following the Company&#146;s delivery of written notice to Parent stating the Company&#146;s intention to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> and the basis for such termination;
<U>provided</U> that the Company may not terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> if the Company is then in breach of any representation, warranty, covenant or agreement of the Company set forth in this
Agreement such that Parent has the right to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(e)</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by Parent,
if the Company shall have breached or there is any inaccuracy in any of its representations or warranties contained in this Agreement, or shall have breached or failed to perform any of its covenants or other agreements contained in this Agreement,
which breach, inaccuracy or failure to perform (i)&nbsp;would give rise to the failure of the conditions set forth in clause <U>(iv)</U>&nbsp;or <U>(v)</U> of <U>Exhibit A</U> and (ii)&nbsp;cannot be cured by the End Date or, if curable, is not
cured with twenty (20)&nbsp;Business Days following Parent&#146;s delivery of written notice to the Company stating Parent&#146;s intention to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(e)</U> and the basis for such
termination; <U>provided</U> that Parent may not terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(e)</U> if either Parent or Merger Sub is then in breach of any representation, warranty, covenant or agreement of Parent or
Merger Sub set forth in this Agreement such that the Company has the right to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(d)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by the Company, to enter into a definitive written agreement for a Superior Proposal, <U>provided</U> that (i)&nbsp;the Company has
complied in all material respects with the provisions of <U>Section</U><U></U><U>&nbsp;5.4</U> in respect of such Superior Proposal and (ii)&nbsp;the Company has paid, or concurrently with the termination of this Agreement pays, the Company
Termination Fee due under <U>Section</U><U></U><U>&nbsp;7.3</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by Parent, if a Change of Recommendation shall have occurred; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) by Parent or the Company if, at the expiration of the Offer (as such expiration date may
be extended in accordance with <U>Section</U><U></U><U>&nbsp;1.1</U>), any of the conditions set forth in <U>Exhibit A</U> shall not have been satisfied or validly waived by Parent and Parent is not required to, and does not otherwise, extend the
Offer pursuant to <U>Section</U><U></U><U>&nbsp;1.1(b)</U>; <U>provided</U> that the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(h)</U> shall not be available to any party whose failure to perform any
agreements or covenants under this Agreement has been the principal cause of, or resulted in, the failure of such conditions to be satisfied at such expiration of the Offer that is not extended as required or permitted pursuant to
<U>Section</U><U></U><U>&nbsp;1.1(b)</U>; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) by the Company, if Merger Sub (i)&nbsp;shall have failed to commence (within the meaning
of Rule <FONT STYLE="white-space:nowrap">14d-2</FONT> under the Exchange Act) the Offer within the period specified in <U>Section</U><U></U><U>&nbsp;1.1(a)</U> without the prior written consent of the Company, (ii)&nbsp;shall have terminated the
Offer prior to its expiration date (as such expiration date may be extended in accordance with <U>Section</U><U></U><U>&nbsp;1.1</U>), other than in accordance with this Agreement, (iii)&nbsp;shall have failed to accept all Shares validly tendered
(and not validly withdrawn) as of the expiration of the Offer (as such expiration date may be extended in accordance with <U>Section</U><U></U><U>&nbsp;1.1</U>) within the period specified in <U>Section</U><U></U><U>&nbsp;1.1</U> following the
expiration of the Offer; or (iv)&nbsp;shall have failed to purchase all Shares validly tendered (and not validly withdrawn) pursuant to the Offer within the period specified in <U>Section</U><U></U><U>&nbsp;1.1</U> following the Acceptance Time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 <U>Effect of Termination</U>. In the event of termination of this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.1</U>, the terminating party shall forthwith give written notice thereof to the other party or parties, and this Agreement shall terminate, and the transactions contemplated by this Agreement shall be abandoned,
without further action by any of the parties hereto. In the event of termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, this Agreement shall forthwith become null and void, and there shall be no liability or obligation
on the part of the Company, Parent, Merger Sub or their respective Subsidiaries or Affiliates, or their respective former, current or future officers, directors, partners, stockholders, managers or members, except that (i)&nbsp;no such termination
shall relieve any party for liability for such party&#146;s Willful Breach of any covenant or agreement in this Agreement prior to its termination or Fraud (which liability the parties acknowledge and agree may include the loss of the premium that
holders of Shares and Company Equity Awards would be entitled to receive pursuant to the terms of this Agreement if the Offer and the Merger were consummated in accordance with its terms); and (ii)&nbsp;the Confidentiality Agreement, the Clean Team
Agreement, <U>Section</U><U></U><U>&nbsp;1.1(d)</U>, this <U>Section</U><U></U><U>&nbsp;7.2</U>, <U>Section</U><U></U><U>&nbsp;7.3</U> and <U>Article 8</U> shall survive the termination hereof, in accordance with their respective terms. Prior to the
termination of this Agreement, nothing in this <U>Article 7</U> shall limit or prevent any party from exercising any rights or remedies it may have under <U>Section</U><U></U><U>&nbsp;8.5</U> in lieu of terminating this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3 <U>Company Termination Fee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If (i)&nbsp;the Company shall have terminated this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)</U>, (ii) Parent shall have
terminated this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(g)</U>,&nbsp;or (iii) (A)&nbsp;after the date of this Agreement, an Alternative Proposal (substituting 50% for the 20% and the 80% thresholds set forth in the definition of
&#147;Alternative Proposal&#148;) is (x)&nbsp;solely in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;7.1(e), </U>delivered or made known to the Company Board or executive management of the Company prior to, and not withdrawn
prior to, the time of the termination of this Agreement or (y)&nbsp;publicly proposed or publicly disclosed prior to, and not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withdrawn publicly prior to, the time of the termination of this Agreement, (B)&nbsp;thereafter this Agreement is terminated by either Parent or the Company pursuant to
<U>Section</U><U></U><U>&nbsp;7.1(b)</U> or <U>Section</U><U></U><U>&nbsp;7.1(h)</U>, but only, in the case of a termination pursuant to <U>Section</U><U></U><U>&nbsp;7.1(h)</U>, if all of the Offer Conditions are satisfied or have been waived
(other than the Minimum Tender Condition and such other conditions which by their nature are to be satisfied at the expiration of the Offer (which such other conditions would be capable of being satisfied or capable of being waived by Parent were
the expiration of the Offer to occur at such time)), or by Parent pursuant to <U>Section</U><U></U><U>&nbsp;7.1(e)</U> as a result of a Willful Breach by the Company of any agreement or covenant of the Company in this Agreement and
(C)&nbsp;concurrently with or within twelve (12)&nbsp;months after such termination, the Company consummates any Alternative Proposal (substituting 50% for the 20% and the 80% thresholds set forth in the definition of &#147;Alternative
Proposal&#148;) or enters into a definitive agreement with respect to any Alternative Proposal (substituting 50% for the 20% and the 80% thresholds set forth in the definition of &#147;Alternative Proposal&#148;) that is subsequently consummated
(whether during or after the expiration of such twelve (12)-month period), then the Company shall pay, by wire transfer of immediately available funds to an account designated by Parent, a fee of $163,000,000.00 (<I>one hundred sixty three million
dollars</I>) in cash (the &#147;<U>Company Termination Fee</U>&#148;), such payment to be made concurrently with such termination in the case of clause (i)&nbsp;above, within two (2)&nbsp;Business Days after such termination in the case of clause
(ii)&nbsp;above, or on the date of the consummation of the applicable Alternative Proposal in the case of clause (iii)&nbsp;above; it being understood that in no event shall the Company be required to pay the Company Termination Fee on more than one
occasion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each party acknowledges that the agreements contained in this <U>Section</U><U></U><U>&nbsp;7.3</U> are an integral part of
this Agreement and that, without this <U>Section</U><U></U><U>&nbsp;7.3</U>, Parent would not have entered into this Agreement. Accordingly, if the Company fails to pay the Company Termination Fee when due and payable, the Company shall pay to
Parent all reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees, costs and expenses of enforcement (including reasonable and documented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#146; fees as well as reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with any
action initiated by such party), together with interest on the amount of the Company Termination Fee, from the date the Company Termination Fee becomes due and payable, at the prime lending rate published in the <I>Wall Street Journal</I> in effect
on the date the Company Termination Fee becomes due and payable (collectively, &#147;<U>Collection Costs</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event
that this Agreement is validly terminated under circumstances where the Company Termination Fee is due and payable and Parent or its designee shall have received full payment of the Company Termination Fee, (x)&nbsp;none of the Company Related
Parties shall have any further liability with respect to this Agreement or the transactions contemplated by this Agreement to Parent, Merger Sub or their respective Affiliates or Representatives, and (y)&nbsp;the payment of the Company Termination
Fee pursuant to <U>Section</U><U></U><U>&nbsp;7.3(a)</U> shall be deemed to be liquidated damages for any and all losses or damages suffered or incurred by Parent, Merger Sub, any of their respective Affiliates or Representatives or any other Person
in connection with this Agreement (and the termination hereof), the transactions contemplated by this Agreement (and the abandonment thereof) or any matter forming the basis for such termination, and none of Parent, Merger Sub, any of their
respective former, current or future officers, directors, employees, partners, stockholders, optionholders, managers, members, other Representatives or Affiliates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, &#147;<U>Parent Related Parties</U>&#148;) or any other Person shall be entitled to bring or maintain any claim, action or proceeding against the Company or any of its Affiliates
arising out of or in connection with this Agreement, any of the transactions contemplated by this Agreement or any matters forming the basis for such termination. Parent&#146;s right to receive the Company Termination Fee pursuant to
<U>Section</U><U></U><U>&nbsp;7.3(a)</U> and, if applicable, the Collection Costs pursuant to <U>Section</U><U></U><U>&nbsp;7.3(b)</U> shall be the sole and exclusive remedy of the Parent Related Parties against the Company and its Subsidiaries and
any of their respective former, current or future officers, directors, employees, partners, stockholders, optionholders, managers, members, other Representatives or Affiliates (collectively, &#147;<U>Company Related Parties</U>&#148;) for any loss
suffered as a result of the failure of the transactions contemplated by this Agreement to be consummated or for a breach or failure to perform hereunder or otherwise, and upon payment of the Company Termination Fee and, if applicable, the Collection
Costs pursuant to <U>Section</U><U></U><U>&nbsp;7.3(b)</U>, none of the Company Related Parties shall have any further liability or obligation relating to or arising out of this Agreement or the transactions contemplated by this Agreement.
Notwithstanding the foregoing, nothing in this <U>Section</U><U></U><U>&nbsp;7.3</U> shall limit the rights of Parent or Merger Sub in the case of a Willful Breach of this Agreement or Fraud. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1 <U>No Survival of Representations and Warranties</U>. None of the representations and warranties and, subject to the
following sentence, covenants and agreements, in this Agreement or in any instrument delivered pursuant to this Agreement shall survive the Effective Time. This <U>Section</U><U></U><U>&nbsp;8.1</U> shall not limit any covenant or agreement of the
parties which by its terms contemplates performance after the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2 <U>Expenses</U>. Except as set forth in
<U>Section</U><U></U><U>&nbsp;7.3</U> and <U>Section</U><U></U><U>&nbsp;8.13</U>, whether or not the Offer or the Merger is consummated, all costs and expenses incurred in connection with the Offer or the Merger, this Agreement and the other
transactions contemplated by this Agreement shall be paid by the party incurring or required to incur such expenses, except that all filing fees paid by any party required under the HSR Act or other required filing under any Antitrust Laws or
Foreign Investment Laws shall be borne by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3 <U>Counterparts; Effectiveness</U>. This Agreement may be executed in
counterparts (including by facsimile, by electronic mail in &#147;portable document format&#148; (.pdf) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document), each of which shall be
an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when one or more counterparts have been signed by each of the parties and delivered (by telecopy,
facsimile, electronic mail or otherwise as authorized by the prior sentence) to the other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4 <U>Governing Law</U><U>; Jurisdiction; Waiver of Jury Trial</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement, and any action, suit or other Legal Proceeding arising out of or relating to this Agreement (including the enforcement of
any provision of this Agreement), any of the transactions contemplated by this Agreement or the legal relationship of the parties (whether at law or in equity, whether in contract or in tort or otherwise), shall be governed by, and construed and
interpreted in accordance with, the Laws of the State of Delaware, regardless of the choice of laws principles of the State of Delaware, as to all matters, including matters of validity, construction, effect, enforceability, performance and
remedies. In any action between any of the parties arising out of or relating to this Agreement, any of the transactions contemplated by this Agreement or the legal relationship of the parties (whether at law or in equity, whether in contract or in
tort or otherwise), each of the parties: (i)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware in and for New Castle County, Delaware (unless the
federal courts have exclusive jurisdiction over the matter, in which case the United States District Court for the District of Delaware) and appellate courts therefrom; (ii)&nbsp;agrees that it will not attempt to deny or defeat such jurisdiction by
motion or other request for leave from such court; and (iii)&nbsp;agrees that it will not bring any such action in any court other than the Court of Chancery of the State of Delaware in and for New Castle County, Delaware (unless the federal courts
have exclusive jurisdiction over the matter, in which case the United States District Court for the District of Delaware) and appellate courts therefrom. Service of any process, summons, notice or document to any party&#146;s address and in the
manner set forth in <U>Section</U><U></U><U>&nbsp;8.6</U> shall be effective service of process for any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) EACH PARTY
ACKNOWLEDGES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, WHETHER IN CONTRACT OR IN TORT OR UNDER ANY OTHER BODY OF LAW,
TO A TRIAL BY JURY IN RESPECT OF ANY ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY ACKNOWLEDGES, AGREES AND CERTIFIES THAT: (i)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD, IN THE EVENT OF LITIGATION, SEEK TO PREVENT OR DELAY ENFORCEMENT OF SUCH WAIVER; (ii)&nbsp;IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER;
(iii)&nbsp;IT MAKES SUCH WAIVER VOLUNTARILY; AND (iv)&nbsp;IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;8.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5 <U>Specific Enforcement</U>. The parties agree that irreparable damage would occur in the event that any of the provisions of
this Agreement were not performed in accordance with their specific terms or were otherwise breached. Each party agrees that, in the event of any breach or threatened breach by any other party of any covenant or obligation contained in this
Agreement, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party shall be entitled (in addition to any other remedy that may be available to it whether in law or equity, including monetary damages) to obtain (a)&nbsp;a decree or order of
specific performance to enforce the observance and performance of such covenant or obligation and (b)&nbsp;an injunction restraining such breach or threatened breach. In circumstances where Parent and Merger Sub are obligated to consummate the Offer
and the Merger and the Offer and/or the Merger has not been consummated, Parent and Merger Sub expressly acknowledge and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agree that the Company and its stockholders shall have suffered irreparable harm, that monetary damages will be inadequate to compensate the Company and its stockholders, and that the Company on
behalf of itself and its stockholders shall be entitled (in addition to any other remedy that may be available to it whether in law or equity, including monetary damages) to enforce specifically Parent&#146;s and Merger Sub&#146;s obligations to
consummate the Offer and the Merger. Each party further agrees that no other party or any other Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred
to in this <U>Section</U><U></U><U>&nbsp;8.5</U>, and each party irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument. It is agreed that, as to any claims or Actions in which
a party seeks specific performance or other equitable relief pursuant to this <U>Section</U><U></U><U>&nbsp;8.5</U>, the parties shall use their reasonable best efforts to seek and obtain an expedited schedule for such proceedings and shall not
oppose any party&#146;s request for expedited proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.6 <U>Notices</U>. Any notice required to be given hereunder
shall be sufficient if in writing, and sent by email, by reliable overnight delivery service (with proof of service), hand delivery or certified or registered mail (return receipt requested and first-class postage prepaid), addressed as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">To Parent or Merger Sub: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Stryker Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1941 Stryker
Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Portage, Michigan 49002 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General
Counsel </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Sidley Austin LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">One South
Dearborn </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Chicago, Illinois 60603 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;Seth H. Katz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&#8194;Scott R. Williams </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&#8194;Sally Wagner Partin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8196;&#8195;&#8195;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&#8194;[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&#8194;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">To the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Inari Medical,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">6001 Oak Canyon, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Irvine California, 92618 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Shannon Trevi&ntilde;o </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Wachtell, Lipton, Rosen&nbsp;&amp; Katz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">51 West 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
New York 10019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;Raaj S. Narayan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&#8194;Steven R. Green </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195; [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">&#8194;[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as any
party shall specify by written notice so given, and such notice shall be deemed to have been delivered (a)&nbsp;when received when sent by email, <U>provided</U> that no error or other message indicating
<FONT STYLE="white-space:nowrap">non-delivery</FONT> is received, (b)&nbsp;upon proof of service when sent by reliable overnight delivery service, (c)&nbsp;upon personal delivery in the case of hand delivery or (d)&nbsp;upon receipt of the return
receipt when sent by certified or registered mail. Any party to this Agreement may notify any other party of any changes to the address or any of the other details specified in this paragraph; <U>provided</U>, however, that such notification shall
only be effective on the date specified in such notice or two (2)&nbsp;Business Days after the notice is given, whichever is later. Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was
given shall be deemed to be receipt of the notice as of the date of such rejection, refusal or inability to deliver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.7
<U>Assignment; Binding Effect</U>. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by any of the parties (whether by operation of law or otherwise) without the prior written consent of the other
parties and any prohibited assignment is void. Subject to the preceding sentence, this Agreement shall be binding upon and shall inure to the benefit of solely the parties and their respective successors and assigns. The formation of Merger Sub and
the execution of the Joinder by Merger Sub shall not be deemed an assignment for purposes of this <U>Section</U><U></U><U>&nbsp;8.7</U> and is otherwise permitted pursuant to this <U>Section</U><U></U><U>&nbsp;8.7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.8 <U>Severability</U>. If any term or provision of this Agreement is determined by a court of competent jurisdiction to be
illegal, invalid or unenforceable, the other terms and provisions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is illegal, invalid or unenforceable, the parties shall
negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated by this Agreement are fulfilled to the extent possible.
If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.9 <U>Entire Agreement; No Third-Party Beneficiaries</U>. This Agreement, the
Joinder, the Confidentiality Agreement and the Clean Team Agreement constitute the entire agreement, and supersede all other prior agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject
matter hereof and thereof. Notwithstanding any provision of this Agreement to the contrary, the Company Disclosure Letter and the Parent Disclosure Letter are &#147;facts ascertainable&#148; as that term is used in Section&nbsp;251(b) of the DGCL,
and do not form part of this Agreement but instead operate upon the terms of this Agreement as provided herein. Except (a)&nbsp;for the provisions of <U>Section</U><U></U><U>&nbsp;1.1</U> (which, from and after the Acceptance Time, shall be for the
benefit of holders of Shares validly tendered in the Offer),<U>&nbsp;Article 2</U> (which, from and after the Acceptance Time, shall be for the benefit of holders of Shares validly tendered in the Offer, and from and after the Effective
Time,&nbsp;shall also be for the benefit of holders of Shares (not validly tendered in the Offer) and Company Equity Awards as of the Effective Time) and <U>Section</U><U></U><U>&nbsp;5.9</U> (which, from and after the Effective Time, shall be for
the benefit of the Indemnified Parties), (b) that the Company shall have the right, on behalf of the holders of Shares and Company Equity Awards (who are third party beneficiaries hereunder solely to the extent necessary for this clause (b)&nbsp;to
be enforceable) to pursue and recover damages against Parent and Merger Sub for the loss of the Offer Price, the Merger Consideration and any other applicable amount pursuant to this Agreement (including the loss of the premium that such holders
would be entitled to receive pursuant to the terms of this Agreement if the Offer and the Merger were consummated in accordance with its terms), and other relief, including equitable relief; <U>provided</U> that the rights granted pursuant to clause
(b)&nbsp;shall be enforceable on behalf of the holders of Shares and Company Equity Awards only by the Company, in its sole and absolute discretion, on behalf of such holders, and any amounts received by the Company in connection therewith may be
retained by the Company, and (c)&nbsp;for the limitations on liability of the Company Related Parties set forth in <U>Section</U><U></U><U>&nbsp;7.3</U>, this Agreement is for the sole benefit of the parties hereto and their permitted assigns and
nothing in this Agreement is intended to and this Agreement shall not confer upon any Person other than the parties hereto any rights or remedies hereunder. The Company shall, in its sole discretion and as a representative of holders of Shares and
Company Equity Awards, have the sole and exclusive authority to take action on behalf of holders of Shares and Company Equity Awards to enforce their rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10 <U>Amendments</U><U>; Waivers</U>. At any time prior to the Effective Time, any provision of this Agreement may be amended
or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the Company, Parent and Merger Sub, or in the case of a waiver, by the party against whom the waiver is to be effective; <U>provided</U>,
that (a)&nbsp;after the Acceptance Time, (i)&nbsp;there shall be made no amendment to this Agreement that decreases the Merger Consideration or termination of this Agreement (other than pursuant to <U>Section</U><U></U><U>&nbsp;7.1(i)</U>, if
applicable) and (ii)&nbsp;any amendments to this Agreement shall require, in addition to the consent of Parent and Merger Sub, the consent of the Company Board and, at the time of such consent, either (A)&nbsp;a majority of the directors on the
Company Board shall have been directors on the Company Board on the date hereof or shall have been nominated or designated to be directors by a majority of the directors on the Company Board on the date hereof (such directors, &#147;<U>Continuing
Directors</U>&#148;) or (B)&nbsp;if the Continuing Directors constitute a minority of the Company Board, each Continuing Director shall approve such amendment and (b)&nbsp;no amendment shall be made to this Agreement after the Effective Time. The
foregoing notwithstanding, no failure or delay by any party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, at any time prior to the Acceptance Time, the Company, on the one hand, and Parent and Merger Sub, on the other hand, may (i)&nbsp;extend the time for the performance of any of the
obligations or other acts of the other party or parties, (ii)&nbsp;waive any inaccuracies in the representations and warranties contained in this Agreement or in any document delivered pursuant to this Agreement of the other party or parties, or
(iii)&nbsp;waive compliance with any of the agreements or conditions contained in this Agreement that are for their benefit (subject to <U>Section</U><U></U><U>&nbsp;1.1</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11 <U>Headings</U>. Headings of the Articles and Sections of this Agreement are for convenience of the parties only and shall
be given no substantive or interpretive effect whatsoever. The table of contents to this Agreement is for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12 <U>Interpretation</U>. When a reference is made in this Agreement to an Article or Section, such reference shall be to an
Article or Section of this Agreement unless otherwise indicated. All exhibits annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Whenever the words &#147;include,&#148;
&#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation.&#148; The words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of
similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. All references in this Agreement to &#147;$&#148; or &#147;dollars&#148; shall be to U.S. dollars. The phrase
&#147;date hereof&#148; or &#147;date of this Agreement&#148; shall be deemed to refer to January&nbsp;6, 2025. The words &#147;day&#148; or &#147;days&#148; when used in this Agreement shall refer to calendar days unless specified as Business Days.
The word &#147;or&#148; is not exclusive. The word &#147;extent&#148; in the phrase &#147;to the extent&#148; shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply &#147;if.&#148; The word
&#147;will&#148; shall be construed to have the same meaning and effect as the word &#147;shall.&#148; The term &#147;third party&#148; shall mean any person, including any &#147;group&#148; as defined in Section&nbsp;13(d) of the Exchange Act,
other than the Company, Parent or any of their respective Affiliates or any &#147;group&#148; that includes the Company, Parent or any of their respective Affiliates. All&nbsp;references to information or documents having been &#147;made
available&#148; (or words of similar import) shall be deemed satisfied, among other means (such as by electronic data room, management presentation or otherwise), by such information or documents being publicly available on the Electronic Data
Gathering, Analysis and Retrieval (EDGAR) database of the SEC. All terms defined in this Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant thereto unless otherwise defined therein.
The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such terms. Each of the parties has participated in the
drafting and negotiation of this Agreement. References to specific Laws or to specific provisions of Laws shall include all rules and regulations promulgated thereunder and references to specific Laws, Contracts or specific provisions thereof are to
such Laws, Contracts or provisions as amended, restated, supplemented, <FONT STYLE="white-space:nowrap">re-enacted,</FONT> consolidated, replaced or modified from time to time, in each case as of the applicable date or period of time. All accounting
terms used in this Agreement and not expressly defined shall have the meanings given to them under GAAP. If an ambiguity or question of intent or interpretation arises, this Agreement must be construed as if it is drafted by all the parties, and no
presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authorship of any of the provisions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.13 <U>Transfer Taxes</U>. Except as otherwise provided in
<U>Section</U><U></U><U>&nbsp;2.2(b)(iv)</U>, all transfer, documentary, sales, use, stamp, registration and other similar Taxes imposed with respect to the transfer of Shares pursuant to the Offer or the Merger shall be borne by Parent and
expressly shall not be a liability of holders of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.14 <U>Definitions</U>. For purposes of this Agreement, the
following terms (as capitalized below) will have the following meanings when used in this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquired
Companies</U>&#148; means, collectively, the Company and the Company&#146;s Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliates</U>&#148; means, with
respect to any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common control with, such Person. As used in this definition, &#147;<U>control</U>&#148; (including, with its correlative meanings,
&#147;<U>controlled by</U>&#148; and &#147;<U>under common control with</U>&#148;) shall mean the possession, directly or indirectly, of the power to direct or cause the direction of management or policies of a Person, whether through the ownership
of securities or partnership or other ownership interests, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Antitrust Laws</U>&#148; means the HSR Act,
the Sherman Antitrust Act of 1890, the Clayton Act of 1914, the Federal Trade Commission Act of 1914, and any other federal, state, foreign, and transnational statutes, rules, regulations, Orders, decrees, administrative and judicial doctrines and
other Laws that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition through merger or acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day other than a Saturday, Sunday or a day on which the banks in Irvine, California or New York, New
York are authorized by Law or executive order to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Balance Sheet</U>&#148; means the consolidated balance sheet
of the Company and its consolidated Subsidiaries as of September&nbsp;30, 2024 included in the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the nine-month period ended September&nbsp;30, 2024, as filed
with the SEC on October&nbsp;28, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Benefit Plan</U>&#148; means: (a)&nbsp;each &#147;employee benefit plan&#148; (as
defined in Section&nbsp;3(3) of ERISA), whether or not subject to ERISA; and (b)&nbsp;any other management, employment, consulting, salary, bonus, commission, other remuneration, stock option, restricted stock, restricted stock unit, stock
appreciation rights, stock purchase or other equity-based award (whether payable in cash, securities or otherwise), benefit, incentive compensation, profit sharing, savings, pension, retirement, disability, insurance, vacation, deferred
compensation, severance, termination, redundancy, retention, transaction bonus, change of control, death and disability benefits, hospitalization, medical, flexible benefits, supplemental unemployment benefits, relocation, repatriation or
expatriation and similar fringe, welfare or other employee benefit plan, program, agreement, contract, policy or binding arrangement (whether or not in writing) maintained, sponsored or contributed to or required to be contributed to by any of the
Acquired Companies for the benefit of or relating to any current or former employee of any Acquired Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Contract</U>&#148; means any Contract other than a Company Benefit Plan to
which any of the Acquired Companies is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Credit Agreement</U>&#148; means that certain Loan, Guaranty and
Security Agreement, dated as of September&nbsp;4, 2020, by and among the Company, each of the lenders party thereto, Bank of America, N.A., as agent for the lenders, and the other parties thereto, as amended, restated, supplemented, or otherwise
modified prior to the Closing Date, including through the Seventh Amendment and Joinder to Loan, Guaranty and Security Agreement, dated as of January&nbsp;24, 2024, and without limiting any restrictions to modifications thereof set forth in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Award</U>&#148; means a Company RSU Award or Company Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Plans</U>&#148; means the Company&#146;s 2020 Incentive Award Plan and 2011 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company IP</U>&#148; means all Intellectual Property Rights owned by the Acquired Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Material Adverse Effect</U>&#148; means an event, change, condition occurrence, development, circumstance or effect that has
a material adverse effect on the business, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>, any event, change, condition, occurrence, development, circumstance or
effect to the extent arising or resulting from any of the following shall not be deemed in and of itself, either alone or in combination, to constitute, and shall not be taken into account in determining whether such event, change, condition,
occurrence, development, circumstance or effect has, or would reasonably be expected to have, a Company Material Adverse Effect: (a)&nbsp;any change in the market price or trading volume of the Common Stock (<U>provided</U>, <U>however</U>, that the
underlying cause of such change in price or trading volume, to the extent not otherwise expressly excluded by this definition, may be taken into account in determining whether there is, or would reasonably be expected to be, a Company Material
Adverse Effect); (b)&nbsp;the negotiation, execution, announcement, consummation, existence or pendency of this Agreement or the terms hereof (including the identity of Parent or Merger Sub) or the announcement, pendency or consummation of the
transactions contemplated by this Agreement, including the impact thereof on the relationships, contractual or otherwise, of the Company with employees, financing sources, customers, suppliers, partners, Governmental Entities or other business
relationships; <U>provided</U>, <U>however</U>, that this clause (b)&nbsp;shall not apply to the representations and warranties in <U>Section</U><U></U><U>&nbsp;3.4</U>, <U>Section</U><U></U><U>&nbsp;3.5</U>,
<U>Section</U><U></U><U>&nbsp;3.18(g)(i)</U> or <U>Section</U><U></U><U>&nbsp;3.18(g)(ii)</U> (or the related condition to consummation of the Offer in clause <U>(iv)</U>&nbsp;of <U>Exhibit A</U>); (c)&nbsp;the general conditions in the industries
in which the Company and its Subsidiaries operate or in the economy generally or other general business, financial or market conditions, including domestic, foreign or global political, economic, regulatory, financial or capital markets conditions
(including interest rates, inflation rate, exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rates, tariffs, trade wars and credit markets); (d)&nbsp;any act of civil unrest, civil disobedience, protests, public demonstrations, insurrection, terrorism, war, cybercrime, cyberterrorism,
military activity, sabotage, data breach, national or international calamity or any other similar event, including an outbreak or escalation of hostilities involving the United States or any other Governmental Entity or the declaration by the United
States or any other Governmental Entity of a national emergency or war, or any worsening of any such conditions threatened or existing on the date of this Agreement; (e)&nbsp;any natural or manmade disasters, epidemics, pandemics or disease
outbreaks or any acts of God; (f)&nbsp;the failure of the Company to meet internal or analysts&#146; expectations or projections, forecasts, guidance, estimates or budgets (<U>provided</U>, <U>however</U>, that the underlying causes thereof, to the
extent not otherwise expressly excluded by this definition, may be taken into account in determining whether there is, or would reasonably be expected to be, a Company Material Adverse Effect; <U>provided</U>, <U>further</U>, that this
clause&nbsp;(f) shall not be construed as implying that the Company is making any representation or warranty hereunder with respect to any internal or analysts&#146; expectations or projections, forecasts, guidance, estimates or budgets);
(g)&nbsp;any Legal Proceeding bought by a stockholder of the Company (in its capacity as such) or by Parent or Merger Sub, in each case, in connection with this Agreement or the transactions contemplated by this Agreement; (h)&nbsp;any action taken
by the Company at the express written direction of Parent or any action required or expressly permitted to be taken by Parent, Merger Sub or the Company pursuant to the terms of this Agreement, or the failure of the Company to take any action that
the Company is prohibited by the terms of this Agreement from taking or which the Company did not take on account of withheld consent from Parent (if the Company has timely requested a consent or waiver from Parent); (i)&nbsp;any breach by Parent or
Merger Sub of this Agreement; (j)&nbsp;any change in, or any compliance with or action required to be taken to comply with, any applicable Law or GAAP or any other applicable accounting principles or standards (or interpretations of any applicable
Law or GAAP or any other applicable accounting principles or standards); and (k)&nbsp;any matter set forth in <U>Section</U><U></U><U>&nbsp;8.14(a)</U> of the Company Disclosure Letter; <U>provided</U> that in the case of the foregoing clauses (c),
(d), (e) or (j), to the extent such event, change, condition, occurrence or development, circumstance or effect referred to therein is not otherwise expressly excluded from the definition hereof, and then to the extent that the business, results of
operations or financial condition of the Company and its Subsidiaries, taken as a whole, are disproportionately adversely impacted relative to other persons engaged in the same industry, then the incremental disproportionate adverse effect of such
event, change, condition, occurrence, development, circumstance or effect shall be taken into account for the purpose of determining whether such event, change, condition, occurrence, development, circumstance or effect has, or would be reasonably
expected to have, a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Option</U>&#148; means each compensatory option to purchase Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Preferred Stock</U>&#148; means preferred stock, par value $0.001, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Privacy Policies</U>&#148; means any (a)&nbsp;published data protection, data usage, privacy and security policies of any
Acquired Company, (b)&nbsp;public written statements, representations, obligations, promises, commitments relating to privacy, security, or the Processing of Personal Data, and (c)&nbsp;binding policies and obligations applicable to any Acquired
Company as a result of any certification obtained by such Acquired Company relating to privacy, security, or the Processing of Personal Data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Product</U>&#148; means the products and services sold or distributed by an
Acquired Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company RSU Award</U>&#148; means each award of restricted stock units representing the right to vest in and
be issued Shares by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consent</U>&#148; means any approval, consent, ratification, permission, license, permit,
order, waiver or authorization of or from, or registration, declaration or filing with, or notice to any Governmental Entity (including any Governmental Authorization). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; means any legally binding contract, subcontract, note, bond, mortgage, indenture, deed of trust, lease, sublease,
instrument, license, option, warranty, purchase order, sales order, commitment, agreement or other legally binding obligation or arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Data Processor</U>&#148; means a natural or legal Person, public authority, agency or other body to the extent that it Processes
Personal Data on behalf of or at the direction of any Acquired Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Data Protection Requirements</U>&#148; means any and all
Laws, industry requirements and obligations under Contracts, in each case, relating to the protection or Processing of Personal Data and legally binding on and applicable to the Acquired Companies, including, to the extent applicable to the
operations of the Acquired Companies: (a)&nbsp;HIPAA and U.S. state and federal Laws that prohibit unfair or deceptive acts and practices, such as the Federal Trade Commission Act, 15 U.S.C. &#167; 45, et seq., and other Laws relating to data
protection, information security, cybercrime, Security Incident notification, social security number protection, outbound communications or electronic marketing, use of electronic data and privacy matters (including online privacy) in any applicable
jurisdictions; (b)&nbsp;each binding obligation under a Company Contract relating to the Processing of Personal Data; and (c)&nbsp;each applicable binding rule, code of conduct, or other requirement of self-regulatory bodies and applicable industry
standards, including, to the extent applicable, the Payment Card Industry Data Security Standard (&#147;<U><FONT STYLE="white-space:nowrap">PCI-DSS</FONT></U>&#148;).<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Device Regulatory Laws</U>&#148; means Laws administered by the FDA or any other Governmental Entity relating to the regulation of
the procurement, raw material sourcing, design, research, development, testing, studying, manufacturing, quality, licensing, production, processing, handling, packaging, labeling, storage, advertising, use, promotion, marketing, complaint handling,
adverse event reporting, medical device report submission, importation, exportation, sale and distribution of medical devices or components thereof, and any analogous applicable Laws of any applicable state or jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Enforceability Exceptions</U>&#148; means: (a)&nbsp;legal limitations on enforceability arising from applicable bankruptcy and other
similar Laws affecting the rights of creditors generally; and (b)&nbsp;legal limitations on enforceability arising from rules of Law governing specific performance, injunctive relief and other equitable remedies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Authorization</U>&#148; means any Governmental Authorization required
under Environmental Laws to own or operate the business and real property of the Acquired Companies as currently owned, leased and operated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Law</U>&#148; means any Law relating to (i)&nbsp;the protection, preservation or restoration of the environment
(including air, water vapor, surface water, groundwater, drinking water supply, surface land, subsurface land, plant and animal life or any other natural resource) or human health and safety or (ii)&nbsp;the exposure to, or the use, storage,
recycling, treatment, generation, transportation, processing, handling, labeling, production, release or disposal of Hazardous Substances, in each case as in effect at the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means the Employee Retirement Income Security Act of 1974. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA Affiliate</U>&#148; means any Person under common control with any of the Acquired Companies within the meaning of Sections
414(b), (c), (m) and (o)&nbsp;of the Code, and the regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the United States Food and
Drug Administration, or any successor agency thereto having the administrative authority to regulate the marketing of human pharmaceutical products or biological therapeutic products, delivery systems and devices in the United States of America.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Federal Healthcare Program</U>&#148; has the meaning set forth in 42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(f)</FONT> and any implementing regulations thereto, including Medicare, Medicaid, TRICARE, and the Veterans Health Administration programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Foreign Export and Import Law</U>&#148; means any Law of a Governmental Entity (other than a U.S. Governmental Entity) regulating
exports, imports or <FONT STYLE="white-space:nowrap">re-exports</FONT> to, from or within such foreign country, including the export, import, transfer or <FONT STYLE="white-space:nowrap">re-export</FONT> of any goods, software, services or technical
data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Foreign Investment Law</U>&#148; means any federal, state, foreign, and transnational statutes, rules, regulations,
Orders, decrees, administrative and judicial doctrines and other Laws that are designed or intended to screen, prohibit, restrict or regulate investments on cultural, public order or safety, privacy, or national or economic security grounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fraud</U>&#148; means actual and intentional common law fraud under Delaware law of the Company, Parent or Merger Sub, as applicable,
in the making of the representations and warranties set forth in <U>Article 3</U> (in the case of the Company) or <U>Article 4</U> and the Joinder (in the case of Parent or Merger Sub), <U>provided</U> that Fraud shall exclude constructive fraud,
equitable fraud or negligent misrepresentation or negligent omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United States generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Good Clinical Practices</U>&#148; means the FDA&#146;s standards for the design, conduct, performance, monitoring, auditing,
recording, analysis, and reporting of clinical trials contained in 21 C.F.R. Parts 50, 54, 56 and 812, and equivalent foreign Laws to which any Acquired Company is subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authorization</U>&#148; means any permit, license, certificate, certification, franchise, approval, concession,
permission, variance, clearance, registration, qualification, identification number, approval, or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Entity or pursuant to any applicable
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Entity</U>&#148; shall mean any federal, state, local, foreign or transnational governmental, regulatory or
administrative agency, commission, court, body, entity, authority or official, including any <FONT STYLE="white-space:nowrap">sub-division</FONT> thereof, or any <FONT STYLE="white-space:nowrap">non-governmental</FONT> self-regulatory agency,
commission, authority, arbitration forum or arbitrator, in each case with competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Hazardous Substance</U>&#148;
means any substance, material or waste that is listed, defined, designated or classified as hazardous, toxic, radioactive or dangerous or as a pollutant or contaminant under any Environmental Law, including any substance to which exposure is
regulated by any Governmental Entity or any Environmental Law, including any toxic waste, pollutant, contaminant, hazardous substance, toxic substance, hazardous waste, special waste, industrial substance or petroleum or any derivative or byproduct
thereof, radon, radioactive material, asbestos or asbestos-containing material, urea formaldehyde, foam insulation, polychlorinated biphenyls or <FONT STYLE="white-space:nowrap">per-</FONT> and polyfluoroalkyl substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Healthcare Laws</U>&#148; means any applicable Laws relating to healthcare regulatory matters governing the Acquired Companies&#146;
products or services, including: (i)&nbsp;applicable fraud and abuse Laws, including the federal Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b),</FONT> the federal criminal False Claims Statutes (18 U.S.C.
&#167;&#167; 286, 287 and 1001), the False Statements Relating to Health Care Matters Law (18 U.S.C. &#167; 1035), the HIPAA <FONT STYLE="white-space:nowrap">All-Payor</FONT> Fraud Statute (18 U.S.C. &#167; 1347), the federal criminal False
Statements Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the federal False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the federal Civil Monetary Penalties Law (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the federal exclusion Laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the Federal Program Fraud Civil Remedies Act (31 U.S.C. &#167; 3801 et seq.), the federal Physician
Self-Referral Prohibition, commonly referred to as the &#147;Stark Law&#148; (42 U.S.C. &#167; 1395nn), and any regulations or guidance promulgated pursuant to each of the foregoing, and similar foreign, state, or local statutes or regulations;
(ii)&nbsp;all applicable Laws relating to the Federal Healthcare Programs and the regulations promulgated thereunder; (iii)&nbsp;HIPAA and the implementing regulations and any similar state or local health care privacy, security or confidentiality
Laws; (iv)&nbsp;the federal Physician Payment Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h)</FONT> and the regulations promulgated thereunder; (v)&nbsp;any applicable foreign, state, or local Laws regulating the
interactions with healthcare professionals and reporting thereof; and (vi)&nbsp;Device Regulatory Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>HIPAA</U>&#148; means the Health Insurance Portability and Accountability Act of
1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, any regulations promulgated thereunder, including the Omnibus Rule effective March&nbsp;26, 2013 (78 Fed. Reg. 5566), and other implementing rules
and regulations at 45 CFR Parts 160 and 164 and related binding guidance from the United States Department of Health and Human Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; means any and all common law or statutory intellectual property
rights or similar proprietary rights arising anywhere in the world, including in or with respect to, or arising under any of the following: (a)&nbsp;patents, patent applications, statutory invention registrations, registered designs, and similar or
equivalent rights in inventions and designs, (b)&nbsp;trademarks, service marks, trade dress, trade names, logos and other designations of origin, (c)&nbsp;rights in domain names and uniform resource locators, social media identifiers and accounts,
and other names and locators associated with Internet addresses and sites, (d)&nbsp;copyrights and any other equivalent rights in works of authorship (including rights in software as a work of authorship) or mask work rights, or (e)&nbsp;trade
secrets, industrial secret rights and rights in <FONT STYLE="white-space:nowrap">know-how,</FONT> in each case that derive independent economic value from not being generally known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>IRS</U>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>IT Systems</U>&#148; means all information technology and computer systems and similar equipment relating to the transmission,
storage, maintenance, organization, presentation, generation, processing or analysis of data and information whether or not in electronic format, owned or leased by, licensed to or used in or necessary for the conduct of the business of the Acquired
Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Joinder</U>&#148;&nbsp;means a&nbsp;joinder&nbsp;to this Agreement, substantially in the form of <U>Exhibit C</U>
attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Knowledge</U>&#148; means (a)&nbsp;with respect to Parent, the actual knowledge of any of the individuals
listed in <U>Section</U><U></U><U>&nbsp;8.14(a)</U> of the Parent Disclosure Letter and (b)&nbsp;with respect to the Company, the actual knowledge of any of the individuals listed in <U>Section</U><U></U><U>&nbsp;8.14(a)</U> of the Company
Disclosure Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any federal, state, local or foreign law, statute, ordinance, rule, regulation, judgment,
order, decree, writ, injunction, code or principle of common law issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Leased Real Property</U>&#148; means all real property leased, subleased or licensed to the Acquired Companies pursuant to the
Leases, including all buildings, structures, fixtures and other improvements thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Legal Proceeding</U>&#148; means any action, suit, litigation, arbitration,
proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), civil investigative demand, criminal information, subpoena, search warrant, hearing, claim, complaint (including a <I>qui tam </I>complaint), inquiry,
audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Entity or any arbitrator or arbitration panel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liability</U>&#148; means any debt, obligation, duty or liability of any nature (including any unknown, undisclosed, unmatured,
unaccrued, unasserted, contingent, indirect, conditional, derivative, joint, several or secondary liability), regardless of whether such debt, obligation, duty or liability is immediately due and payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means a lien, mortgage, deed of trust, trust deed, pledge, security interest, charge, title or survey defect, easement
or right of way, claim, option, encumbrance, right of first refusal, preemptive right, right to purchase or other lien or encumbrance of any kind or nature whatsoever, but excluding, for the avoidance of doubt, any license, covenant not to sue or
similar right with respect to Intellectual Property Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Made Available to Parent</U>&#148; means that such information,
document or material was: (a)&nbsp;filed with the SEC and publicly available on EDGAR in unredacted form at least one (1)&nbsp;Business Day before the date of this Agreement; (b)&nbsp;made available for review by Parent or Representatives of Parent
as of 8:00 a.m. Eastern Time on the date of this Agreement, in the &#147;Project Alpine&#148; virtual data room maintained by the Company with Donnelley Financial Solutions Venue in connection with the transactions contemplated by this Agreement
(including any clean room folder); or (c)&nbsp;physically made available for review by Parent or Representatives of Parent by the Company or its Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub</U>&#148; means, from and following the execution and delivery of the Joinder, the entity party to such Joinder which
shall be a Delaware corporation and a directly wholly owned subsidiary of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>NASDAQ Stock Market</U>&#148; means the NASDAQ
Stock Market LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Notified Body</U>&#148; means an entity licensed, authorized or approved by the applicable government agency,
department or other authority to assess and certify the conformity of a medical device with the requirements of (i)&nbsp;Regulation (EU) 2017/745 of the European Parliament and of the Council of 5&nbsp;April 2017 on medical devices, amending
Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC concerning medical devices, and (ii)&nbsp;applicable harmonized standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>OFAC</U>&#148; means the Office of Foreign Assets Control of the U.S. Department of the Treasury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any order, writ, injunction, award, judgment, ruling or decree of any Governmental Entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>PBGC</U>&#148; means the Pension Benefit Guaranty Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Lien</U>&#148; means a Lien (a)&nbsp;for Taxes or governmental assessments, charges or claims of payment (i)&nbsp;not yet
due and payable or (ii)&nbsp;which are being contested in good faith by appropriate proceedings and&nbsp;for which adequate accruals or reserves have been established on the appropriate financial statements in accordance with GAAP, (b)&nbsp;that is
a carriers&#146;, warehousemen&#146;s, mechanics&#146;, materialmen&#146;s, repairmen&#146;s or other similar Lien arising in the ordinary course of business, (c)&nbsp;that is a zoning, entitlement or other land use or environmental regulation by
any Governmental Entity (excluding Liens imposed by applicable Environmental Laws related to the investigation or remediation of contaminated real property) to the extent not violated by the Acquired Companies&#146; current use of such real property
(or in the case of Liens with respect to Parent or any of its Subsidiaries, to the extent not violated by Parent&#146;s or any of its Subsidiaries&#146; current use of such real property), (d) that secures indebtedness (i)&nbsp;in existence on the
date of this Agreement, including in respect of the Company Credit Agreement, or (ii)&nbsp;not prohibited by <U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U>, in each case of this clause <U>(d)</U>, to the extent such Lien will be discharged at or prior
to the Closing (in the case of the Company Credit Agreement, to the extent required by <U>Section</U><U></U><U>&nbsp;2.4</U>) or (e)&nbsp;Liens described in <U>Section</U><U></U><U>&nbsp;8.14(b)</U> of the Company Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other
entity, group (as such term is used in Section&nbsp;13 of the Exchange Act) or organization, including a Governmental Entity, and any permitted successors and assigns of such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Personal Data</U>&#148; means any information about or associated with an identified or identifiable natural person that alone or in
combination with other information identifies, or could be used to identify, a natural person or household, or that otherwise constitutes &#147;personal data,&#148; &#147;personally identifiable information,&#148; &#147;individually identifiable
health information,&#148; &#147;protected health information&#148; or &#147;personal information&#148; under any applicable data privacy Laws; <U>provided</U> that &#147;Personal Data&#148; does not include information that is lawfully available to
the public, whether through federal, state or local Governmental Entity records or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Processing</U>,&#148;
&#147;<U>Process</U>,&#148; or &#147;<U>Processed</U>&#148; means any collection, access, acquisition, storage, protection, use, recording, maintenance, operation, dissemination, <FONT STYLE="white-space:nowrap">re-use,</FONT> disposal, disclosure, <FONT
STYLE="white-space:nowrap">re-disclosure,</FONT> deletion, destruction, sale, transfer, modification, or any other processing (as defined by applicable data privacy Laws) of Personal Data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registrations</U>&#148; means any authorizations, approvals, clearances, consents, licenses, permits, certificates, exemptions, or
registrations issued or otherwise granted by any Regulatory Authority (including 510(k) <FONT STYLE="white-space:nowrap">pre-market</FONT> notification clearances, de novo classifications, <FONT STYLE="white-space:nowrap">pre-market</FONT>
approvals, investigational device exemptions, product recertifications, manufacturing approvals and authorizations, CE Marks, pricing and reimbursement approvals, labeling approvals, registration notifications, or their foreign equivalent), in each
case, that are required for the research, development, production, manufacture, labeling, distribution, marketing, storage, shipping, transportation, export, import, use, or sale of Company Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Authority</U>&#148; means the FDA and any other Governmental Entity of
competent jurisdiction that regulates the research, development, production, manufacture, labeling, distribution, marketing, storage, shipping, transportation, export, import, use, or sale of Company Products, including any Notified Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Release</U>&#148; means any presence emission, spill, seepage, leak, escape, leaching, discharge, injection, pumping, pouring,
emptying, dumping, disposal, migration, threatened release or release of Hazardous Substances from any source into, through or upon the indoor or outdoor environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctioned Country</U>&#148; means a country or territory that is, at the applicable time of determination, itself the subject or
target of comprehensive Sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctioned Person</U>&#148; means any Person that is, at the applicable time of
determination, the target of Sanctions, including, at the applicable time of determination, (i)&nbsp;any Person listed in any Sanctions-related list of designated Persons maintained by OFAC or the U.S. Department of State, the United Nations
Security Council, the European Union, His Majesty&#146;s Treasury of the United Kingdom, the European Union or its Member States, (ii)&nbsp;any Person ordinarily located, organized or ordinarily resident in a Sanctioned Country, or (iii)&nbsp;any
Person 50% or more owned or otherwise controlled by any such Person or Persons described in the foregoing clauses (i)&nbsp;and (ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctions</U>&#148; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by
the U.S. Government through OFAC, the Bureau of Industry and Security of the U.S. Department of Commerce, and the U.S. Department of State, the United Nations Security Council, the European Union and its Member States, His Majesty&#146;s Treasury,
or any other similar Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sarbanes-Oxley Act</U>&#148; means the Sarbanes-Oxley Act of 2002, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Solvent</U>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Fair Value (as defined below) of the assets of Parent and its Subsidiaries, taken as a whole, shall be greater than the total amount of
the liabilities, including contingent liabilities, of Parent and its Subsidiaries, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent and its Subsidiaries,
taken as a whole, shall be able to pay their debts and obligations in the ordinary course of business as they become due; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent
and its Subsidiaries, taken as a whole, shall have adequate capital to carry on their businesses and all businesses in which they are about to engage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this definition of &#147;Solvent&#148;, &#147;<U>Fair Value</U>&#148; means the amount
at which the assets (both tangible and intangible), in their entirety, of Parent and its Subsidiaries would change hands between a willing buyer and a willing seller, within a commercially reasonable period of time, each having reasonable knowledge
of the relevant facts, with neither being under any compulsion to act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; of a Person means any other Person
with respect to which the first Person (a)&nbsp;has the right to elect a majority of the board of directors or other Persons performing similar functions or (b)&nbsp;beneficially owns more than 50% of the voting stock (or of any other form of voting
or controlling equity interest in the case of a Person that is not a corporation), in each case, directly or indirectly through one or more other Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means any return, report or similar filing required to be filed with any Governmental Entity with respect to
Taxes, including any information return, claim for refund, amended return, attached schedules or declaration of estimated Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; means any and all U.S. federal, state, local or foreign taxes of any kind (together with any and all interest,
penalties, additions to tax and additional amounts imposed by a Governmental Entity with respect thereto) imposed by any Governmental Entity, including any income, capital gains, franchise, windfall, profits, license, capital, transfer, estimated,
alternative, gross receipts, property, sales, use, capital stock, payroll, employment, unemployment, severance, social security, disability, workers&#146; compensation, net worth, excise, withholding, environmental, registration, stamp, goods and
services, ad valorem and value added taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; means the regulations promulgated under the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>U.S. Export and Import Law</U>&#148; means any applicable U.S. Law regulating exports,
<FONT STYLE="white-space:nowrap">re-export,</FONT> deemed <FONT STYLE="white-space:nowrap">(re-)exports,</FONT> transfers or imports of goods, services, software or technical data, including the United States Export Control Reform Act of 2018, the
Export Administration Regulations, the Tariff Act of 1930, the Trade Act of 1974 and anti-boycott Laws and regulations implemented by the U.S. Department of Commerce and the U.S. Department of the Treasury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>U.S. Government</U>&#148; means the federal government of the United States of America and any agencies, instrumentalities and
departments thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Willful Breach</U>&#148; means a material breach of a covenant or obligation set forth in this Agreement
that is the consequence of an intentional act or omission by the breaching party with the actual knowledge that the taking of such act or failure to take such action would cause or constitute such material breach of a covenant or obligation set
forth in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.15 <U>Terms Defined Elsewhere</U>. For purposes of this Agreement, each of
the following terms (as capitalized below) when used in this Agreement will have the meaning ascribed to such term in the Section set forth opposite such term: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Absence of Legal Restraint Condition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Exhibit A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acceptance Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alternative Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Benefits Continuation Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Book-Entry Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cancelled Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.1(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Capex Budget</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.1(b)(xvi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Change of Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Clean Team Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.2(b)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Collection Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;7.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Disclosure Letter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Article 3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company ESPP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.2(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Registered IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.11(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Related Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;7.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company SEC Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Termination Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;7.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confidentiality Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Continuing Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;8.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Depository Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DGCL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissenting Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DTC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.2(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EDGAR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Article 3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">End Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;7.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ESPP Offering Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Loan Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fair Value</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;8.14</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FCPA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.14(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDA Application Integrity Policy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.16(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Filed SEC Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Article 3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnified Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.9(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Intervening Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(h)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Intervening Event Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(d)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Intervening Event Notice Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leases</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.10(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Legal Restraint</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;6.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Material Contract</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.12(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Maximum Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.9(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Measurement Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.1(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Minimum Tender Condition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Exhibit A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offer Conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offer Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.1(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Old Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;4.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Disclosure Letter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Article 4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Material Adverse Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Related Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;7.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Paying Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Payment Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Payoff Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Payoff Letter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;2.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PMA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.16(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Regulatory Condition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Exhibit A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Remedy Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Representatives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Security Incident</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.11(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Superior Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Superior Proposal Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Superior Proposal Notice Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Takeover Statute</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Termination Condition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Exhibit A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Termination Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;5.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trade Authorizations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Section&nbsp;3.14(f)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">STRYKER CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ J. Andrew Pierce</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>J. Andrew Pierce</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Group President, MedSurg and Neurotechnology</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">INARI MEDICAL, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Hykes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Andrew Hykes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Agreement and Plan of Merger</I>]<I></I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Offer Conditions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other term of the Offer or the Agreement and Plan of Merger to which this <U>Exhibit A</U> is attached, Merger Sub shall
not be required to, and Parent shall not be required to cause Merger Sub to, accept for payment or, subject to any applicable rules and regulations of the SEC, including <FONT STYLE="white-space:nowrap">Rule&nbsp;14e-1(c)</FONT> under the Exchange
Act (relating to Merger Sub&#146;s obligation to pay for or return tendered Shares promptly after the termination or withdrawal of the Offer), pay for any Shares tendered pursuant to the Offer if the following conditions shall not have been
satisfied as of immediately prior to the expiration of the Offer: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) there shall have been validly tendered and not
properly withdrawn prior to the expiration of the Offer that number of Shares that, when added to Shares then owned by Parent or Merger Sub, would represent at least a majority of Shares issued and outstanding as of immediately following the
expiration of the Offer (such condition in this clause (i), the &#147;<U>Minimum Tender Condition</U>&#148;), <U>provided</U>, <U>however</U>, that for purposes of determining whether the Minimum Tender Condition has been satisfied, the parties
shall exclude Shares tendered in the Offer that have not yet been &#147;received&#148; by the &#147;depository&#148; (as such terms are defined in Section&nbsp;251(h)(6) of the DGCL); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the waiting period pursuant to the HSR Act applicable to the purchase of Shares pursuant to the Offer and the consummation
of the Merger shall have expired or been terminated (such condition in this clause (ii), the &#147;<U>Regulatory Condition</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) there shall not be any Legal Restraint in effect enjoining, prohibiting or otherwise preventing the consummation of the
Offer or the Merger (such condition in this clause (iii), the &#147;<U>Absence of Legal Restraint Condition</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;(A) the representations and warranties of the Company set forth in <U>Section</U><U></U><U>&nbsp;3.7(c)</U> (Absence
of Changes) shall be true and correct in all respects, both when made and at and as of the expiration of the Offer, as if made at and as of the expiration of the Offer; (B)&nbsp;the representations and warranties of the Company set forth in
<U>Section</U><U></U><U>&nbsp;3.1(a)</U> (Qualification, Organization, Subsidiaries), <U>Section</U><U></U><U>&nbsp;3.3</U> (Corporate Authority; Binding Nature of this Agreement), <U>Section</U><U></U><U>&nbsp;3.5(a)(i)</U> <FONT
STYLE="white-space:nowrap">(Non-Contravention),</FONT> <U>Section</U><U></U><U>&nbsp;3.21</U> (Takeover Statutes; No Rights Agreement), <U>Section</U><U></U><U>&nbsp;3.22</U> (Fairness Opinion) and <U>Section</U><U></U><U>&nbsp;3.23</U> (Financial
Advisors&#146; Fees) if qualified by materiality or Company Material Adverse Effect shall be true and correct in all respects and if not qualified by materiality or Company Material Adverse Effect shall be true and correct in all material respects,
both when made and at and as of the expiration of the Offer, as if made at and as of the expiration of the Offer (except to the extent expressly made as of an earlier date, in which case as of such date); (C) the representations and warranties of
the Company set forth in <U>Section</U><U></U><U>&nbsp;3.2(a)</U>, <U>(b)</U> and <U>(c)</U> (Capitalization) (in each case, other than with respect to the equity, securities or capitalization of the Company&#146;s Subsidiaries) shall be true and
correct in all respects, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
other than for <I>de minimis</I> inaccuracies, both when made and at and as of the expiration of the Offer, as if made at and as of the expiration of the Offer (except to the extent expressly
made as of an earlier date, in which case as of such date); and (D)&nbsp;the other representations and warranties of the Company set forth in <U>Article 3</U> (disregarding all materiality and Company Material Adverse Effect qualifications contained
therein) shall be true and correct both when made and at and as of the expiration of the Offer, as if made at and as of the expiration of the Offer (except to the extent expressly made as of an earlier date, in which case as of such date), except
with respect to this <U>clause (D)</U>&nbsp;where the failure of such representations and warranties to be so true and correct would not have, or reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the Company shall have performed or complied in all material respects with each of the obligations and covenants
required by this Agreement to be performed or complied with by it prior to the expiration of the Offer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Parent shall
have received from the Company a certificate, dated as of the date covering the time that is immediately prior to the expiration of the Offer and signed by an executive officer of the Company, certifying to the effect that the Offer Conditions set
forth in <U>clauses (iv)</U><U></U>&nbsp;and <U>(v)</U> immediately above have been satisfied as of immediately prior to the expiration of the Offer; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) this Agreement shall not have been terminated in accordance with its terms (the &#147;<U>Termination
Condition</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing conditions shall be in addition to, and not a limitation of, the rights and obligations of Merger Sub
and Parent to extend, terminate or modify the Offer pursuant to the terms and conditions of the Agreement. The foregoing conditions are for the sole benefit of Parent and Merger Sub and, subject to the terms and conditions of this Agreement and the
applicable rules and regulations of the SEC, may be waived by Parent and Merger Sub in whole or in part at any time and from time to time in their sole discretion (other than the Minimum Tender Condition, the Regulatory Condition, the Absence of
Legal Restraint Condition and the Termination Condition). The failure by Parent, Merger Sub or any other Affiliate of Parent at any time to exercise any of the foregoing rights shall not be deemed a waiver of any such right, the waiver of any such
right with respect to particular facts and circumstances shall not be deemed a waiver with respect to any other facts and circumstances and each such right shall be deemed an ongoing right that may be asserted at any time and from time to time. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d899660dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g899660g0107033853517.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>January&nbsp;6, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Press release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stryker announces definitive agreement
to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PORTAGE, Mich. and IRVINE, Calif., USA &#150;
January</B><B></B><B>&nbsp;6, 2025 &#150;</B> Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ:
NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9&nbsp;billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous
thromboembolism (VTE) to Stryker. Inari&#146;s innovative product portfolio is highly complementary to Stryker&#146;s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis
and pulmonary embolism. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each year, VTE impacts up to 900,000 lives in the United States, with even more affected worldwide.<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> People are at particularly high risk for this condition during or just after a hospitalization (with or without surgery), during cancer treatment and during or just after pregnancy.<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> Inari provides solutions for VTE clot removal without the use of thrombolytic drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The
acquisition of Inari expands Stryker&#146;s portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases,&#148; said Kevin Lobo, Chair and Chief Executive Officer, Stryker. &#147;These innovations elevate the
standard of care for venous thromboembolism patients and will accelerate Stryker&#146;s impact in endovascular procedures.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Inari has
positively impacted the lives of hundreds of thousands of patients through the development of purpose-built tools that address unmet patient needs,&#148; said Drew Hykes, Chief Executive Officer, Inari. &#147;With Stryker&#146;s capabilities and
global infrastructure, we will be even better positioned to accelerate the development of innovative new solutions and expand our footprint.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
the terms of the definitive agreement, Stryker will commence a tender offer for all outstanding shares of common stock of Inari for $80 per share in cash. The boards of directors of both Stryker and Inari have unanimously approved the transaction.
Consummation of the tender offer is subject to a minimum tender of at least a majority of then-outstanding Inari common shares, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other
customary conditions. Following successful completion of the tender offer, Stryker will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer. The transaction is anticipated to
close by the end of the first quarter of 2025, subject to customary closing conditions. Expected impacts to 2025 financial results will be discussed on Stryker&#146;s upcoming fourth quarter 2024 earnings call scheduled for January&nbsp;28, 2025.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information about this transaction is available on the Investor Relations section of Stryker.com <U>https://investors.stryker.com/</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g899660g0107033853517.jpg" ALT="LOGO" STYLE="width:1.45833in;height:0.38125in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Stryker </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative
products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150&nbsp;million patients annually. More information is
available at <U>www.stryker.com.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inari Medical, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving
lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve
patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and four other targeted disease states. We are just getting started. Learn more at <U>www.inarimedical.com</U> and
connect with us on <U>LinkedIn</U>, <U>X (Twitter)</U>, and <U>Instagram</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking&nbsp;Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are
subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements, including statements regarding the anticipated benefits to Stryker of the acquisition of Inari
and the anticipated timeline to closing the transaction. Such risks and uncertainties include, but are not limited to: uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Inari&#146;s stockholders
will tender their shares in the offer; the failure to satisfy any of the closing conditions to the acquisition of Inari, including the expiration or termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period (and the risk that
such governmental approval may result in the imposition of conditions that could adversely affect the expected benefits of the transaction); delays in consummating the acquisition of Inari or the risk that the transaction may not close at all;
unexpected liabilities, costs, charges or expenses in connection with the acquisition of Inari; the effects of the proposed Inari transaction (or the announcement thereof) on the parties&#146; relationships with employees, customers, other business
partners or governmental entities; weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products; geopolitical risks, including from international conflicts and elections in the
United States and other countries, which could, among other things, lead to increased market volatility; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in
foreign currency exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect approval of new products, including Inari products, by the United States Food and Drug
Administration and foreign regulatory agencies; inflationary pressures; increased interest rates or interest rate volatility; supply chain disruptions; changes in labor markets; changes in reimbursement levels from third-party payors; a significant
increase in product liability claims; the ultimate total cost with respect to recall-related and other regulatory and quality matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; changes in tax
laws and regulations; the impact of legislation to reform the healthcare system in the United States or other countries; costs to comply with medical device regulations; changes in financial markets; changes in our credit ratings; changes in the
competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Inari; our ability to realize anticipated cost savings;
potential negative impacts resulting from climate change or other environmental, social and governance and sustainability related matters; the impact on our operations and financial results of any public health emergency and any related policies and
actions by governments or other third parties; and breaches or failures of our or our vendors&#146; or customers&#146; information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft. Additional
information concerning these and other factors is contained in our filings with the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g899660g0107033853517.jpg" ALT="LOGO" STYLE="width:1.45833in;height:0.38125in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities and Exchange Commission (the &#147;SEC&#148;), including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> The foregoing factors should also be read in conjunction with the risks and cautionary statements discussed or identified in Inari&#146;s filings with the SEC, including Inari&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> The parties disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in
expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by
law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tender offer for the outstanding shares of common stock of Inari referenced in this communication has not yet commenced. This communication is for
informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell shares of common stock of Inari or any other securities. At the time the tender offer is commenced, Stryker will file
with the &#147;SEC&#148; a Tender Offer Statement on Schedule TO, and Inari will file with the SEC a Solicitation/Recommendation Statement on Schedule <FONT STYLE="white-space:nowrap">14D-9.</FONT> INARI STOCKHOLDERS ARE URGED TO READ THE TENDER
OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND THE OTHER TENDER OFFER DOCUMENTS), AND THE SOLICITATION/RECOMMENDATION STATEMENT, AS MAY BE AMENDED FROM TIME TO TIME, WHEN SUCH DOCUMENTS BECOME AVAILABLE, BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Inari stockholders and other investors can obtain the Tender Offer Statement, the Solicitation/Recommendation
Statement and other filed documents for free at the SEC&#146;s website at&nbsp;<U>www.sec.gov</U>. Copies of the documents filed with the SEC by Stryker will be available free of charge on Stryker&#146;s website,&nbsp;<U>www.stryker.com</U>, or by
contacting Stryker&#146;s Investor Relations department at&nbsp;<U>jason.beach@stryker.com</U>. Copies of the documents filed with the SEC by Inari will be available free of charge on Inari&#146;s website,&nbsp;https://ir.inarimedical.com, or by
contacting Inari Investor Relations at<U>&nbsp;IR@inarimedical.com</U>. In addition, Inari stockholders may obtain free copies of the tender offer materials by contacting the information agent for the tender offer that will be named in the Tender
Offer Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stryker&#146;s Contacts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason
Beach, Vice President, Investor Relations at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">269-385-2600</FONT></FONT> or <U>jason.beach@stryker.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yin Becker, Vice President, Chief Corporate Affairs Officer at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">269-385-2600</FONT></FONT> or
<U>yin.becker@stryker.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inari&#146;s Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neil Bhalodkar, Vice President, Investor Relations at <U>neil.bhalodkar@inarimedical.com</U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>https://www.cdc.gov/blood-clots/data-research/facts-stats/index.html</U> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>syk-20250106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/7/2025 4:55:54 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:syk="http://www.stryker.com/20250106"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.stryker.com/20250106"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" namespace="http://fasb.org/us-types/2024" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syk-20250106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syk-20250106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syk-20250106_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="syk_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes0.250Due2024Member" name="SeniorUnsecuredNotes0.250Due2024Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes2.125Due2027Member" name="SeniorUnsecuredNotes2.125Due2027Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes3.375Due2028Member" name="SeniorUnsecuredNotes3.375Due2028Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes0.750Due2029Member" name="SeniorUnsecuredNotes0.750Due2029Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes2.625Due2030Member" name="SeniorUnsecuredNotes2.625Due2030Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes1.000Due2031Member" name="SeniorUnsecuredNotes1.000Due2031Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes3.375Due2032Member" name="SeniorUnsecuredNotes3.375Due2032Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="syk_SeniorUnsecuredNotes3.625Due2036Member" name="SeniorUnsecuredNotes3.625Due2036Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>syk-20250106_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/7/2025 4:55:58 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="syk-20250106.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="syk-20250106.xsd#syk_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="syk_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="syk-20250106.xsd#syk_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="syk_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes0.250Due2024Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes0.250Due2024Member" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes2.125Due2027Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes2.125Due2027Member" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.375Due2028Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.375Due2028Member" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes0.750Due2029Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes0.750Due2029Member" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes2.625Due2030Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes2.625Due2030Member" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes1.000Due2031Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes1.000Due2031Member" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.375Due2032Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.375Due2032Member" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.625Due2036Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.625Due2036Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="syk_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="syk_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes0.250Due2024Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes2.125Due2027Member" order="26" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes3.375Due2028Member" order="27" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes0.750Due2029Member" order="28" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes2.625Due2030Member" order="29" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes1.000Due2031Member" order="30" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes3.375Due2032Member" order="31" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes3.625Due2036Member" order="32" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="52.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="53.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="54.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="55.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="56.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="57.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="58.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>syk-20250106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/7/2025 4:55:54 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="syk_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_DocumentAndEntityInformationTable" xlink:to="syk_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="syk_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="syk_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes0.250Due2024Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes0.250Due2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes0.250Due2024Member" xlink:to="syk_SeniorUnsecuredNotes0.250Due2024Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes0.250Due2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 0.250 Due 2024 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes0.250Due2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 0.250 Due 2024 [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes2.125Due2027Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes2.125Due2027Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes2.125Due2027Member" xlink:to="syk_SeniorUnsecuredNotes2.125Due2027Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes2.125Due2027Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 2.125 Due 2027 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes2.125Due2027Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 2.125 Due 2027 [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.375Due2028Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.375Due2028Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes3.375Due2028Member" xlink:to="syk_SeniorUnsecuredNotes3.375Due2028Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes3.375Due2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 3.375 Due 2028 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes3.375Due2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 3.375 Due 2028 [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes0.750Due2029Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes0.750Due2029Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes0.750Due2029Member" xlink:to="syk_SeniorUnsecuredNotes0.750Due2029Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes0.750Due2029Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 0.750 Due 2029 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes0.750Due2029Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 0.750 Due 2029 [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes2.625Due2030Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes2.625Due2030Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes2.625Due2030Member" xlink:to="syk_SeniorUnsecuredNotes2.625Due2030Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes2.625Due2030Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 2.625 Due 2030 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes2.625Due2030Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 2.625 Due 2030 [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes1.000Due2031Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes1.000Due2031Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes1.000Due2031Member" xlink:to="syk_SeniorUnsecuredNotes1.000Due2031Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes1.000Due2031Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 1.000 Due 2031 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes1.000Due2031Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 1.000 Due 2031 [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.375Due2032Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.375Due2032Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes3.375Due2032Member" xlink:to="syk_SeniorUnsecuredNotes3.375Due2032Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes3.375Due2032Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 3.375 Due 2032 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes3.375Due2032Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 3.375 Due 2032 [Member]</link:label>
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.625Due2036Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.625Due2036Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syk_SeniorUnsecuredNotes3.625Due2036Member" xlink:to="syk_SeniorUnsecuredNotes3.625Due2036Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes3.625Due2036Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Notes 3.625 Due 2036 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="syk_SeniorUnsecuredNotes3.625Due2036Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Unsecured Notes 3.625 Due 2036 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>syk-20250106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/7/2025 4:55:55 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="syk-20250106.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="syk-20250106.xsd#syk_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="syk_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="syk_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="syk_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationTable" xlink:to="syk_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes0.250Due2024Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes0.250Due2024Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes0.250Due2024Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes2.125Due2027Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes2.125Due2027Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes2.125Due2027Member" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.375Due2028Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.375Due2028Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes3.375Due2028Member" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes0.750Due2029Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes0.750Due2029Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes0.750Due2029Member" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes2.625Due2030Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes2.625Due2030Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes2.625Due2030Member" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes1.000Due2031Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes1.000Due2031Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes1.000Due2031Member" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.375Due2032Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.375Due2032Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes3.375Due2032Member" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="syk-20250106.xsd#syk_SeniorUnsecuredNotes3.625Due2036Member" xlink:type="locator" xlink:label="syk_SeniorUnsecuredNotes3.625Due2036Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syk_SeniorUnsecuredNotes3.625Due2036Member" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="53.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="54.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="55.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="56.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="57.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syk_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="58.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g899660g0107033853517.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899660g0107033853517.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D (H# 2(  A$! Q$!_\0
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+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46670360262000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STRYKER CORP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000310764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  06,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-13149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-1239739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1941 Stryker Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Portage<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">49002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">385-2600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $.10 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes0.250Due2024Member', window );">Senior Unsecured Notes 0.250 Due 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.250% Notes due 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK24A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.125Due2027Member', window );">Senior Unsecured Notes 2.125 Due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.125% Notes due 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2028Member', window );">Senior Unsecured Notes 3.375 Due 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.375% Notes due 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes0.750Due2029Member', window );">Senior Unsecured Notes 0.750 Due 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.750% Notes due 2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.625Due2030Member', window );">Senior Unsecured Notes 2.625 Due 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.625% Notes due 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes1.000Due2031Member', window );">Senior Unsecured Notes 1.000 Due 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.000% Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2032Member', window );">Senior Unsecured Notes 3.375 Due 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.375% Notes due 2032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.625Due2036Member', window );">Senior Unsecured Notes 3.625 Due 2036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syk_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.625% Notes due 2036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYK36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syk_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syk_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes0.250Due2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes0.250Due2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.125Due2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.125Due2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes0.750Due2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes0.750Due2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.625Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.625Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes1.000Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes1.000Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.625Due2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.625Due2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $ W)UH'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " ! -R=:<^SKLN\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O:2C3D+7%\4G!<&!XEM(;EM8DX;DI-VW-ZU;A^@'\#%W__SN
M=W"-#E+W$5]B'S"2Q70SNLXGJ<.&'8B"!$CZ@$ZE,B=\;N[ZZ!3E9]Q#4/JH
M]@@5Y[?@D)11I& "%F$ALK8Q6NJ(BOIXQAN]X,-G[&:8T8 =.O240)0"6#M-
M#*>Q:^ *F&"$T:7O IJ%.%?_Q,X=8.?DF.R2&H:A'%9S+N\@X/WYZ75>M[ ^
MD?(:\Z]D)9T";MAE\MOJ_F'[R-J*5W7!1<'76R%DO9;UW<?D^L/O*NQZ8W?V
M'QM?!-L&?MU%^P502P,$%     @ 0#<G6IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MNJ$/V HK6R$H5IUQ=T_SVF+!PWLG[P 3W<I$=S<3(RX38<[\&.F U_J!E<I
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ 0#<G6I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    " ! -R=:<^SKLN\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " ! -R=:F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( $ W)UK]Q <-G08  -@K   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " ! -R=:GZ ;\+$"  #B#
M#0              @ 'A#@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $ W
M)UJ7BKL<P    !,"   +              "  ;T1  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( $ W)UH<.&7J/P$  #P"   /              "  :82  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ! -R=:)!Z;HJT   #X 0  &@
M            @ $2%   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " ! -R=:99!YDAD!  #/ P  $P              @ 'W%   6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !!%@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>10</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>9</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d899660d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d899660d8k.htm">d899660d8k.htm</File>
    <File>syk-20250106.xsd</File>
    <File>syk-20250106_def.xml</File>
    <File>syk-20250106_lab.xml</File>
    <File>syk-20250106_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g899660g0107033853517.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d899660d8k.htm": {
   "nsprefix": "syk",
   "nsuri": "http://www.stryker.com/20250106",
   "dts": {
    "inline": {
     "local": [
      "d899660d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "syk-20250106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "syk-20250106_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "syk-20250106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syk-20250106_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 8,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 10,
   "entityCount": 1,
   "segmentCount": 9,
   "elementCount": 36,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 46
   },
   "report": {
    "R1": {
     "role": "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-01-06_to_2025-01-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d899660d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-01-06_to_2025-01-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d899660d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "syk_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "syk_SeniorUnsecuredNotes0.250Due2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes0.250Due2024Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 0.250 Due 2024 [Member]",
        "terseLabel": "Senior Unsecured Notes 0.250 Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_SeniorUnsecuredNotes0.750Due2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes0.750Due2029Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 0.750 Due 2029 [Member]",
        "terseLabel": "Senior Unsecured Notes 0.750 Due 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_SeniorUnsecuredNotes1.000Due2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes1.000Due2031Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 1.000 Due 2031 [Member]",
        "terseLabel": "Senior Unsecured Notes 1.000 Due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_SeniorUnsecuredNotes2.125Due2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes2.125Due2027Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 2.125 Due 2027 [Member]",
        "terseLabel": "Senior Unsecured Notes 2.125 Due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_SeniorUnsecuredNotes2.625Due2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes2.625Due2030Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 2.625 Due 2030 [Member]",
        "terseLabel": "Senior Unsecured Notes 2.625 Due 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_SeniorUnsecuredNotes3.375Due2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes3.375Due2028Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 3.375 Due 2028 [Member]",
        "terseLabel": "Senior Unsecured Notes 3.375 Due 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_SeniorUnsecuredNotes3.375Due2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes3.375Due2032Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 3.375 Due 2032 [Member]",
        "terseLabel": "Senior Unsecured Notes 3.375 Due 2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "syk_SeniorUnsecuredNotes3.625Due2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.stryker.com/20250106",
     "localname": "SeniorUnsecuredNotes3.625Due2036Member",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Unsecured Notes 3.625 Due 2036 [Member]",
        "terseLabel": "Senior Unsecured Notes 3.625 Due 2036 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.stryker.com//20250106/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-25-002537-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-002537-xbrl.zip
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M6K.U*TBX_T/R2'&!;SQR1Q[9KFWO2Q(>_) \4ES@&X_<6=?L*R@^_"%YI+C
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M\P0)I9,",GJ% IN9DRF>^A:],C9 J8;-A.4BAR&1LJL6(=8YC\7-6-R_<L.
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MCJ+".E.7CUF:6+L<CZ%%6!;'^3[=G;UE[LY)?10X"_AY&L^\T_\'4$L#!!0
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M3/R[D>%F1)J.OPQNHNPZ!MWE*"ZJ1*DR416O+>3T9DN'*]+AAH2<U(%5X'!
M0N3PY_'_39-J%AS>1<6P#"!WU7QS>7Z^+A+=WT;E5Z71S0A.?<JC+#B/9OEH
MM#;:>[XUYXZ#YP]"*(_"5GC$NW]Q?*X,N./3*RQ=N,2TP#\/+RX.3Z].CB_!
MG(.4P:.SW]7O_[&Y)[2UYNY1-#S?$&ON?Z912JJS6EH8R&!*&%Q.^^H@DZA(
MUJ=7[V]SN5:ES,TP\-B[P,2X-O)[N26_%<EO,^PZ'0&)@\-I=9,7RIY[%[Q7
M0T)XY#2JID5,89.D# ZOBS@&&W!M5+KU@JU*I9MAV1WE60G)#EO">[QGY!'>
M9B0>_OSQ[/3*5-[>)%7\K)Q$@_AMEM\5D9KF:9X]4]19%=&M>@M*</C)+UM*
M?;R'ZE'J9B0I7L1*CE?EN^!CDD79(,& E9+KX[7RS6VX8%5JW(QLQ<.^DM<#
MBEIA_&IM)'BPMR7!%4EP,W(1/\77B@>>%_D@CL&:4:SQ#.KZMY3XB _-H\3-
MR#^\2JHT#JH\."S+>'W"^&!_2W^K.K_W-H( +V+BA).XJ&9;\GN\!^63WV8$
M7TZR*DY3M;2I(,-WP8>HBN#/BA:]-KK<IHNL3)>;$7KY79G'!1C*Y, 9K%$T
M;\,O*]/@9L1?/B51/TF3:HVAYX.MDV9EXMN4L,IXDB81.&KNDNHF^!3=;:GP
M$9^73X6;$6/Y-;^-BPS\U$H4<Q2:LB'61HS/MZZ:E8EQ4\(HU],TJO)B%BCU
ML%JCNW!+@ZO3X&8$3ZZB+VLGOF_/8_^W([[-")L<*Y4PG\4QEO-\BOIYH6GQ
M7? ^SN)14@7G:;1&V;RUE5<FS<V(HQQGMTF1:TUQW1SR:Q)MU,,_(I0]_FYC
MNQ# GFP!^U<98/Z_?VZ&CO]W8V,'FQ&-.\G*:0%.ER?%NO[-26\S(G%7T><8
MO"V8&CBM8J73G>;!!9#%(TCO?[YU :Y,EYL1B?L8)446EV5P-DFR-<:"MQ2X
M.@5N1AS.9DT?#F^3,B_*__J/_1>OW@4?X_5%YK;DN#HY;D9D[B0;08?1=>;%
M;(EO=>+;C("<4@D/A\.$D88OXDD10_7=FD-RWTZ.8A.>&K:'1E9Y\2"D\RAP
M.Q[Q[B]&5CD_O- ]=+EW[N4?[S?WK+88*_<H-UYL,5:^DPCY::O1K$B9F^%>
M: "Y4&I-&F%'F2H/KAQT"_2)_3W)T[6JWR^VZ1^K$NMF>"(>7=WBBVWASJJ4
MN'5";&EO7;2W&3X(%Q8-< 2H[18HDEMB?+SGYA'C9B0%7TZA@TP29X,94.+'
M:39<GS3>EBNN2H2;D17\$7X-38R*X'V1?UZG0K@EP55)<#-R@\_N,D5V-\F$
MFP",E61>:U>4+26N3(F;D0I\F:>W((ZWA/>(S\AS<F]&]N:C#(Z^V+:=^'0<
MO'P0TGD4 ;='O/M'9W\_/CT\O:*PZ.&O%\?'OQ^K/S?W,+;1SWL4#"\W)/IY
ME&?#Z0#;8[V?E@EFL_9GV&^6FV*M33AL6TNL2I*;$O;,JB)/@23/)G&Q9A5E
MFTZX*A5N1CSS<#!0O'!+=H_WA#RRVXS@I;+3+O,T&235>@.8VYRC5>EO,P*8
M!D=AS77J+[?:WZH$N!E!R^/1"!I"K(WN7FWI;D6ZVXPXI5]CO"X"?+5-H%R5
M #<C2GD^[2N]+SC,LGR:#=;; &=+A"L3X68$*$_4C\>9*8= -*VU W]LJ7%U
MY_1F1"TQ2^,F3X=*+G]*JN1ZK4;QJVWT?&4ZW(PH"=)A</QE@$W!@H7M%3_$
MS]*DK)+L^ATW5K0_/AQ4W<Z'N(BOU1/%>@EZ"Y>Y,D%O1HSE8IHN0<;[K_K/
MGJ^Y,^B61E>GT<V(P"Q)HR^&ST#;(2Z[9J_EEEA7)];-B-N<*>.=M-,2 M?G
M4;%&1+HM&:Y.AIL1OCG-*VN\0[9[7%11D@7'MVMU)VV#.2O3XV9$<SXDA5I7
M7@07<9E<9^O-Y=F2X>IDN!G!'5N$&WS4M>'O@K_F6)OV+I!NIB-%H.L4W5]#
MHUV)SQ[\/-$[[F[XN]IV!W(;WP!AVBQC<7#>,$W'MLII^)G821+@"Q&S?0LN
MOP67YP'F__OG[PTNOTPIQZL'X8./HGK@49=RG'XX(8B[J[/@ZK=C!K/;W,/8
MEG+<HY;S:H-*.1+R0%1Y8!T28 <>1X,;<$I4,_CN>#12&X!%'J09K4W;V39%
M6I56-R/^\+&8ZN 7NBG2O$RRZ\"2\!.FR"<L2;4>\WIS1><CWGUE7?Q^<HI@
MO9N[_UO5Y1[%P>L-45VNXF*<9"P.BN"P'V5#ZICWA.7 OQLI;H9FPKJQ4DH$
M4:Z-"K<MSU:EPLW(?>#:>TF#T-+G"=/A$];+M%;\YD&(YE%H98]X]W\_N007
M^>'I\=D?6W26K5Z\C!AXLR%Z,52#3XO;Y#9". P/M@NK,_Z,BB+*JC7VIWBU
MK15?E3HW1%7^,HFS<DMX3XCP-D4[GH)N,(F*JGS'T8SD-L[6"-BRI<65:7$S
M$G]_A:+Q#((7GZ*[=\%?IT52#I,!91C]&2504JY$M_I<67-%$J7KHM#7VRK*
M52ET,W*"+R?Q )*"@V-HC#)8:Z_T+1&N3(2;D0@,B>F#]:F*K[<]4%:EN\W(
M_#TL(>^<^N.]5R.!H":%<6VDN*TB7Y44-P/@Y3)6NF#43]*D6ANH[I;X5B:^
MS0!V.<ZJI(B];J%7-TDQ?$9I@>^5^0S=HM;:ZO;UMG!Q94?W9B"]'"JB'"+F
ME;::MT3XB(_+)\+-"+?\%D?8NG9ME+<M4%R9\C8CE'*"_NPB7B_J\Y;^5J>_
MS8BH7!515H[B(KB*OJQ1_=LF7:Y,?YL11?F@;(]LO94?6^);G?@V(T "299E
M@"08#X/CM(SO;N)B;<F6;[X&@KQK(0#LGHI=.+#U_ZUP $[Y/[S]2=:KOUFV
MW/R@N5[]I[V_R#2Z[UIB3H?]2*[%\9>;I)]4P>';;[T)>-?/1B."US 5?@^<
M*/E=&?3C/+KW]W-T@)FBT:0(7BJ&/T^R05Y,<EO&"07%E*](Q9SFR^U9/_Q9
M']WO63,XS@()(Y:-(J9IV5]5^/ A*0=I7DZ+./@4 Z8C8L2H.32]^M5]O)D@
M^UI>'#Q)7)U_"V"=E?937K>?_K*JCUHWB<66L>>?#D^#LX^,-1(&0\45AT&$
M\(]_C;)I5,RX9C\,#O8.7@8[U4U2=CO_]1_[+UZ_^_F/7TPLYN<?__@%/GWS
MKA="\TU(Z^['U5T<0Y_Z8O89Y:9AIF$0!;\G@YOD.LH"R8%WS- :?M*,RT#^
M49$$O\=#Q<'3$-CW+HSU(4ZC._4#=RS@Y68\TPK4#+C+$)<XL.@6&L('83 J
M\C%^%8W@"JD'NIWX2SR8FJX"PS@%+_],RPWF-V$@L+I@4D6LU(9"[6R5!Z"5
M)QGLL9T=)($F<4G3PI'C:' #Z[+?SW;YZSD\Y.#% UQ!M75_PJ8%ZA\G^A]7
M^A^G^A_'^A^7M7\<UW[U&_[C[;RUM++B;R+_/W\[OC@^O SUR0_C,BEB!!N)
M!O\WA?"B((1 G3/\6:%Q!>=23OO_1-B1'+\86+B2,JX"Z/IT$R3PHZ24<<IU
MK1/F,IJJ2<78_ +HM)P.;FBM94(WD;?B+DG38!!-RUB2KUKH./H<*U*L8J!M
M-02HP#N*?I6\'D<S=<L#-5/X4MV9:(S_"/*BVRFGDTF*&Z ^P,M4J6GBUL'_
MPB48J.LZQ)G=)6KG[%[CA9)[& ;.949%7/(&->ID6@QN(C7]*$WUC4S*<@H<
M31U=/JW**J+LF?(F@E-7#PWR\5B=<@GH>:&2#D5P&Z73./C//:7'[ <3M59\
M.-0C:M+8P8VD@4(U3)I2 G<Z"[L=G_' *Q"@#Z8<MMYSN#0PH,-,(\6?@DF1
MJ$V"V> #,)G_? -3Y'E$8T@G5]L>!@G-DTP5M87Z2%;;;V)\P3"!8?!O>H/9
M$!AZ$BE=5&U[.8TRN!.T<'QS2(3F_[[I&(-S6)RSYBPV5ZR,U<X6,/M!5*J]
M@HFKHU0?J)G'9>5?2SB;2!&>D@_]5"TO^H(_ 61$=?+AD[_2X1)WVJ=5)8_I
MDH=T$[YA"[H=ET0:J,IQL!V\W-^YZ>D)_1IG:M:IU 0@Y=S8715;94:<NR+\
MPZ]'G]R[H6:8YRA-)T6D7DN'/E*W,;^#BPX_ARZXDPKG!YOJ2&=%RHI9*!8V
MAL^&M !:%V\&[V&WXTY%8TZ)R9@KI;>]-&:D1:F"J4;!G2+'5(F7.W#6J=U7
MIET2D1Y!!T7TM:*1<C_D!7-]GT>%HI-1MZ/!;\L:_VM2KNB'DB\KAAQ,LRA+
MU/4OU9)WHAX1QC"NL"X<M**;J H$YY"[Q9I9#N0>5!#AB09$FHI*JW@\25%E
MQ7;O+O]2U#.*DH)XPI#H-U9'75K>45L4/E@I(B\MFJKB[CM]/>EIBMRER&]C
MFIA1"$.K#<(HBD^. *65;V@#<^6;5D['8\?YL,(B@1<,TNE0DQBQ4STX;:&:
M_8!GKY:<I[=VPYNFU.WPSIN;$6.F:>PP^GEW'"XICQ9)?#8[HEDUV1I?<8-W
MAH:*!FD$FG4TO$U*XOC-6[UP6P5G6VY?X>^=V.PM:!(D:<W"F8!@9RY)XXAP
M)?Z@I%FI#Y-"/R@WVSR]3JF#EX?9@A+K@BNP_@@W_8'O!^D7]WY!R)1C0E):
MK:4E-46]/'4.:!!IR5#7!IZB?V5_ZUUY0//2=02X3@8V/8V!-> N!X5;'Z^,
MB3M3'0]VQFVLI&E%>END"5 Q42J0BH=U715UYSS+B&5K-<6E7QAM;1H'\GZU
M*Q4P#\6'VP7!D/5#;X$[?6409'D 7 #X:$2R?I042MB_GY8)5-4&'Z*99<U*
M@$&F$NE<1N]L5D+5N_))G*&-"3I+10KW2*.PX^ZIT:9%%L2WB=J- ;H1BC@?
M]8Q]3>(/?N1012F\5]V.=%]I"PQ8K=J9A3HC_J#)@'?X5DQL1N/&*]V-/@">
MK:9.RAM^@GM%=KMDY"WL6AEW24H;@^:]6IB8A7H<5DZF.+)Q9QKT1\("A%[%
M9CM+#7*>.4XZ9U\C9>B/'=,?(]$E.R(="]$^D[L=;\2$7?DK5[O[_87PZ=F?
M(6!"7QQ_/+LX#OE"0SS(C5L!Q[W.X;)H9N-SDV I9@)"-4+5O,9,%#]B\R@F
M5XK:'[6]:7P= 77VE9$_7(K]X>N 2NB&EV_G\)^'\6N^-Z!(( 7?__+ P9F&
M]P/,]]G'C\<7Z(PG)_RBJ3P,A3GZ_/[N/GIKU6D!-Y#NMC40O[(8@8"D@\)Z
M+H2KHL%EZ H6Q\! D:&H6TF-^!8?]IP@FDYO(K+@U;32&<@F8I/H9THR*P.*
M&-W'0[X0YCFEDRJ!(=D)>/EHNWEW^7_,YBNC OWC*)07/'R@K#OX2,D9*?V4
MM-K9WV/;1$K TD8S LQ6BU(U.>S:'8FNW7HWA5'4JSM.2'5V^'"#_ D#,HU(
M*+(.#EH(F^3C.$+L 69BPGE73-.X9.EZ/4TC<=!*3A\?K8,:^[W@:J[D@ 6C
MEVTD3(?&;6%C$(R,230;&_\<J@YT3.IS^#Y$<F/3\%;IMT.@1;(;64YF>05$
MIQ04T!74[@Z+Z"YKMB.M*:Z)/L_2F?&XJF65(S*P ,GTS@! S',.0IQ')]L@
M]>XX/O$FOZ_,HQ%!N2MOFDRF(%V4AE0.;F*E)=!%B[],0(>.8 &*D)),J0U,
MX/O[;U_^%$QVQ[LAGM\_\N)S<)0 >#RZ$-@)>K"GIM_7%V2HMGM'>*:FB.B]
M0A/'G>O>SO.>[N3(6R;;YO8\C59?#=)CFV^%>'^WLV &!W/?G8O8P*XD1[61
MBK3 00?J0G$;EU:'@HU&&D B](X."&2<#Y/1S(\FF!!$AK]3MR=3?P&9*IL<
MM)>RHK!3S1P)U73831)5QN-/QO^D2( DBZ0"'C>@1D>>&Z_!PZM>V\"L\,Z0
M1N]=S9W$^'6&4V9<V73<IWO %]&3&.R]W$D:?BL"'?B$?H0/AY6W,46DA&:G
M!$XT0U[(9&%><LLCX,EPX,T[C-_5S1E/Q\$5^9?,F=%EO""6FBL3POOFL%_&
M[)?Y!'H=-#ZK"J405NZYP[,2W%,,LZ.GEXPG>>EP#?5#EI6D;#J,B?V\:E=$
M+$DP"O@U+C74"U4?V$!C(X6Z!!@-H2XOUJ^MN^AV:*>30C%M=;V 8X"34ADV
M/5A7TM/4"6D2,-V[I!3R7FO,"Z4\A@*#BO</.%+!@=1N)R_$T$U'BXR/=IUM
MXM ACUM#8=XX<_;MJ?JP#K8^K&_)&5/4-EJ.=R^\.HJF@/(TZ?&=P"%(](/;
M0MU]8MGJ!2#@% -.\B''Q!O"B2#]U(8M)7[WYTB_W> TKV!$DP7@F,Q?K]TN
M"J?6>%B3X>+ZIKUHQ,XA[RCQ!_$XZ(Z@^B!W*,AACGZ:6Y 8 \UCU2M UN$C
M"PT$R$D(=G(:'!TZ:9[!@NFD@.]QWL=X6DU1,4-C?FCCS+ZUW\.T!':]60U.
M<#'T&=%.=#NT-BG"&K0.S,\9B>A@;9^MD%=&'(3^U*))N4TP186T&L42&WQ7
M^,? 'VON.!00>C_OJ%"QXR7Q;AJ[L3\#U\H,C9Y0&#SP@L0IK81/E%1U0OW*
M&M(B6='W:*3]CTXNA!M*^N,7Z?,+X8.;_ X /E@TH?:5S;\T]EBMH%ETP%I*
M(:'AO[L=>[0[5@>8J\60TTIMF#@E=%EB% CDMQ*KD (;D9>]'XM#XSF+^37<
M0O7073Y-T7\(N@#LH7JL'V,*40,!6/J_BSF3K.T-:D+Y8#!5*X\J2WF]I>EL
M[L[,)?R:5\[A</B#+!?V+=E9'C$K/DTW)"D&TW&)L=D2.*%@,3?@X%/6$.LA
M@T%4L@]2T5.W@Z>/@^#H);^J3U&W>0QJFJ7P[YHW4>IC:H)@)*B3JE&ZSIZA
M$R8?D+L.V@JQ338,6-L).CL=5O BU4P_>-)J9;.<G=_!L1KC@U+<=K][U&5G
MT O.VB26= ,LDE#27ELL.KN=1MEI[*RZ+P3]]*[+(_AZCT>BS.QAHG8<I)7Q
M@+7=SAV=VJ1("]V#;'>J(=^\W=L+HD5N!0P]=3M.[$E15U&A<UY9^IRE5V.0
M0"EXD2(G<-4+4!YKST';SX>YVBS8%Z*XAF$:7RJ6WJ/$'OTY9Y9IHO;<.!ZU
M"R\.10FL*3R)9KX=;-4+G?)@7+5X/CN8A"T/(6R(\2EM1]&I&^3#W_>:[N,Z
M'(;#GO!H@>($Y]./K>4WM,25*%W--^UVM#;B?^$EWS8G>((FN90IV@LM7W6C
MQ_+ZF2DWO&S^:U[3:W:#DUKX\'[?H+E1M[.R)B^8A/JC*.+;'#2G&0<X#4=$
MG==,5:HT\&#=^10G*&]TAGF6&\?NW'0?WBN1RRNV)R\$SU.*AWUKM[-J:O77
M6C[FQE+PV_E9XT[0*)3]@!HL>)_ TPR.3K6,6#TUJOG3[?!J"",">.=HP[H=
MI9&"1Q&^T88IJ\!H^-W *^IQS:6NA@XQ4U<EF'TEO%X<9_:=X<M<A>_/C)2&
M>>@&Q8HX*A5% Y7+^!C+,9UPL:R;>DE#?7DO=3B7GD9)*N@;;""O3J&$9 X*
M:&7!)=LET&$9?Z3H9U)WX*I)4V8_$"Q1#-E@.CDCAON&-3WH)@5?9:Z5>EN$
M@-D;14R9:2F5X<'*('MMG%15E++J-1Y#&@<Z5Y2*SEM,@E%,6"O]PUPIJFC4
M4VI;S/&BQ-5\:!%/U:7W?.O2^S:7G@RT<H)[- 3U+;^.419QHCLDVV#0K@R%
M.]BZV=E%#P0&#+\AB/=!TZ-?J4<7:)B4BJ0].6E_U.I+5 HDF2;\ &HYE?26
M2,_&'[N7N\$H'F)Q 3C P/13>_(INBLIH&AR\HEO*'&2E#<P>#-[H;BCC>XK
M/C!@B'QI=LKI^'Q,^QS<"HK:#NQ27VL3+0Y-!G93U@Q-W_!OQ9$*+9/D=+WL
M U TIF7<,@/TX=1V&DU:Y$)R8,<]H80"Y-BG)?D?DS(E[#GK-E;W 1(,F,^&
M^C5RVOHAQ4/5""6[<12]0>99:(JDO#2WFB2HL$A-_4/I !-E \7*CB^!KT+"
MEPZ@B(!'TS[HV:&2TO  UYN((K= UKB%VGV1I+J2Q$@E2&2S-V%HM)8:W:/%
M@PL>H!19X1*TTO^\?=,^>L>90E40ZIBF61FGM)1!/DFH9 X>L0'8L=X:<^6)
M7N:."*G<Z+^%^=HQD.8:<L=RG1RO?P^FCZ*@&-S<)D.17:#P'G*!MLIX<>:>
MT8E!;QAX4AGS5\]O%ZXW.BG<PN H.*)+C]VMN R JYR-94=.@53=#A-O\:>R
M8W/5<<\T_ZU3+C#CGDMASL+9$6PI+B%U#AW";1PWI,AL.<E-8A]Y5\<FAO"U
MNZR5./(*?!4-1E9151L]47I8-<W0[0+FP6VBA!^%5<9:V\.S\_?8+%'=K1VW
M-@!<27D)I:IJQ]( 0EUBVWJ+C9MKH$8Q2WCH.L^'W<XHHALD4S;][07YK,6(
M*3\NY!ZLP5<XZKE6H#ZIO-!<TDUV4W_*:ZL4XX@SYX)^5";DLQU-LZ''H876
M;-*<D!F(T4C>E-HS36\S/VPQH+_[CEWWNIT_N40U3<;H@18Q*MRILBU?,1F%
M!C1!6E\MU3&ULBA\CRASUGDJ7DR!=!2N<90UOC;#I30!7?G]((W*4GR-9A#0
M.XL%KIM3O\ L^"$F5<(?)3)#=8^*:V4N_HN98Q'C@(3&HS^))HDRC<PS-&"I
MA%P%7U, VOE0446?>1PF#AE>;-= >U^JXT@CIXH0MTPJ1>29M+5O2M!6Y $:
M_G-:HI#7!<C#*4I>'$8IW#DQD,+XAY0& ^EO+$-P5M^?'KV\WH- U&H>#DSN
MW9K2>J5B#FRV;XK'6-$8Z@ROTK/1,?SUC26B:\H>_:,>O:)RVYN(I4"[0K&Z
M4_3E[@O.$$9,AL4/#WOD1)4.H$9EN6C2=,,&:Z7)27.9J[N34#C[1V^-EXT^
MF_T7'Y[]-$?9\#PF^'B(Y40MZGH=DF*^>2SL86>D-O/8G8I3*2X4/2@#&Q1*
MW6PHV_?V94=G1=;MM!HQ*4YLF;[U$\\9O;V0_\EZD5YLO4C?YD4BY@'D[L@1
M8A,]ADFZ+S]-V.(Q\CA F_E";A[S\%+ITG@OR1'-+OZTS(W/%UZ38<NO@/)H
MBB@IP9M!#G^OX,/6J7E*?'O9_*L#" XZ9?-TE8DIB3&HDA$8:>GNR:K+E&QX
MOF- N,@<NZS=,=8\VM>XR-PCMQXR,9'%)N6W>,@\FGL4#K+ ^,?0O2L=9'69
M^S7N,&_1-6]87;;>JS/,7.DYCC#4L[_!$U;W!&N+5A#OM[N^6@;C 9J<7NU6
M/_BZ(+KY-<XN[T0?U-=%JNOWTT\;/&O&1>4N^UO]:M_!E0:&\W*'V*1@+Z#A
MKW2=>;OXK9ZS^K3!7P:477.8!:OXRWC1OJNLP;3T34E<1,FZ;Y.) _?U,>OG
M*]RL)9ZEB]5;AU6L=,R3)HP*Q]QWB8?$$AQYI=M^*/6<M"S#Y[0.(]0#''D<
M$;](HWZ<FG)W)N=N)XO&7'8:#8=0%A>;*PLP/\6P"=B'R048*N!*@O;*5:#5
M#51 G:OGP2>!6@&\RAM*E$:H)1!X'I8%N3:ID$5J%]*$0:Q<O"J6>S.;)0X/
M0E<H=)=-IL#*29O$50(@ KP",H>L*I,X] C&ZZMW)0RI]J/D-'38NB('!>9:
M4;5F"'W=AR]%N J7-5II*51,J<#Y*A5.L81Z021]P7RF$P*L77D;-,/#G>AV
M<"MZ<(;,32B^9!)C0,T@W##D/XI[@M^OABDDA(3SW>)H]ZY?X>Y4R+E9_$J3
MX;#H%Y,R2UB4J.I%Y)IQ-+[&('RWXT8^4?5 0K,I)LXH%K:+C)158)CF61JP
M&PQI,;+@*;Z581.W"%H/RE+P^H9T_*&@<4O:M" Q%":*+4>JUD:H@8$L6Y6O
M;5K@536ZQF3K1FR>9J J,K>36CC >*MM=F"H\_BF$UHRTJ^!X/*-.D5!0RCQ
MS,F^LSRF-F=,C!X@A/Y,Y-C[ Q+[@B&G[&=/) VSD'F*/J676Y_2 \8GGFO<
M$0NON=M>K3 ?KA2L9 \.)%L5KQ2<,J'VRE#+;;#"6F!$$4.T'4*4U)@RGD28
M0VBS">,O6 M/?J9ZSFRLTPD;M""UMTDVC5GWY0$!IER/.-70@F@!MV-<,1ZY
MA2R52%2L"?#47.3/EEX9;BZ8AK%R0:PN&T"LUJ!^>C3X F-D:0[0#T2 0) #
M^D!O8.-6B!_IQ0MOC!*.@]@4RXV4T"$>^V<TN*EBQ:R[G4_*S@!F>:$41I[/
M?T7CR;O@;U'UKS!XN1_\"6K(RP.UI9>5HNO*%J&(<A3%"?9_8AMTG&/)2W_F
MA$:'CN2'[O)8*E=BV6>%J38Q!"^+7*DZ:%1!_6%45.4RH+L:6\=6SW PJ8S&
M'%&*RA[IVK48-FLUR4*TD4,EA ;JO:]$BC:75LBBN="SQPCOH:KYC%"MT@5V
M5OB1#@Z2#A-JT1>%]Y#IH7; L@#(+4O)]2!4#K7LRN!V?N."3&E'E+&&A]>_
MX"D#2#@5\$()BA7JGB-;Y+\XSI=:C<V525W0*Q8[UNTHDJ&J82YV2DJG08+3
M&<'>*BR7P_LH^B"L,93^$A%O')% W,+3Y&W&!R=^>3*IDIO3&CZ-6.DR?8O&
MC0S(?::&4?T5TL^JI$94-$ G FF,M<N92(Q<<B5Z]<C4Q3_]< "^HT4)IOD3
M/7D8PNA9C\WNRQI:34"-FQ%HC$'/+SUO<9 $4VF+HQ*W1[^-"[%L$3QRMH9K
M@\S6!>ILG6=S"0]N%QZZ7;RLX>-?4XGRO%M5IUR#O[1N ?S*WJS279<5QPXY
MH!/-[LE<X'ZC2 E.Z21E4>X\[/-NT)C(=4T8]N!7:(1=--JIS@JH]Y&IJ9+L
MQ56LO%)J(@48T<5]J\CT&H,AZ'8@W,9)?H?^C1$T %"KB]'X519*J1TZ4S7O
M@F<8UX-GC79XMW/+/@[4$)O4NM"XBX9QGTSNJ*_N.4U+0*)!JI8R_I*!!;P8
M3BLV*I>=D+[FZ'__AO>U+F?]I/X:2/U,),5%J>M_;IU[3=8L<O#^1/X(DC?=
MCDN!\\ WV[ OOSG["_4[E_DE2W?CLUX/'8 DF$ L^-(:7/VJ80 1'$V8H9Y+
MU+KWL$'K04*&M#!T1LU2-M)<A&"(A%+QH2QC=Y0P=YFD@NN=*;$Q"VL:X-Q>
M<F=)6#1TW'+[;^CWA,(3Y2RF_54$O%)9O,,%S6I,;P&4QO2&]=_B-T!&M489
MRUU;7V&G8*,8RJ4$N",^"9B@N$<#SFEHK,_A4M,43GKTSI*Y:H\K*724$MZF
M#@/<Q# HJ%"$X9Q2TP@8Z/^4NI\0](@U+Z,B34"7BJ/J!C/B"&S-) )7[/Y&
MUHX&*H<<P*:]C=)=<, ]31_BJZT/\0%OXT\!U28J@BU*%H)+W,DKXY4Q=T/H
M\,TWKX7Y-EX\;^R'NG>*G^1)]O4W#XRUA5=OC5#=!VN"ZCXZ._W[\<7ER1GV
MR[S\[?#B^/)=</R_1[\=GOX**-[!T;&:XL>3H\.KX\NOG>3]W8,#PO FR@1'
MS!$55M@V=&O*^3]L=J8KJ_DV*:JI;\D"%>N*"[R)#$M,5@JX).>!OW+VCHBW
M4I6*S0OS[!#U _OSK]&*^2/LC_SB+]^Z7TF/"C8RG5.CINNW$^3T2.H+2)!6
M94O?PVYG21:FSF,*6%<ZT'X$:EB:6M0-&/@#1)6SRA8:"05P@%-&-C15>Q.!
MDSC%<*<.<&MD89W99J.>5(/##?^<PS<]_U!CA-AFT-25#='D;.J0'XQ@3ZBH
MWA8- DL&C3=@KO/MJH/= Z6\ QHO'<6AQ:S"HQ!%5V9'YN\!DY^S G].R\#Z
M* :@KIOPC8.IY)S%P!PJ[B2[V[WL+2&1*!"%:'!)::'*Y>UZG^>?GQUG53$3
MD*#"P<6[LJP@-=TKXJ%$BM+)4V9"N,MXHI2:[:?1290I#UUPZ3.@6#H$R H-
M,$+C.LM32ZGOP<JI6XJJ.'O & J+C]LEQ+5S+F9=1&/&GJ<=:69;!@L.^NU@
M@-!WI3+JYYP@HN-3@MPP12+38L85@Q)660)UZQ>&MML. K[HO\)E*39T,Q)=
M2;1@ZKKN'0PZ@1 .S%PB46&P!7(M(7PSM_IU+@*_S]'K04L$O=0/S><"6>XE
M:YH1;%4$^#"^6+CS BR5N2K(]Z+3)ADK#JY%W):Z#>^\!L)^_V"G(1((:*I>
MD"6[*]L8<R4MC,Y>5$ )UBAK]/(P&$WA2>SB2\>819C<A^Z(KUIANV5C?#@0
M!%96AO9QHR\;7V_=W28;@>N7<[E*2XF*Y*JDFG(^&J93M31Y9MV7N<!<E_#'
MY;SU \GUC9R271WTEKD'#W<;M=">O"3QF&\T!@*F!:13ER25>&3RW=7JLT>U
M5[6? %*$B<?."*-6JB6-+C>7()60I+T%H:R>>[J)7*^W3IC[=F&C%Q1M NMY
MH;1A[8:YP%M/;-1'8\=:.1V)TZ@'LMVT3?>J"B4S,:>P,9R,SF\)9>M7"U54
M$= +'5V=6OTU]HM?VNWN:9>^E.T%!ED:WG83ISASH4&#2MGM\+24MH#/ 6>I
MN.7-,!Y3MN[0@M_JSTR)HM9-3<YU*1W-7E-MWXQS2I6%9D&R'N:$^K9Y>_PE
M+@9)R=L&C5W)]4ON)II;2=S-KZ&D[#2=C T]C8 +I:8@CE3YL%8WZ60HN,LY
M-.^PQ.8J-IPD]"T&&6V%=VQU@U@ 28@3U(-KG&/M;.3=40^1?&T?MH55^TM7
M&F[%J0"XT4I&Y'1(T>!SEM^I^5SK=L5S%P"PN]0"H.\ C&B#W]4\EE(<;83.
MCT6&)AL=YT2;[(\QW^*CR/M2IM[RF^[RDFBD"'IH&8^_][W% /L<E"-UH&&Q
MHPB<OKF^48[UPH]P\Q]=0 2/I#EGJ)GENG1&3=$7+=:FC?H+$Y I] 8]",^=
M$8% IVQ^&_24;R8SF^DJ#79?38+K2R^ICV.IS3ZOJ<7SPK1%B)$;F$)<6<BK
MS1?2CO,4A(%NZN#3EH6)T3XK+MHE1[K$CFGW^BS?-- Z>YP^AJNY#*YJJ6>(
M:,7F[([HZC*>5+(R/IL9+L_+KYON#OMWZH$T\?+'7#I P[EU*4D&!07<[QB:
ME VU'WB96GNWT-Y!)\<3;*V1!"=S,D@FD*/ XBF+K]7R(YMMHC9E$,?D0*3V
M!K[[B9?4M,W8G(SS7@TS;VUTIOT$E&\'B^;[[7N]Y+FXTC?7\+@PN;BJ4DQG
MXW^)^@V>\5H* CF=$8 8#A%[R8", BSV2CA9OGQ!:W%IF"S02>X9)RMX C!9
MBE\UXF0U<JJ5 ;."%?"RUI?:<4" 6<=BMZ2W=XU1-#6K\V@&Q'L(5:\TD_,Y
M6=E>N^S8M@17VE%D.ZFKZX:Y49S)R#67HA:2FT%0/R%*EM1-GKCT!9P64WJB
M'V7H=55L6ZE\ X.:VSR:P\IWR%/!N;7B&UV(ZM;]]I#C#5"OI$)@S\JQ>/-F
MQ[19 ,RQ7M'K*XK7UU Y6)GJ20I3&9>*T(&LSD)Z@];]5VH";#H VW5-Z,2;
MEN<3PU<NK?%R.TNTD+7?NL8#C8+O$";W!<!\!?KDJ3J8WFP=3-^&/B411IDL
M0)SL?-$M@] D:@ UJ;$^D>;O<@&L["'FI#5Y*@A&3:M^<6I]B-RNK!BP5A\!
MS%6W,\Q3)4>ALA^R>!(-3L"=<#Q^(GKBS.M[)-]'N:H[L^;M<-L,^RJ0V1')
M.%;<#7>] 2^WVUFTWD8F(\-#>A.T-YL5E ?PQS7G,8#;B[ON8LQW.(W=N&_E
M9BZ3_S!<(;M"!K9Y)CM-53R.]PIJ\T3)B]KD872;4)ZXLOK1+90F\52'[KEG
M%/1<SL1LS1OE))2&VH>X=8QQ:SN76C!;3DCS>I. VH!N*\K9#J@M..EW0#D$
MK=(GLE8Z[A2"'NH'ZH;C:XBL(1];?39C\]:-:2XN=#EGZ^CC-!LZ92XG1!)4
MH,A7P3QI-5IE=#;1<[?3?(&!=!=2^FK9 %(96-X-X.,V$U>0XK6%OT9#W>2(
MD9HUK^AV?/9)??$D W$<S=R]*XC&4$!J<I-BR$K4-Z.\42; "&LH^6N)JX<V
M+A(,&[F>MF#!R6I3XU_;-)7:$URTC0]QG-KD$#A'"KW'^7.'1EH:;DF$V9;9
MRDVKS]3Y=MXL&^D+3*VOG.V5]QN=:,,>\VFIHY3D:L'.WI+#+I)N#LZ2*<1:
M>%WL4HV;Q.F];9O7FR2I$>9OU!:X%L!?P83.P4TTG!9+V([?+<'PT)9SM_2"
M:HN$&T %4^<-A.(UZ!LE(T5I.R^KFYY3#MWMN!J*+/,-E[\WY"+'DC)V0.<C
M#:WDF>LXW7IVUH[#LWHN[B!T@P(JUP$Y/V2^:N"HVUG90,+VS\JJ;FXA!9)3
M*6PY]I!"RWTIZUH4I>[(?E=4G3HCA:;F46Q6'.0>"QZE)6BW0TH+RA:HT4K*
MST9E028 EB,,[QP6"ZZHA$H_B.62*B8XH//XZLH1[X@D*8:J,SV<R>',184"
M(I1?Q)3KJ(9R4MW.5ZEL-1)M$JN.LMQ&;;O!'[6<Q?O?-1^BC-P$C>0:4I$"
M!GMCG<VCC9SX"W0NGY.)(D^CTM6U6)9@0"P5TR'-#YTDVE4TAIRFZYB! SAB
MY_"2'0VB1>(LOB4@JI"C<Z%9Q\BB)SD#D-K9[3@?-L.(];1,0S )'?)H.'4/
MC;R9 SS ED;<>%5P0;$W CND)'!2S8 2"O[Z.1DNK9A>]I5)'6Y.I;V?NS,_
M!-^4E"@T5IV#[IFX1H,E]Z=2.H;3 9*?\4U43K96,]_$)3]5[]9/6^_6 L5L
M16\7706#LJB3:PSO5C3S$-?#<2&UI[LLJ,) :.:'J*M($C9G';GL,PL/7BZ$
MC%&Y<?6$YL>@>B=N Q2ADNG\5J !A%O,6SOR-FC%@L=Z>'_6!.YVKM#/9Z(M
M-E!R=212]]Y@ZIX1^SKYQ>:2H?BEXP[Q\#DOH G)V) KV@#U.B\B+D_E,N<(
M2VRA7TT74/W?3P%2=&(,+9J)6A7RZSA3XW&]06WKL%6F%JTP:?A5]-7F45/%
M",\:$_^LH:*$ ;RJ04BKCS5+L&J^'5$L4X-N93G;8JX=!B"GS88876/JF3XO
M&84]HG FJ!@T:BW!SL-45_4>B[T,M_8TMSS0L!;,> +M83 HII290FCCJ$G,
M]R<OR]@5CVWC[/Y]J]T4S^$)NK+5:-5?A'YZDTQDG)!=<F#6B_[:K+Z:7Q,5
M^[64H9]XUDA6S1L2.:A(J&2:I#+.I[&SCV.-%B=_!+8P2E G.5\FEB5 BEH?
M:[1KX#;"6A(&5X/XI-%^I9]2VPN$RTLUMP1(98+4F?L@Y0!G#F(;Y6N8GUQ%
M7\"&M DIAL2PA[QDP[MK+_>Z[6GOH;0+&T-N#HTT @-SWR8IT)NT>,5#IH/*
ME ACQ3R#+>F+)]V$Y@YR;J,+HHLTQ;]A#&6OPPN^ QEWP:^&TDF3*'D"+ &\
MYA=PPZ:PQB&:=_L_O7E%)CR#FWB@;>HQF7+=[8"C@1.CO91XAUA0\4GS 25T
M@=*LM%>@&D 2:13 X^@S8UBZ/O6K.F*]V0I '\SM>IG5X#Z0\P:[.SKIZ$2G
M0N\HXC2^!9_7K_!I!B]5DSZ&HYR%["]H?@//PB(J*$FEJ]^<6IF&[*\2<KD0
MQ]!<'GW+$8L=^)C>(/5SD<9!<V'0 R&^@CMNT?8()-$M=)(#6 BIZ$8M2-S+
MB%G2LU&T.Y!T=:M!AP5,CNU2&&=.-1-59ZR8<E]?W)(9)FM+8+2@L5>:J\-F
MEC4@.U_72EI=-@2#+,*KB^N(J9<ZT/HT-=)XX!0\BKZK<_.G]<R@<I!1234B
M W4DX'S\":5N,C2XD+J[;0 0Z$EU!2!$I&L(#=:6@TSWH8F:%:(F4NG HVE1
M84<#TEL$HAB/7AI0VCDO;2ZD\Q0D# I\178"Y;&V7Q@W=@'7[JDZB_;WMMZB
M;\N%JBFJ+919U*U:#! 81;\0^?1DS]+5LYY8D__=$(Y1=PMJ C+ H\TG)@[=
M')J261D Q[ZL$.*P(OD!8NZ'!M5A+7YK-$?4/6P-D$&A3N'+&'3L-F5O8HI"
M4SIC8S[+.H3+$(7+%7=[8([DY[DH1@O:(R58-R8$U+LX00F#Z7.69( '*CJ<
M8O@'-KJ(QXJW*PU=C0*\->E/!662X=60/.<@8^_L0R DRC+P3Y4"O:&QSMVZ
M*%Q0@;F7@0.&8PQG:/]2Z^QDJEB]L A@3+3O4)=G]FPM)!G(7/I28=VCM_-S
MTN;%XE(E?)S*U>:5(?:#8URK%P[2*!G/#0?.<^.N!0UU)T9*/LV#3PSL.C.D
MJVX;-4KTU'JO"ABV7I81AY#M%M=<$;IH1MJ8SOY"I9+ N:UQ48=QLOU@>"+
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MX*<1H_,+:)AZ=]Z%!T<A$9&ODG<[!O]R&%<V%8:P&(?Y!!(RRCR=TH>DQF&
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M02.SPT$2F"DO#=OM1A-&BN.2#K6C\!2H+=(G84=E%,60XW><UJ[)Q^A"NF0
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M4O_(B+E4-LP<)(6BY+*B4DG:,--@;$8%L8"3A5FXP3@ITQ@;@KTS/5O"@ $
M&?P/'4(R6A1 K3!A;94F@P8:A$6#F=8A1H8EJF'_&6L<ISJ6H5B7+LED]*V,
MJ^8I!F;A'1?S*9X3<JD\!<^3;B7@]+6%]\R,=_G"T&#P\8-#>J8TQ:7S)YP@
M]&9KM#\$RAE87'F:#)%J[ T0).Y5/.O"84B(+WN"^8#9:KU21.&FTLEO[E#C
M^C/)VN<GT]*E4-(4[]%"CMS4@Q6?ATP8Z@,-;*+UI2%E^N)M3G2F]J^'A^?$
MU&'ET,%%@SQ@O"\"6%J=H8XH?Y2&JY38@<U-BFD3C41HVOY>:#RG#<>D.Y*%
MS&]M@@ZY[$PR-(LQ4/>Q'EP#CM'.8:KT"(!&?;FC<W^<]TLWH.QH*N0D/&@R
M>QW_KQGE0:9CN2:VO80G;W6#+=0^K%S<:;&\IEFDJ+WM.H3Z#6KA_5)WEQSE
M>845(@)Q-G([:F0@#-)@H0M_%D?%,Z6.F< ?3":(AO^<4O"R[-7"(LVJF @W
MQQJ"$=)H*(<.4QUT6HI/\^S?J;@-SY"E4[?S-S5+['W@'TQEZ[\HZ$)7 "$9
MS#C67S=G@ZF*0C^!66G)>!%G\M'6S-VR+27XYM=2JTDTDSYCI;/?7*;;$1QK
M#6GB@UX-.13V53-!.*.Q8L/ BB'ENB0,;(P38 ^SE-P#>4IMO^UVDGT%S!U4
M8%(J,2M?V2S=CFC-,XF*Z%I1Z$VP,](%4Z/@0G'?Q32]_SQZMO]24[1LVF%5
MDQ[U?&2-4\F.^QM:-\T8RB[3HO$5)%(5H'QV.Z;$E?)_I'E/J V0S4,Y>6[O
M:LJRH!X;QC/52+54S<6G8I2[%AF#1;!B1ARU(SZ)S9N&B")2YY1%;'/)FBLQ
M% =SDT4:8SZ*_J)K-XSG9L<ZM:S@C"D8@"1F7Q0JR11-A017!R,?;KK-'!T0
M4"@*M"E5["J&*MMN-DR0G?^X/>0P$BZ=B)Q)54..5-/A[ 8?=1<QRUEKV2T>
M)D>601]PALP'51Q4F,6$N_?L;YILM= :*>FAA@(1$)!%WHC>]#Q<PA*OK1=9
M:E[4Z]+I&-V$1LP5C8=.%!(]C>H>810RJ[!OUR!1(I +DXT4N5-:-5A"L>X$
MQ1>P#ON\-'/BJ% 12S=?FGP&HL*,-O0= G2S/?$:H7""(0HEN TAIE=AURD,
M2P,5"J>3F(BTY?R0:C JU-9BZ5,EZG#U;K!%FF2WD%CLW"=;L<?@+25VD\>3
MB)RM5GOCJ]!Z57H/,7@R=Q-W?7#T52K8/$>+"R^$JG94]"-UZL_.OJ3Q3+I:
M' ?-BNE*Y%9K]]N%UDUMTC=L+,WV!&P<6E%H8<J7%U[8+,^>V>W25Q<WA[H^
M-BUM3366\J"M7B"44Z85[FD'MV!(C1W<?GQ"Z,>NT%\F@VTIJ2_NLQ33<4:=
M3.#N>-WB[%7<@>"A('7VGID/>KX+R_9T\=PO?+>TMYFN+#5 H73;:5\)YM+M
MXR<T#/31DFY@N K\T_"5H6 LK%_R.]&'I\V56A<Z2U7H'A>&K07F$\W*@!#E
M#B683S\=3U/3W@P2X:<9VZ&Z\6:KS,^IDPOQ*1N$(21PL'AU@3JI/J9G6V&=
ME4Z/L1R83'YG%8(!LQ&K.9@S\XPIZ5JTV3"2@9@VF#H='CJ9C-1CNMS(?&]I
M1G_OZ4]Z$JTG[M=5RE4_83?;3ULWVWW7]U[1'6NSG9>I-JD$$ %XV8 V6>M*
M,*W95,XQ7\.<XX+]T*QD>4^B[4"YKM#3-P+O]=#KU6PO)=H4RH:89A5I]UB(
M5+,[:CH&2&9".(#:/\#I!=M5L=;8;;8M,!^152.X8R1^BD:X [<;+I;9%,]3
M5_Q9/TJEV%96<UQQ3R2)[*L#Z@S;:^:$H*46CZ6& LF/H7,4,RQI3<* ))\*
MJP7PJGY<W8&JG6/+7<[*-#0!/\ABM5G9,*02/ KN.)ZOPQ%8)NA=<2=45L5T
M 'ND?2SJ"10MUN3$9!QH,$QE:_A13 TC*/<$,8,YFD?L'R>CMVCAWK?MNMS(
MFL)Q FZ+YWO/(28,^5\BPK'PA9?6H&I1-GJA:,5 _L=0[@<YR&+=-,"$V<SY
MDDLKNLV384,3.J,ZRV,GQ1]]5-)&DIUM_91FJ%]JLE\6>,WHD!H\[&OP5XUZ
MRSDI!5=S(-? !VAJ,:ETK](&"]Y :E186JW?J/H80JN4&=C<MZ\UKAJ2K5$M
MXM8+P[,N^IZZV0A"!(\4\6T2WZW#)KCN!9=SC*A5,=5OHM*UMZSM7T!8F0U+
ML#RP(WG,6+\0+4"CB_CA0#TQED+&")C0BBTA=;35$M)=< 11*,P8@'"O;O)A
MGN;7VCF!'S3E1[>L,20B3*.[T=29!&+I\MLUH%(33H_["D0@\=^QAHMYTPM.
M\PKF:RX;>IXT6);+B4#?+ANBZ37EUS(B#+(OC 7*NHQ:PTGJS.AET00:^X-
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M*9%W(B&ZLT*:08PQ_E>:*,6#_/M@6:GA!S,!;5;K,+9 =<912_N"TKRA-*^
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M:2-]F,GF5(*0)I[.RJ/I<*?BYW[%D97S;Y&5^R[:2=/&1'UV ?7:E"E88IL
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M;R&#.M.")@704=9OI<T .%:-O$@(WZ(W&,1)N8$NU8H',Z&TGN T>0 L:X+
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MKPJ2+6U9OI?<1^I$!8?%E)C$@5"SLK7A@9QW\+HI#,"!JO=@P_N"VY8+_HM
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M/0.!.E' N#+8%X\HY-X0#6CP3E@$\'QSN_+@X6]+Q,!O?*NR_R47*J(4$&8
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M*J%\=^9[CPDKIU9;T&'W!?_P-UVIZ5=<@/G]MSC=?=?"1-B?TQP*RN)W FH
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MDPFHSR%?F%<[Q:FUILYXF7:G*5![>Z#)B>YJSWOH!=!,!6[<3<$8Y5W0<^X
MD:6=MW9_19I^5DX1;(GT+M-1AF=U8J)P:"X17)/5$NY19K;(#15S]A8!U:G
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MRI@(MF>"04=0:!_9M(W.W:*.OPE-VTS/MH#LU%"@IMJWP<E&V*HT8W/:/*B
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MNS/HU3D, )J"ON$<]5YIAZY@4M[UL5>PY&9&^%6O>Y?VE_V3,.C_'_SC$I8
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MEM_ BA(P\ZG73U[7/S /*7)F CI.&D'#+B<N2G7ZPK@O-1]%\E.T"<OO@+\
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M+8G)2#<G&V/NEJ\ZXX#+<F/9R972\5<8CHZ95-3G4+,R D?NTZ&MCFD>[1W
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M/U[W+_IG+QE'>,I^N8#AS1D6DM!2XRIL)./B@Z:_0,[EX1R]>@* .P;C!JM
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M5\38/]D4E9F:%8<@?.UD>,V7<+@EKV8-5)VT"?*89L)TZD/FY/:MG*555&@
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M7+W>VL!/%GHO+,[R _]6(.;8WP%02P,$%     @ 0#<G6A&!395L!   DQ8
M !    !S>6LM,C R-3 Q,#8N>'-DU5??4^,V$'Z_F?L?5#^U,[4=)P2*![BY
M-D>'&: W_.CTC5'L3= @2ZXD _GONY+MQ$E,<.#:7GC!D;YOM=_N:B4=?7K.
M.'D$I9D4QUX4]#P"(I$I$]-CK] ^U0ECWJ>3CQ^.?O!],CH]NR0^N3<FUW$8
M/CT]!>F$"2UY8=""#A*9A<3W:_QO-[?DS])Z3*Z  ]5 ,JH-*/)KP7@:]WO]
MO2CJ]X.H25- K3V24@,QB<*#$'%#LA</A_%PCWR](%^<$4%N6 9-ILQGBDWO
M#?DQ^8DXTD@* 9S#C)PR047"*"?7M<,_DS.1!.0SY^3*TC1ZJ4$]0AI45I]U
M&NOD'C+Z\0,A&"ZA8X$FB^S8LW&HPO \5CR0:AJF1H5FED.((!]1H%CB-:BO
M\]8XF <[H^?$"=5C1ZIG;'CV&@P]>UA:11LU>P#ETF.#THMZ^PUX"FP.=PYI
M2(*I? QQ8M6TG6?M$OJ]WB#$:C 896A0.!,/&QAV>HR%T5QDC?(T<(3H\/ P
M=+,K+J5F64%E?1B6D\O1G%*:MP;33BP$4V,4&Q<&3J7*1C"A!<=5"O%W03F;
M,$@="JLZ V&6,,L(0]44S"7-0.<T@6TR@]77%@94%H5_79Q?N\+T3BR!$%>K
M+,NE,J0LV7.9N(VT(?KVEU\GS;=#?M3W!U& QCPB6IU^(>,D?+<C=2V\R9%Y
M(75V1+]4\/;#MQ\OK=Z^3=X<@=7=;_4?6OW1?B?]:]WC&W@BQ>5[G6FTP+?G
M1%"6E!VN_.R>EP7S7;59-Q$;A^'&A5>[SO:B6[M1"-SH>F2C_/9F]JW=<&=.
M9S\:)U3EB'.#"B&-6[OI',US)B:R&L)!NZGC>F=?P82X[A]3E2C)8?,9$>9*
MYJ ,P_47S:$T<*]@<NSA0>G7;?>.TW& ;;=&K-E?[C9V.D0*\/.%=S77,&/)
MYW::V'F\:5 ^-VU#@HMC)GBC6_VW:G,%VZI%BL:CSB7M9=%?&ZCO5'L*DVVU
M(X4)MEGY:([96K==XP81Q'[<7IV]>$F8WQ)"0Y^ED-FL]&\DD\+>0^K_GT7Z
M1:!?LS/<3BISV? (P^O$%<+O.L'G/M9>+H)P$O7L'SX&:@O-3RI24IHC#7M'
MX:J15?N%AO0/<>*^$\J3@L]KK2)7B$W$U2KMSES.<3NO&JWS5?>N<+5Y52/+
M3<ZUN.K"Z'*!57FW*04W=&RKQ398+*_7@661N3MZC%6#S[@S YEUU".Z&&MD
MN8?/[TH6>0E,37R/\RHIQF#!6*^.CD-,IC?.8%JHJH $X]PN=>P95:!1BC85
M34S].WR;3HRW6UQWT=H OT$OB]F_J?(:!)/J5N =I%"07DH#NA?@EAT58,_
M"\C&H&J97=&ESO+=&:<RHTQ\CT+Q&=\?EJX?O"ZT#;TC0@?!X*!R_9?7A;:A
M=T1H+SBHB_&P2^FNHW=$:#_8KXIQT.M2NNOH'1$:!7ANEZY'KPMM0^^(T,6N
M&_2WV:,+],X(G1?C?A>AZ^C_4VAY42I?H_CS'U!+ P04    " ! -R=:*$-X
MZU<&   %/P  %    '-Y:RTR,#(U,#$P-E]D968N>&ULW5O9;N,V%'TOT']@
MU9<6J"S+2Q8C[L#-,C":#;'3%GT):(FVB5"D05*)_?<E:='Q(GND1.K,Z"F6
M?._A.=QTQ1.??9I'!+P@+C"C7<>OU1V :,!"3"==)Q8N% '&SJ???_SA["?7
M!1=7_5O@@JF4,]'QO-?7UUHXQE0P$DN%(&H!BSS@NC;^?/@(_EJB=\ #(@@*
M!"(H).+@CQB3L-.H-UJ^WVC4_/4TCJ#& R&4J -\[]A3<6W0ZK3;G?8)N+\!
MEP:$@B&.T'HFFRTXGDPE^"7X%9BD"T8I(@0MP!6FD 88$C"PA'\#?1K40(\0
M\*#3A&(I$']!82U!)9@^CS1MU5-4=!VM/9$^'W%28WRBR-6;G@UTEI$=?9TC
M?"[P1O1KT\;ZWC\WUX-@BB+HJKZ62L-;UDXK29Y_>GKJF6]7H:KY4*YBU]FT
MO>67*E3@CC!-7;/ C$$&"6!OA+YR;9BK;[E^PVWZM;D('=6[ )Q!'G!&T ,:
M T.W(Q<SU'4$CF9$RS3WIAR-]Q*Q[#5^6R/_# EQ0 +\^-#?U8RI]$(<>4F,
M9Q*\\@BIMA#5J\ -T1C&1.:CEY+^_Y!E$<3TW5R3[#*IFB;<"$4CQ'/RW$PM
MD>140? @'B%WU3?YJ*8")(0-(4MY&U%S$Y(OGA$W.[/91>M^_<B3<,XHBQ:>
M:>""!;$"EO9OCX:75&*YZ-,QXY'9!S;%B\6S:\&,R >%\Y0'9[-CU]6H.8XI
MUK'7ZG(C',TEHB$*+8AF7XY:P\<R(BPXK%[=>#H$-X2CM^FSE$+T_LJXO4G@
M"!&#G 7(*Y:>ZF?4ER@215!< SM,TU819MZ/H1B9R:^*C@F$,SUX+0\1*>P=
M+:EEY"0WG@92E0>:QCF!0MR-!Y(%S[TYSB0C TC)]-<;O$CVRNR\T[*_,\)/
MC?(ILRABU+1YD^ST.1CO)K]CX0T0Q8P_4H&"F*/PEDDDZC45=!$CS3<[KSQH
M!1%5=7FCO80^_CC1-+2"B#9KS>,$^N3C1-/0"AOZ8SM8IT4,_2Y:84-_E Q6
MLU[$T.^B%414O;76EWW0]#].- VM\#G:;!0Y1]_0"B.Z&JRC(HCNHN78]A54
M;<)>O!#AY8ZO/KQM].KB:5F"/* )5N4?I/(61IF*K?VYA=+KJ>HBU!7&%8&3
MK+RVDDKHKW,%SB'IJWIZ_B=:Y.NPG>1""=KR<JBX9.6UF5,*G7O$,5,%;WBA
M2L:\O+:22QC0/@T8GS%NJG!3UIZS6 W3XIR%.=?#%Z!*('^%";J-LVXUZ7DE
MT!K">3]4HX?'>'D<]AZ.>T%*(-P+0XZ$2/[H=S$_']E4@/*(GJN/=WS(7C.]
M2QQ,+X^D60%W_)ZS%[P\?,W/= >C/+KW3$A(_L6S_ L_':%0JGK(>AS!/.0V
M<PJEH\^YR?V4T9S;SVY>H;3^YEA*1/4K:$R3;2/3N<:!Y$()#AC! 9:83F[4
MQ.88DJSLTC(+I7;/D9:.U#(S%8$^,N1WXW'VP3V$4";5OA QXA\GG()3[.#K
M\EZM2;\Q&F*9[6@S/:]06D,.M7,Y6$0CEGDZ;B65TD^7\V *Z03E>3-)SRWA
MJ7$9(3Y1/?"9LU<Y5=-H!FG.UX$]$"NR;T?Z/1YL($,>6-3$[LCHUBUSQIQ%
MN8ZDD[99YJ-VQM4:ZCJJ")JI EX/2-=I." 6BBB;Z4"S\QG/IQ,P*M%<7A*S
M"E4;:*(_O'U/F$!AUY$\1J5U3ZI=E*>[-MT*ENFL/%LWE:1XUW-<EYO=+F"'
MC]<3C8WFUQ9I3> 25.HS^95.?13VE49TTYU-$WK C6 'S_"MO-;WJ2R/"V"E
MMJLE-<U'L%*/JB4US8FP4H^K)37-R[!23ZHE-<T-L5)/JR4US4])I#;KU9*:
MYLA8J=_I8S2/IV.E-KXUJ>]Z/=AO#EF=K=HW6!V]6^N6X61%MBLE<H]Y9<4>
M54KLIB.6:&S5*ZEQRUVS8OU*B<WDS5GIC0I*7S?[K,YF!77N-0RMZ&H]>@X8
MCU9P%1]#*1:FE5NM!]%A']1J/JZNYBT[U2H^J93B38_6:CRME,9=TS?1V:Y6
M6;7'0+9BJU56I?G15FFUJJA#MK957*UZZLN^N-5=K9)JUVBW.JM526V9]U9D
MM>JG]/\$L%JK6#?M^7\"*SESX71F?J.\]8M"_:ONU6^7U<5_4$L#!!0    (
M $ W)UJ+2MYR! D  $!M   4    <WEK+3(P,C4P,3 V7VQA8BYX;6S-75UO
MVS@6?1]@_@/7^[(#C+_S,3&:#K)).@@F;8(FW1U,L2ADB7:$2F) R8W][Y>D
M)$>V*)HT+R,_3,>5>,^YQSE'OI*E]-WORSA"/S!-0Y*<=X:]00?AQ"=!F,S/
M.XNTZZ5^&'90FGE)X$4DP>>=%4X[O[__^:=W_^AVT=6'FT^HBYZR[#F=]/LO
M+R^]8!8F*8D6&8-,>SZ)^ZC;+==?/GY!_\GI)N@SCK"78A1[:88I^O<BC(+)
M:# Z&@Y'H]ZP6D:QQ_%0X&5X@H;]TSY;=XR.)L?'D^,C=/\170N0!#V&,:Y6
MDN<5#>=/&?J7_PL215<D27 4X17Z$"9>XH=>A![*AG]%-XG?0Q=1A#[SLI1U
MF6+Z P>] C4*D^\3_L>4]XY^_@DA]B8FJ=AVWN%O1?%.+*<TZA$Z9[T.QOVR
MI/-:L:R5O(Q%P?#L[*PO]E97IZ%L+0,?]O_Z>/O@/^'8Z[(WG_VP_((F#2>I
MV'Y+?/$.:C2(&E?POW7+95V^J3L<=<?#WC(-.N\Y8?'N>%,<W;)72&B84!)A
M!3'?+=@[Q?IL]<S6XV6&DP 7R&MLXA>KGBB>Y:C<>@(RQ7YO3G[T QQR@QSQ
M%UW^@G?X3_:7;Y>$N?UBFF;4\[--OHB_1826&X6(\XZDJ+_9$%]W0?T-+(_Z
M)0Y[N4-_L:+O$_9S>\ZZ K$LGU$22[LHZ(ADY[=H&DG;Y$YBKWBX<=+]\K!+
M:PY4%49Q2A:4V<OD1ROTO!?(Z&N)_;]W_5?N0VF5'4)2?&O:KYTEKY,LS%:?
M\3SD1$GVR8NQKC/EM2T95"F$-*^QL6LS'I!K<P+TRH XA;5WW?5=M;!I\W9&
MOHC9\9K]EWV(O+FN@[>*6K*NO'4BV6EC5@D0D$O7R(A#6[O30:-56^IV"W%<
MO60TU(MNV"2Q_!.OS ZLM>)6CZQ-4HABD?VQ50H(>W M*)#@0(P$Z/#JI'7)
M\=6@?SM+7Q%_P7/SR+K7=?)F34L&EC9.ZOML[%K' 7)I"8PXLK4UX=NL.E*S
M5Q@;WF,:DN Z":[8:;FI'[>*6S:F7 I1+(*PJ@00VK,Y!6(<B). V==!ZU(?
M:_</,2S<)#ZASX2*2R4/&>.[) MV;%]=DL#PG&P'5*N#A)Y,HEUB/V1HP,..
M'!N$2#"B@A)Q3J )Y UT2>:1_<5!A.A#&.%/BWB*J5EBJG6MQD,B@,CWVQM_
M&PO6Y1P=Y?! AH;N5^)>K:8AC/KH+6\"]AD3SL+\XO@^KFT$:=7"NZ01C<7V
MYE8"PSJ=4:%-+EC?.Y4B"<$>>B B<1$$3$!:_.\V3/#0+ Y2@%:CH))$=BRT
MCT C**S]"_Q?RQ>(,Z&[!&J.<29#8OT]M !:_Y*]O*./Y"79R_C5\D.PO42.
MS/2OR\ LOPWIR/"<!A&*.!&LV:$%J*RNIP+0YN*DX([>4_(C3'S#<]LFC$,P
M?),PF>NWUH)97XKKR/_YV1VS3LD&&P(G4E1),- #&(=[DF9>]'?X;'ZA1XYP
M"%&0BY(%86,E6 PDJ(Y"D#,A1@5Y\<:=#%4 M+58W@C%!5+LF1A^LZ:MVZ!D
MC9/Z/JN;H&HX0,85G_,<&<:G\'UNW "EV:R=$?F=B=']$TD,+QK6ZUHR9*,
M(M]O8TPY%I Y!3@2Z% 73]ST6S6I2=-V1OTO#;,,)Y<DCA=)<5$FU75K0W%+
MEE5+(8I%-N95  (YN&! FQ36+G;8>-7*IMW;V?F!1*$?9F$R_\@F;AIZD:Z7
M994M&5DA@C2ML+%P$QJ0?U_A48EO;5Y7+5>=:]2WG6WO*>;YP,P6XBX:_H@
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M#JKD7U!+ 0(4 Q0    ( $ W)UH<S5X'/"@  /WO   .              "
M 0    !D.#DY-C8P9#AK+FAT;5!+ 0(4 Q0    ( $ W)UJUY]-V4U<! /&V
M!P 0              "  6@H  !D.#DY-C8P9&5X,C$N:'1M4$L! A0#%
M  @ 0#<G6BR^>Z,A%0  \T   !$              ( !Z7\! &0X.3DV-C!D
M97@Y.3$N:'1M4$L! A0#%     @ 0#<G6F=FE#SU"   B0D  !D
M     ( !.94! &<X.3DV-C!G,#$P-S S,S@U,S4Q-RYJ<&=02P$"% ,4
M" ! -R=:$8%-E6P$  "3%@  $               @ %EG@$ <WEK+3(P,C4P
M,3 V+GAS9%!+ 0(4 Q0    ( $ W)UHH0WCK5P8   4_   4
M  "  ?^B 0!S>6LM,C R-3 Q,#9?9&5F+GAM;%!+ 0(4 Q0    ( $ W)UJ+
M2MYR! D  $!M   4              "  8BI 0!S>6LM,C R-3 Q,#9?;&%B
M+GAM;%!+ 0(4 Q0    ( $ W)UHXP2,Y'08  %1$   4              "
M ;ZR 0!S>6LM,C R-3 Q,#9?<')E+GAM;%!+!08     "  (  0"   -N0$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d899660d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:syk="http://www.stryker.com/20250106"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syk-20250106.xsd" xlink:type="simple"/>
    <context id="duration_2025-01-06_to_2025-01-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes0.250Due2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes2.125Due2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes3.375Due2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes0.750Due2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes2.625Due2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes1.000Due2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes3.375Due2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310764</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syk:SeniorUnsecuredNotes3.625Due2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-06</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2025-01-06_to_2025-01-06"
      id="Hidden_dei_EntityRegistrantName">STRYKER CORP</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-399">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-01-06_to_2025-01-06"
      id="Hidden_dei_EntityCentralIndexKey">0000310764</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-482">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-483">2025-01-06</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-484">MI</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-485">001-13149</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-486">38-1239739</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-487">1941 Stryker Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-488">Portage</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-489">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-490">49002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-491">(269)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-492">385-2600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-493">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-494">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-495">true</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-496">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-497">Common Stock, $.10 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-498">SYK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-499">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member"
      id="ixv-500">0.250% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member"
      id="ixv-501">SYK24A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.250Due2024Member"
      id="ixv-502">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member"
      id="ixv-503">2.125% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member"
      id="ixv-504">SYK27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.125Due2027Member"
      id="ixv-505">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member"
      id="ixv-506">3.375% Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member"
      id="ixv-507">SYK28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2028Member"
      id="ixv-508">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member"
      id="ixv-509">0.750% Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member"
      id="ixv-510">SYK29</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes0.750Due2029Member"
      id="ixv-511">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member"
      id="ixv-512">2.625% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member"
      id="ixv-513">SYK30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes2.625Due2030Member"
      id="ixv-514">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member"
      id="ixv-515">1.000% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member"
      id="ixv-516">SYK31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes1.000Due2031Member"
      id="ixv-517">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member"
      id="ixv-518">3.375% Notes due 2032</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member"
      id="ixv-519">SYK32</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.375Due2032Member"
      id="ixv-520">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member"
      id="ixv-521">3.625% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member"
      id="ixv-522">SYK36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2025-01-06_to_2025-01-06_us-gaap-StatementClassOfStockAxis_syk-SeniorUnsecuredNotes3.625Due2036Member"
      id="ixv-523">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-01-06_to_2025-01-06" id="ixv-524">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
